Document:

exv10w43

Exhibit 10.43

TECHNOLOGY DEVELOPMENT AND LICENSE AGREEMENT

     THIS TECHNOLOGY DEVELOPMENT AND LICENSE AGREEMENT (this “Agreement”) dated as of August 6,
2003 (the “Effective Date”), is entered into between Archemix Corp., a Delaware corporation, having
a place of business at 1 Hampshire Street, Cambridge, MA 02139 (“Archemix”), and Aptamera, Inc., a
Delaware corporation, having a place of business at 640 S. Fourth Street, Suite 400, Louisville, KY
40202, (“Aptamera”). Each of Archemix and Aptamera may be referred to herein as a “Party” and
together as the “Parties.”

     WHEREAS, Archemix owns or has rights in certain technology regarding aptamers and their
modifications.

     WHEREAS, Aptamera desires to obtain a worldwide license under Archemix’ rights in such
technology to develop and commercialize products for use in therapeutics.

     NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants herein
contained, the parties agree as follows:

	1	 	DEFINITIONS

	 	1.1	 	“Affiliate” shall mean, with respect to any Person, any other Person
which directly or indirectly controls, is controlled by, or is under common control
with, such Person. A Person shall be regarded as in control of another Person if it
owns, or directly or indirectly controls, at least fifty percent (50%) of the voting
stock or other ownership interest of the other Person, or if it directly or indirectly
possesses the power to direct or cause the direction of the management and policies of
the other Person by any means whatsoever.
	 
	 	1.2	 	“Aptamera Improvements” shall mean any inventions, patentable or not,
information and/or data Controlled by Aptamera after the Effective Date and during the
term of this Agreement, that were derived from the practice of the Licensed IP Rights,
and that relate to: (a) improvements in the SELEX Process and (b) improvements made to
the Licensed IP Rights.
	 
	 	1.3	 	“Aptamers” shall mean oligonucleotides, including any structural
variations and modifications, derivatives, homologs, analogs and/or mimetics thereof,
identified through the SELEX Process.
	 
	 	1.4	 	“Gilead-Archemix License Agreement” shall mean the License Agreement
Between Gilead Sciences, Inc. and Archemix Corp. dated October 21, 2001.
	 
	 	1.5	 	“Controlled” shall mean, with respect to a particular item of
information or intellectual property right, that the applicable Party owns or has a
license to such item or right and has the ability to grant to the other Party access to
and a license or

Portions of this Exhibit were omitted and
have been filed separately with the Secretary of the Commission pursuant to the Company’s
application requesting confidential treatment under Rule 406 of
the Securities Act.

1

 

	 	 	 	sublicense (as applicable) under such item or rights as provided for in this Agreement
without violating the terms of any agreement or other arrangement with any Third
Party.
	 
	 	1.6	 	“Damages” shall mean any and all costs, losses, claims, liabilities,
fines, penalties, damages and expenses, court costs, and reasonable fees and
disbursements of counsel, consultants and expert witnesses incurred by a Party hereto
(including any interest payments which may be imposed in connection therewith).
	 
	 	1.7	 	“Excluded Aptamers” shall mean (a) [***], (b) [***], and (c) any
Aptamer directed to a target other than Nucleolin, including without limitation the
following targets:

	 	i.	 	[***]
	 
	 	ii.	 	[***]
	 
	 	iii.	 	[***]
	 
	 	iv.	 	[***]
	 
	 	v.	 	[***]
	 
	 	vi.	 	[***]
	 
	 	vii.	 	[***]
	 
	 	viii.	 	[***]

	 	1.8	 	“Field” shall mean any research, development, manufacture, marketing,
promoting, selling, distributing, or any other commercial activity related to the
commercialization of any Product.
	 
	 	1.9	 	“First Commercial Sale” shall mean, with respect to any Product, the
first sale for use or consumption by the general public of such Product.
	 
	 	1.10	 	“Interested Party” shall mean Aptamera, Archemix or Gilead and
“Interested Parties” shall mean Aptamera, Archemix and Gilead.
	 
	 	1.11	 	“In Vitro Diagnostics” shall mean the use of the SELEX Process or
Aptamers identified through the use of the SELEX process in the assay, testing or
determination outside of a living organism, of a substance in a test material.
	 
	 	1.12	 	“In Vivo Diagnostic Agent” shall mean any product containing one or
more Aptamers that is used for any human in vivo diagnostic purpose related to (inter
alia) the identification, quantification or monitoring of the propensity toward, or
actual existence of, any disease state.

Portions of this Exhibit were omitted and
have been filed separately with the Secretary of the Commission pursuant to the Company’s
application requesting confidential treatment under Rule 406 of
the Securities Act.

2

 

	 	1.13	 	“Licensed IP Rights” shall mean, collectively, the Licensed Patent
Rights and the Licensed Know-How Rights.
	 
	 	1.14	 	“Licensed Know-How Rights” shall mean all trade secrets, know-how and
unpatented or unpatentable inventions and discoveries in all information and data
Controlled by Archemix as of the Effective Date that is not generally known (including,
but not limited to, information and data regarding formulae, procedures, protocols,
techniques and results of experimentation and testing), which is necessary or useful
for Aptamera to make, use, develop, sell or seek regulatory approval to market
Products, or to practice any method or process, at any time claimed or disclosed in any
issued patent or pending patent application within the Licensed Patent Rights.
	 
	 	1.15	 	“Licensed Patent Rights” shall mean any patent or patent application
related to the Products and owned as of the effective date by Archemix or for which
Archemix has rights to license or sublicense including, without any limitation, (a)
those certain patent applications and patents listed on Schedule A hereto and
any patent or patent application claiming priority therefrom; (b) all patents that have
issued or in the future issue from such patent applications, including utility, model
and design patents and certificates of invention; and (c) all divisionals,
continuations, continuations-in-part, reissues, renewals, extensions or additions to
any such patent applications and patents.
	 
	 	1.16	 	“Net Revenue” shall mean, with respect to any Product, the payment of
license fees, milestone payments, royalties, or any other fees received from a Third
Party including sublicensees excluding (a) any payment or reimbursement for research or
development conducted by or for Aptamera or its Affiliates including costs associated
with materials, equipments, or clinical testing, b) income received by Aptamera or its
Affiliates for selling goods or services associated with the Products, and c) proceeds
from the sale and issuance of Aptamera securities at or below the fair market value of
said securities.
	 
	 	1.17	 	“Net Sales” shall mean, with respect to any Product, the invoiced sales
price of such Product billed to independent customers who are not Affiliates, less (a)
credits, allowances, discounts and rebates to, and chargebacks from the account of,
such independent customers for spoiled, damaged, out-dated, rejected or returned
Product or bad debts; (b) actual freight and insurance costs incurred in transporting
such Product to such customers; (c) cash, quantity and trade discounts and other price
reductions; (d) sales, use, value-added and other direct taxes incurred; (e) customs
duties, surcharges and other governmental charges incurred in connection with the
exportation or importation of such Product; and (f) the cost to Aptamera of the devices
for dispensing or administering such Product as well as diluents or similar materials
which accompany such Product as it is sold.
	 
	 	1.18	 	“Party” shall mean Aptamera or Archemix and “Parties” shall
mean Aptamera and Archemix.

Portions of this Exhibit were omitted and
have been filed separately with the Secretary of the Commission pursuant to the Company’s
application requesting confidential treatment under Rule 406 of
the Securities Act.

3

 

	 	1.19	 	“Person” shall mean an individual, corporation, partnership, limited
liability company, trust, business trust, association, joint stock company, joint
venture, pool, syndicate, sole proprietorship, unincorporated organization,
governmental authority or any other form of entity not specifically listed herein.
	 
	 	1.20	 	“Products” shall mean

(a) AGRO100, which is a [***]            and                 
                            
                                       
                          [***]

[***]

(b) AGRO100 Derivatives, which solely consist of molecules having the
[***] resulting from a modification to AGRO100 intended to alter one or more
functions of AGRO100, e.g., stability, binding affinity, or pharmacokinetics
in vivo, including without any limitation, PEG modification, adding
molecules to the [***] or conjugating the [***] with other molecules.

	 	1.21	 	“Proprietary Information” shall mean, subject to the limitations set
forth in Section 10.1 hereof, any confidential information of a Party disclosed by such
Party to the other Party in the course of negotiating or performing under this
Agreement that is identified as confidential by the disclosing party at the time of its
disclosure.
	 
	 	1.22	 	“Radio Therapeutic” shall mean any product for human therapeutic use
that contains one or more Aptamers that targets specifically any diseased tissue, cells
or disease-specific molecules or any tissue or cells which are affected by a disease or
located in the close neighborhood of a disease process and is linked to or incorporates
(a) radionucleotides or (b) any structure or elements which develop therapeutic effects
similar to the effect of linking or incorporating radionucleotides after submission of
any kind of radiation.
	 
	 	1.23	 	“Royalty Term” shall mean, severally with respect to each Product in
each country, if the manufacture, use or sale of such Product in such country would
infringe a Valid Claim but for the license granted by this Agreement, the term for
which such Valid Claim remains in effect.
	 
	 	1.24	 	“SELEX Process” means any process for identification or use of a
nucleic acid, which process is disclosed in or falls within the claimed scope of U.S.
Patent Nos. [***] or [***].
	 
	 	1.25	 	“Territory” shall mean the world.
	 
	 	1.26	 	“Third Party” shall mean any Person other than Archemix, Aptamera and
their respective Affiliates.

Portions of this Exhibit were omitted and
have been filed separately with the Secretary of the Commission pursuant to the Company’s
application requesting confidential treatment under Rule 406 of
the Securities Act.

4

 

	 	1.27	 	“URC License Agreement” shall mean the Restated Assignment and License
Agreement, dated July 17, 1991, by and between University Research Corporation and
Gilead as successor in interest to NeXstar.
	 
	 	1.28	 	“UTC” shall mean University Technology Corporation, the successor to
the University Research Corporation.
	 
	 	1.29	 	“Valid Claim” shall mean (a) a claim of an issued and unexpired patent
within the Licensed Patent Rights, which has not been held permanently revoked, found
unenforceable or invalid by a decision of a court or other governmental agency of
competent jurisdiction, unappealable or unappealed within the time allowed for appeal,
and which has not been admitted to be invalid or unenforceable through reissue or
disclaimer or otherwise, or (b) a claim of a pending patent application so long as
there exists an issued and unexpired patent meeting the criteria of clause (a) above.

	2	 	REPRESENTATIONS AND WARRANTIES

	 	2.1	 	Mutual Representations and Warranties. Each Party hereby represents
and warrants to the other Party as follows:

	2.1.1	 	Corporate Existence. Such Party is a corporation duly organized, validly existing
and in good standing under the laws of the state in which it is incorporated.
	 
	2.1.2	 	Authorization and Enforcement of Obligations. Such Party (a) has the corporate
power and authority and the legal right to enter into this Agreement and to perform its
obligations hereunder, and (b) has taken all necessary corporate action on its part to
authorize the execution and delivery of this Agreement and the performance of its obligations
hereunder. This Agreement has been duly executed and delivered on behalf of such Party, and
constitutes a legal, valid, binding obligation, enforceable against such party in accordance
with its terms.
	 
	2.1.3	 	Consents. All necessary consents, approvals and authorizations of all governmental
authorities and other Persons required to be obtained by such Party in connection with this
Agreement have been obtained.
	 
	2.1.4	 	No Conflict. The execution and delivery of this Agreement and the performance of
such Party’s obligations hereunder (a) do not conflict with or violate any requirement of
applicable laws or regulations, and (b) do not conflict with, or constitute a default under,
any contractual obligation of it.

	 	2.2	 	Aptamera Representations and Warranties. Aptamera acknowledges and
agrees that it has been provided a copy of the documents listed in Schedule C.
Aptamera

Portions of this Exhibit were omitted and
have been filed separately with the Secretary of the Commission pursuant to the Company’s
application requesting confidential treatment under Rule 406 of
the Securities Act.

5

 

	 	 	 	represents and warrants that it has read and understands the contents of such
documents.
	 
	 	2.3	 	Warranty Disclaimer. Except as expressly provided in this Section
2, neither party makes any representation or warranty as to the licensed ip rights,
express or implied, either in fact or by operation of law, by statute or otherwise,
including without limitation any implied warranty of merchantability, fitness for a
particular purpose, non-infringement of third party rights, or warranty against
infringement, or otherwise, and each party specifically disclaims any and all implied
or statutory warranties. archemix makes no warranties as to the validity or
enforceability of any licensed ip rights. Without limiting the foregoing, each
Party acknowledges that it has not and is not relying upon any implied warranty of
merchantability, fitness for a particular purpose, non-infringement of third party
rights, or warranty against infringement, or otherwise, or upon any representation or
warranty whatsoever as to the prospects (financial, regulatory or otherwise), or the
validity or likelihood of success, of any products or services based on the Licensed IP
Rights or any Archemix intellectual property after the Effective Date.

	3	 	LICENSE GRANT

	 	3.1	 	Licensed IP Rights. Archemix hereby grants to Aptamera an exclusive,
worldwide license under the Licensed IP Rights for use in the Field.
	 
	 	3.2	 	Sublicense Rights. Aptamera shall have the right to grant sublicenses
under this Agreement in conjunction with any license or grant of rights to the
Products. Aptamera shall give Archemix prompt written notice of each sublicense under
this Agreement. Each sublicense shall be subject to the terms and conditions of this
Agreement.
	 
	 	3.3	 	Negative Covenant of Company. Aptamera shall not use or practice the
Licensed IP Rights (a) outside the Field, (b) for any other purpose except activities
that it conducts in compliance with this Agreement, (c) to make, use, sell, offer for
sale, import or export any products containing any Excluded Aptamers, (d) to make, use,
sell, offer for sale, import or export any Excluded Aptamers, or (e) to make, use,
sell, offer for sale, import or export any Aptamers for In Vitro Diagnostics, as In
Vivo Diagnostic Agents or as Radio Therapeutics.
	 
	 	3.4	 	Grant Back To Archemix. As of the Effective Date, and subject to the
terms and conditions hereof, Aptamera hereby grants back to Archemix, and Archemix
hereby accepts the following worldwide, royalty-free, paid-up, perpetual, irrevocable
and nonexclusive licenses: (a) (i) under the rights licensed to Aptamera under Section
3 hereof, and (ii) under Aptamera’s intellectual property rights to such of the
Aptamera Improvements as constitute improvements to the SELEX Process, in both cases
solely to conduct internal research and (b) under Aptamera’s intellectual property
rights in the Aptamera Improvements to use and practice any

Portions of this Exhibit were omitted and
have been filed separately with the Secretary of the Commission pursuant to the Company’s
application requesting confidential treatment under Rule 406 of
the Securities Act.

6

 

	 	 	 	Aptamera Improvements developed by Aptamera under the licenses granted pursuant to
Section 3 hereof as may be necessary for Archemix to fulfill its obligations,
including, without limitation, sublicensing obligations, to Gilead.

	4	 	ROYALTIES

	 	4.1	 	Royalty Rate. In consideration for the licenses granted to Aptamera
herein, Aptamera shall pay royalties to Archemix equal to (i) [***] percent ([***]%) of
Net Sales of AGRO100 and [***] percent ([***]%) of Net Sales of AGRO100 Derivatives
beginning with the First Commercial Sale by Aptamera or its Affiliates during and to
the extent of the Royalty Term, and (ii) [***] percent ([***]%) of Net Revenue of
AGRO100 and [***] percent ([***]%) of Net Revenue of AGRO100 Derivatives received by
Aptamera or its Affiliates from a Third Party including its sublicensees which are the
result of or directed to sales of Products during and to the extent of the Royalty
Term.
	 
	 	4.2	 	Combination Product. If a Product is sold in a combination product
with other active components, Net Sales, for purposes of royalty payments on the
combination product, shall be calculated by multiplying the Net Sales of that
combination by the fraction A/B, where A is the gross selling price of the Product sold
separately and B is the gross selling price of the combination product. If no such
separate sales are made by Aptamera or its Affiliates, Net Sales for royalty
determination shall be calculated by multiplying Net Sales of the combination by the
fraction C/(C+D), where C is the fully allocated cost of the Product and D is the fully
allocated cost of such other active components.
	 
	 	4.3	 	Third Party Royalties. If Aptamera or its Affiliates is required to
pay royalties to any Third Party in order to exercise its rights hereunder to develop,
make, use, offer for sale, sell or import any Product, then Aptamera shall have the
right to credit [***] percent ([***]%) of such Third Party royalty payments against the
royalties owing to Archemix under Section 4.1 above with respect to Net Sales of such
Product.

	5	 	ROYALTY REPORTS AND ACCOUNTING

	 	5.1	 	Royalty Reports. During the term of this Agreement following the First
Commercial Sale of a Product, Aptamera shall furnish to Archemix a [***] written report
showing in reasonably specific detail the calculation of royalties owing with respect
to the sale of Products by Aptamera and its Affiliates for the reporting period.
During the term of this Agreement, Aptamera shall also furnish to Archemix a quarterly
written report for any quarter in which Aptamera or its Affiliates receives any Net
Revenue showing in reasonably specific detail the

Portions of this Exhibit were omitted and
have been filed separately with the Secretary of the Commission pursuant to the Company’s
application requesting confidential treatment under Rule 406 of
the Securities Act.

7

 

	 	 	 	calculation of any royalty owing with respect to the Net Revenue received by Aptamera
or its Affiliates for the reporting period. With respect to sales of Products
invoiced in United States dollars, all amounts shall be expressed in United States
dollars. With respect to sales of Products invoiced in a currency other than United
States dollars, all amounts shall be expressed in the domestic currency of the party
making the sale together with the United States dollar equivalent. The United States
dollar equivalent shall be calculated using the average of the exchange rate (local
currency per US$1) published in The Wall Street Journal, Eastern Edition, under the
heading “Currency Trading” on the last business day of each month during the
applicable calendar quarter. Reports shall be due on the [***] day following the
close of each [***]. Aptamera shall keep complete and accurate records in sufficient
detail to enable the royalties payable hereunder to be determined.
	 
	 	5.2	 	Audits.

	5.2.1	 	Upon the written request of Archemix and not more than [***] in each [***], Aptamera shall
permit an independent certified public accounting firm of nationally recognized standing
selected by Archemix and reasonably acceptable to Aptamera, at Archemix’ expense, to have
access during normal business hours to such of the records of Aptamera as may be reasonably
necessary to verify the accuracy of the royalty reports for any year ending not more than
[***] months prior to the date of such request. The accounting firm shall disclose to
Archemix only whether or not the reports are correct and the amount of any discrepancies. No
other information shall be shared.

	5.2.2	 	If such accounting firm concludes that additional royalties were owed during such period,
Aptamera shall pay the additional royalties within [***] days of the date Archemix delivers to
Aptamera such accounting firm’s written report so concluding. The fees charged by such
accounting firm shall be paid by Archemix; provided, however, if the audit
correctly discloses that the royalties payable by Aptamera for the audited period are more
than [***] percent ([***]%) of the royalties actually paid for such period, then Aptamera
shall pay the reasonable fees and expenses charged by such accounting firm.

	 	5.3	 	Confidential Financial Information. Archemix shall treat all financial
information subject to review under this Section 5 as confidential, and shall cause its
accounting firm to retain all such financial information in confidence under Section 10
below.

	6	 	PAYMENTS

	 	6.1	 	Payment Terms. Royalties shown to have accrued by each royalty report
provided for under Section 5.1 above shall be due on the date such royalty report is
due. Payment of royalties in whole or in part may be made in advance of such due date.

Portions of this Exhibit were omitted and
have been filed separately with the Secretary of the Commission pursuant to the Company’s
application requesting confidential treatment under Rule 406 of
the Securities Act.

8

 

	 	6.2	 	Exchange Control. If at any time legal restrictions prevent the prompt
remittance of part or all royalties with respect to any country worldwide where the
Product is sold, Aptamera shall have the right, in its sole discretion, to make such
payments by depositing the amount thereof in local currency to Archemix’s account in a
bank or other depository institution in such country. If the royalty rate specified in
this Agreement should exceed the permissible rate established in any country, the
royalty rate for sales in such country shall be adjusted to the highest legally
permissible or government-approved rate.
	 
	 	6.3	 	Withholding Taxes. Aptamera shall be entitled to deduct the amount of
any withholding taxes, value-added taxes or other taxes, levies or charges with respect
to such amounts, payable by Aptamera, its Affiliates or sublicensees, or any taxes
required to be withheld by Aptamera, its Affiliates or sublicensees, to the extent
Aptamera, its Affiliates or sublicensees pay to the appropriate governmental authority
on behalf of Archemix such taxes, levies or charges. Aptamera shall use reasonable
efforts to minimize any such taxes, levies or charges required to be withheld on behalf
of Archemix by Aptamera, its Affiliates or sublicensees. Aptamera promptly shall
deliver to Archemix proof of payment of all such taxes, levies and other charges,
together with copies of all communications from or with such governmental authority
with respect thereto.

	7	 	RESEARCH AND DEVELOPMENT OBLIGATIONS

	 	7.1	 	Research and Development Efforts By Aptamera. Aptamera shall use
commercially reasonable efforts and shall bear all costs it incurs to research, develop
and commercialize such Products as Aptamera determines are commercially feasible, as
described in Schedule B.
	 
	 	7.2	 	Research and Development Efforts By Archemix. Archemix shall use
commercially reasonable efforts to provide assistance in the form of consulting at no
charge to Aptamera on commercial development and manufacture of the Products,
especially AGRO100 Derivatives, as outlined in Schedule B .

	8	 	PROGRESS REPORT AND COMMERCIAL APPLICATION

	 	8.1	 	Progress Report. On or before February 28 and August 30 of each year,
commencing as of August 30, 2003 and ending on August 30 of the calendar year following
the calendar year in which Aptamera, its Affiliates or sublicensees first begins to
market any product or service utilizing the Licensed IP Rights, Aptamera shall provide
a semi-annual progress report to Archemix, each report covering the [***] month period
preceding the due date of the report. Thereafter, Aptamera shall provide such reports
on an annual basis covering the [***] month period

Portions of this Exhibit were omitted and
have been filed separately with the Secretary of the Commission pursuant to the Company’s
application requesting confidential treatment under Rule 406 of
the Securities Act.

9

 

	 	 	 	preceding the due date of the report. Each report shall describe any Aptamera
Improvements, notice of any patents filed by Aptamera in connection with any Aptamera
Improvements and the progress made by Aptamera, its Affiliates or sublicensees toward
the commercial development of any products or services utilizing the Licensed IP
Rights. Such report shall include at a minimum, information reasonably sufficient to
enable Archemix to satisfy its reporting obligations to Gilead under the
Gilead-Archemix License Agreement with respect to this Agreement, including any
reporting obligations of the U.S. Government, and to assess the progress made by
Aptamera toward meeting the diligence requirements of Section 8.2 below.
	 
	 	8.2	 	Commercial Application. Aptamera, either directly or with and through
the efforts of its Affiliates and sublicensees, shall at all times use commercially
reasonable efforts to proceed with the development, manufacture and sale of products
and services utilizing the Licensed IP Rights, including, without limitation,
maintaining sufficient facilities, resources and personnel to fulfill its obligations
under this Agreement. In the event that Aptamera, its Affiliates, assignees and
sublicensees cease reasonable efforts to develop the commercial applications of the
products and services utilizing the Licensed IP Rights for a period of at least [***]
months Archemix will have the option, at its sole discretion, to terminate this
Agreement pursuant to Section 12.2 below. In such event, Archemix may exercise its
option; provided that (a) Archemix delivers advance written notice of its decision to
exercise such option to force a reversion of the technology to Archemix, and (b) for a
period of [***] months following Aptamera’s receipt of such notice, Aptamera, its
Affiliates, and all assignees and sublicensees, shall have the right and opportunity to
cure the alleged cessation of such reasonable commercial development. Aptamera
acknowledges and agrees that under the URC License Agreement and the Gilead-Archemix
License Agreement, Archemix’s rights in the Licensed IP Rights may revert to Gilead or
the UTC if Archemix, its Affiliates and all assignees and sublicensees cease reasonable
efforts to develop the commercial applications of the products and services utilizing
the Licensed IP Rights.

	 	 	Aptamera further acknowledges and agrees that, in the event of any termination of the URC
License Agreement, the sublicenses granted to Aptamera hereunder shall remain in full force
and effect in accordance with Section 3.4 of the URC License Agreement, provided that
Aptamera is not then in breach of this Agreement and agrees to be bound to UTC as a licensor
under the terms and conditions of this Agreement.
	 
	 	 	Aptamera further acknowledges and agrees that, in the event of any termination of the
Gilead-Archemix License Agreement, the sublicenses granted to Aptamera hereunder shall remain
in full force and effect in accordance with Section 2.3 of the Gilead-Archemix License
Agreement provided that Aptamera agrees to be bound to Gilead as a licensor under the terms
and conditions of this Agreement and provided that if the termination of the Gilead-Archemix
License Agreement arises out of the action or inaction of Aptamera, Gilead, at its option, may
terminate such sublicense.

Portions of this Exhibit were omitted and
have been filed separately with the Secretary of the Commission pursuant to the Company’s
application requesting confidential treatment under Rule 406 of
the Securities Act.

10

 

	9	 	ARCHEMIX RIGHT OF FIRST REFUSAL

	 	9.1	 	Marketing Rights. Aptamera shall have the sole and exclusive right to
market the Products worldwide and to enter into such agreements with respect to the
transfer of such marketing rights as it deems appropriate in its sole discretion.
However, if and to the extent that Aptamera intends to commence negotiations with one
or more Third Parties with respect to potential collaborations that may result in a
transfer of U.S. marketing rights with respect to one or more Products (a “Marketing
Agreement”), Aptamera shall give written notice (a “Right of First Refusal Notice”) to
Archemix that shall include a statement of the minimum terms that Aptamera expects that
it will accept for the Marketing Agreement (the “Minimum Terms”).
	 
	 	9.2	 	Good Faith Election and Negotiations. Upon receipt of the Right of
First Refusal Notice, if Archemix determines in good faith, subject to due diligence,
that it would like to enter into a Marketing Agreement with Aptamera upon terms which
are at least as favorable to Aptamera as the Minimum Terms, Archemix shall be entitled
to give written notice to Aptamera that it elects to exercise its right to enter into
negotiations (an “Affirmative Notice”) to enter into a Marketing Agreement upon terms
which are equal to or better than the Minimum Terms. If Archemix does not deliver a
written Affirmative Notice to Aptamera within [***] days of the delivery of the Right
of First Refusal Notice by Aptamera, then Aptamera shall be free to enter into one or
more Marketing Agreements with one or more Third Parties under terms which are equal to
or better than the Minimum Terms within the [***] month period following Aptamera’s
delivery of the Right of First Refusal Notice. If Archemix delivers an Affirmative
Notice to Aptamera within the requisite [***] day time period, then Archemix and
Aptamera shall immediately commence good faith negotiations to enter into a Marketing
Agreement upon terms which are equal to or better than the Minimum Terms. If Aptamera
and Archemix acting in good faith do not enter into a Marketing Agreement on terms
which are equal to or better than the Minimum Terms within [***] days of Aptamera’s
delivery of the Right of First Refusal Notice, then Aptamera shall be free to enter
into one or more Marketing Agreements with one or more Third Parties under terms which
are equal to or better than the Minimum Terms within the [***] month period following
Aptamera’s delivery of the Right of First Refusal Notice.
	 
	 	9.3	 	Additional Notices. In the event that Aptamera fails to enter into a
Marketing Agreement with a Third Party within the time periods described above after it
has given an initial Right of First Refusal Notice, if Aptamera shall subsequently
decide to commence negotiations with one or more Third Parties with respect to a
Marketing Agreement, Aptamera shall be obligated to give Archemix an additional Right
of First Refusal notice as described in Section 9.1 hereof and comply with the
provisions of Section 9.2 hereof with respect to such subsequent Right of First Refusal
Notice. Also, in the event that, after giving an initial Right of First

Portions of this Exhibit were omitted and
have been filed separately with the Secretary of the Commission pursuant to the Company’s
application requesting confidential treatment under Rule 406 of
the Securities Act.

11

 

	 	 	 	Refusal Notice, Aptamera determines that the Minimum Terms should be adjusted to terms
which are not as favorable to Aptamera as the Minimum Terms described in the prior
Right of First Refusal Notice, then, before entering into a Marketing Agreement with a
Third Party on such revised terms, Aptamera shall be obligated to give Archemix an
additional Right of First Refusal notice as described in Section 9.1 hereof and to
comply with the provisions of Section 9.2 hereof with respect to such subsequent Right
of First Refusal Notice.

	10	 	CONFIDENTIALITY AND PUBLICITY

	 	10.1	 	Proprietary Information, Exceptions. Each Party will maintain all
Proprietary Information of the other Party received by it under this Agreement in trust
and confidence and will not disclose any such Proprietary Information of the other
Party to any Third Party or use any such Proprietary Information of the other Party for
any purposes other than those necessary or permitted for performance under this
Agreement without the express prior written permission of the other Party. In
particular, Aptamera shall not use any Licensed Know-How Rights for any purpose other
than those expressly licensed under Section 3 hereof. Each Party may use Proprietary
Information of the other Party only to the extent required to accomplish the purposes
of this Agreement. Neither Party shall use Proprietary Information of the other Party
for any purpose or in any manner that would constitute a violation of any laws or
regulations, including without limitation the export control laws of the United States.
Neither Party shall use Proprietary Information of the other Party in any form except
as required to accomplish the intent of this Agreement. Neither Party shall disclose
Proprietary Information of the other Party to any employee, agent, consultant,
Affiliate, or sublicensee who does not have a need for such information. To the extent
that disclosure is authorized by this Agreement, the disclosing Party will obtain prior
agreement, from its employees, directors, agents, consultants, Affiliates, sublicensees
or clinical investigators to whom disclosure is permitted to be made, to obligations to
hold in confidence and not make use of such Proprietary Information of the other Party
for any purpose other than those permitted by this Agreement, that are at least as
restrictive as those of this Section 10.1. Each Party will use at least the same
standard of care as it uses to protect its own Proprietary Information of a similar
nature to ensure that such employees, agents, consultants and clinical investigators do
not disclose or make any unauthorized use of Proprietary Information of the other
Party, but no less than reasonable care. Each Party will notify the other Party
promptly upon discovery of any unauthorized use or disclosure of the Proprietary
Information of the other Party. For purposes of this Agreement, Proprietary
Information concerning the Licensed IP Rights is deemed to be the Proprietary
Information of both Parties.

	 	 	Proprietary Information shall not include any information that the receiving Party can
demonstrate by competent written evidence:

Portions of this Exhibit were omitted and
have been filed separately with the Secretary of the Commission pursuant to the Company’s
application requesting confidential treatment under Rule 406 of
the Securities Act.

12

 

	 	i.	 	is now, or hereafter becomes, through no act or failure
to act on the part of the receiving Party, its employees or contractors in
breach hereof, generally known or available;
	 
	 	ii.	 	is known by the receiving Party at the time of
receiving such information, as evidenced by its contemporaneous written
records;
	 
	 	iii.	 	is hereafter furnished to the receiving Party by a
Third Party, as a matter of right and without restriction on disclosure; or
	 
	 	iv.	 	is independently developed by the receiving Party
without any breach of this Agreement, as shown by independent,
contemporaneous, written records.

	 	10.2	 	Authorized Disclosure. Notwithstanding any other provision of this
Agreement, each Party may disclose Proprietary Information if such disclosure:

	 	i.	 	is in response to a valid order of a court or other
governmental body of the United States or a foreign country, or any political
subdivision thereof; provided, however, that the receiving Party shall first
have given notice to the other Party hereto to allow the other Party the
opportunity to obtain a protective order, with the reasonable cooperation of
the receiving Party as necessary, requiring that the Proprietary Information
so disclosed be used only for the purposes for which the order was issued;
	 
	 	ii.	 	is otherwise required by governmental law, rule or
regulation, including without limitation rules or regulations of the U.S.
Securities and Exchange Commission, or by rules of the National Association
of Securities Dealers; provided, however, that the receiving Party shall
first have given notice to the other Party hereto in order to allow such
Party the opportunity to seek confidential treatment of the Proprietary
Information; or
	 
	 	iii.	 	is otherwise necessary to prosecute or defend litigation or
comply with applicable governmental regulations or otherwise enforce
obligations under this Agreement, but only to the extent that any such
disclosure is necessary for such enforcement.

	 	10.3	 	Return of Proprietary Information. In the event that the license
granted to Aptamera pursuant to Section 3 hereof terminates or expires, Aptamera shall,
at Archemix’s election, promptly return or destroy all Proprietary Information received
by it from Archemix and shall certify in writing to Archemix the completion thereof.
	 
	 	10.4	 	Publicity. Aptamera shall make no public announcement of this
Agreement or the relationship between the Parties or Interested Parties without
Archemix’s prior

Portions of this Exhibit were omitted and
have been filed separately with the Secretary of the Commission pursuant to the Company’s
application requesting confidential treatment under Rule 406 of
the Securities Act.

13

 

	 	 	 	written consent. The Parties intend to issue a mutually agreed upon press release
within thirty (30) days after the Effective Date.

	11	 	PATENTS

	 	11.1	 	Prosecution and Maintenance. Archemix shall be solely responsible for
and shall control, at its sole cost, the preparation, filing, prosecution and
maintenance of the Licensed Patent Rights.
	 
	 	11.2	 	Ownership of Inventions Developed Under This Agreement. Any invention
arising, developed, invented, or discovered during the course of development of the
Products solely by an employee or by employees of a single Party shall be owned by the
Party whose employees made such invention; provided, however, that to the extent that
such invention is owned by Archemix but is useful with respect to the Products such
invention shall be deemed to be licensed under this Agreement as Licensed IP Rights.
Any invention arising, developed, invented, or discovered during the course of
development of the Products which is jointly made by employees of both Aptamera and
Archemix shall be jointed owned by both companies; provided, however, that to the
extent that such jointly owned invention is useful with respect to the Products, such
invention shall be deemed to be licensed to Aptamera under this Agreement as Licensed
IP Rights. Aptamera and Archemix shall each perform all such acts as shall be
reasonably requested by the other in order to pursue such patent and other intellectual
property protection for the inventions described above as the owner of such invention
(as determined above) shall deem appropriate.
	 
	 	11.3	 	Enforcement.

	11.3.1	 	Notice. Each Party shall promptly notify the other in writing its knowledge of any
actual or potential infringement or misappropriation of any Licensed IP Rights by Third
Parties within the Territory and provide any information available to that Party relating to
such actual or potential infringement or misappropriation. Aptamera shall have no rights with
respect to any infringement or misappropriation of Licensed IP Rights that occurs outside of
the Field except the right to receive notice pursuant to this Section 11.3.1; provided
however, that, to the extent within the control of Archemix, Archemix shall not enter into any
settlement, consent judgment or other voluntary final disposition with respect to any such
infringement or misappropriation if it would have a material adverse effect on any Licensed IP
Rights within the Field without the prior consent of Aptamera, which consent shall not be
unreasonably withheld.
	 
	11.3.2	 	Enforcement of Licensed Patent Rights. With respect to any infringement of Licensed
Patent Rights within the Field or with respect to any Products within the Field, Aptamera
shall have the primary right, but not the obligation, to initiate, prosecute and control any
action with respect to such infringement, by counsel of its own choice, to secure the

Portions of this Exhibit were omitted and
have been filed separately with the Secretary of the Commission pursuant to the Company’s
application requesting confidential treatment under Rule 406 of
the Securities Act.

14

 

	 	 	cessation of the infringement or to enter suit against the
infringer. Archemix and/or Gilead shall have the right to
participate in any such action and to be represented by
counsel of its own choice and at its own expense. If
Aptamera fails to exercise its right to bring an action or
proceeding to so enforce a Licensed Patent Right within a
period of [***] days after receipt of written notice of
infringement of such Licensed Patent Right, then Archemix
shall have the right to bring and control any such action by
counsel of its own choice and at its own expense. If both
Aptamera and Archemix fail to exercise its right to bring an
action or proceeding to so enforce a Licensed Patent Right
within a period of [***] days after receipt of written
notice of infringement of such Licensed Patent Right, then
Gilead shall have the right to bring and control any such
action by counsel of its own choice and at its own expense.
In such an event, Gilead shall have the right to extend the
right to participate in and control, as applicable, any such
action to its Affiliates and sublicensees, as Gilead in its
sole discretion deems necessary to satisfy its obligations
to such other sublicensees of the Licensed Patent Rights.
If any such action or proceeding is brought by an Interested
Party hereunder, the other Interested Parties agree to be
joined as necessary as party plaintiffs and to give the
Interested Party bringing suit reasonable assistance and
authority to control, file and prosecute the suit as
necessary, at the sole expense of the Interested Party
bringing suit. The costs and expenses of the Interested
Party bringing suit under this Section 11.3.2 (including the
internal costs and expenses specifically attributable to
such suit) shall be reimbursed first out of any damages or
other monetary awards recovered in favor of the Interested
Parties, and any remaining damages shall be paid to the
Interested Party that controlled such action. No settlement
or consent judgment or other voluntary final disposition of
a suit under this Section 11.3.2 relating to a Licensed
Patent Right may be entered into without the consent of the
Interested Parties not controlling such action, such consent
not to be unreasonably withheld, delayed or conditioned.

	 	11.4	 	Infringement of Third Party Rights.

	 	11.4.1	 	Notice of Claim. If the practice of the Licensed IP Rights by Aptamera, its
Affiliates or sublicensees, in accordance with the licenses granted under Section 3 hereof,
results in a claim of patent infringement against Aptamera, its Affiliates or sublicensees,
the Party to this Agreement first having notice of that claim shall promptly notify the other
Party and Gilead in writing. The notice shall set forth the facts of the claim in reasonable
detail.
	 
	 	11.4.2	 	Resolution of Claims. If a Third Party asserts that a patent or other right owned
by or licensed to it is infringed within a country by the practice of the Licensed IP Rights
by Aptamera, its Affiliates or sublicensees, in accordance with the licenses granted under
Section 3 hereof, Aptamera may attempt to resolve the asserted infringement; provided, however
that Archemix and/or Gilead shall have the right, at its sole discretion, to participate in
any such resolution and to be represented by counsel of its own choice and at its own expense.
Aptamera shall control the process to resolve any such infringement. The matter shall be
deemed resolved if Aptamera obtains: (i) a license permitting Aptamera to manufacture, use,
import, offer for sale and sell Products in that country on a royalty-free basis (ii) a
legally binding statement or representation from the Third Party

Portions of this Exhibit were omitted and
have been filed separately with the Secretary of the Commission pursuant to the Company’s
application requesting confidential treatment under Rule 406 of the Securities Act.

15

 

	 	 	that: (A) no action will be taken against Aptamera, its Affiliates or its sublicensees, or
(B) that the patent or other right is not infringed by the practice of the Licensed IP
Rights by Aptamera, its Affiliates or its sublicensees in such country; or (iii) a final
judgment by a court of competent jurisdiction from which no appeal has or can be taken that
the Third Party’s patent(s) alleged to be infringed is invalid, or the Third Party’s
patent(s) or other right(s) are unenforceable or not infringed by the practice of the
Licensed IP Rights by Aptamera, its Affiliates or sublicensees. Aptamera shall have the
primary right to defend any such claim. Archemix and/or Gilead shall have the right, but
not the obligation, to participate in any such suit at its sole option and at its own
expense. Each Interested Party shall reasonably cooperate with the Interested Parties
conducting the defense of the claim. The Interested Party conducting the defense shall not
enter into any settlement that affects the other Interested Parties’ rights or interests
without such other Interested Parties’ prior written consent, not to be unreasonably
withheld, delayed or conditioned.

	12	 	TERMINATION

	 	12.1	 	Expiration. Subject to the provisions of Sections 12.2 and 12.3 below,
this Agreement shall expire on the expiration of Aptamera’s obligation to pay royalties
to Archemix under Section 4.1 above.
	 
	 	12.2	 	Termination for Cause. A Party may terminate this Agreement upon or
after the material breach of this Agreement by the other Party if the other Party has
not cured such material breach within [***] days after written notice thereof by the
non-breaching Party; provided, however, if any material breach is not capable of being
cured within such [***] day period and the other Party is diligently undertaking to
cure such material breach as soon as commercially feasible thereafter under the
circumstances, the non-breaching Party shall have no right to terminate this Agreement.
	 
	 	12.3	 	Effect of Expiration or Termination. Upon expiration of this Agreement
under Section 12.1, Aptamera shall have a paid up, exclusive, worldwide license under
the Licensed Know-How Rights for use in the Field. Expiration or termination of this
Agreement shall not relieve the Parties of any obligation accruing prior to or upon
such expiration or termination, and the provisions of Sections 10, 11 and 13 shall
survive the expiration or termination of this Agreement.
	 
	 	12.4	 	Rights Upon Termination. In the event of termination of this Agreement
under Section 12.2 the license granted by Archemix to Aptamera shall immediately
terminate.

Portions of this Exhibit were omitted and
have been filed separately with the Secretary of the Commission pursuant to the Company’s
application requesting confidential treatment under Rule 406 of the Securities Act.

16

 

	13	 	INDEMNIFICATION

	 	13.1	 	Indemnification. Aptamera shall indemnify, defend and hold harmless
Gilead, its Affiliates and UTC and any of their respective directors, officers,
employees and agents (each, a “Gilead Indemnitee”), and Archemix, and its respective
directors, officers, employees and agents (each, a “Archemix Indemnitee”) from and
against any Damages that are incurred by a Gilead Indemnitee or Archemix Indemnitee as
a result of Third Party claims, demands, actions or proceedings (collectively, the
“Claims”) to the extent such Claims arise out of:

	 	i.	 	the breach or alleged breach of any representation or
warranty by Aptamera hereunder;
	 
	 	ii.	 	failure to perform duly and punctually any of Aptamera’s
covenants or undertakings under this Agreement, including, without limitation
Aptamera’s covenants in Section 2 hereof;
	 
	 	iii.	 	the possession, research, development, manufacture, use,
offer for sale, sale or other commercialization, distribution,
administration, storage or transport, by Aptamera or its Affiliates or
sublicensees of (A) any Aptamers or Products or (B) any other products,
services and activities developed by Aptamera relating to the Licensed IP
Rights, including any Products or Aptamers; and
	 
	 	iv.	 	manufacture, use, sale or promotion of the Products.

	 	13.2	 	Procedure. Archemix promptly shall notify Aptamera of any claim,
demand, action or other proceeding for which Archemix intends to claim indemnification.
Aptamera shall have the right to participate in, and to the extent Archemix so desires
jointly with any other indemnitor similarly noticed, to assume the defense thereof with
counsel selected by Aptamera; provided, however, that Archemix shall have the right to
retain its own counsel, with the fees and expenses to be paid by Archemix. The
indemnity obligations under this Section 13 shall not apply to amounts paid in
settlement of any claim, demand, action or other proceeding if such settlement is
effected without the prior express written consent of Aptamera, which consent shall not
be unreasonably withheld or delayed. The failure to deliver notice to Aptamera within
a reasonable time after notice of any such claim or demand, or the commencement of any
such action or other proceeding, if prejudicial to its ability to defend such claim,
demand, action or other proceeding, shall relieve such Indemnitor of any liability to
Archemix under this Section 13 with respect thereto, but the omission so to deliver
notice to Aptamera shall not relieve it of any liability that it may have to Archemix
other than under this Section 13. Aptamera may not settle or otherwise consent to an
adverse judgment in any such claim, demand, action or other proceeding, that diminishes
the rights or interests of Archemix without the prior express written consent of
Archemix, which consent shall not be unreasonably withheld or delayed. Archemix, its
employees and agents, shall reasonably cooperate with Aptamera and its legal
representatives

Portions of this Exhibit were omitted and
have been filed separately with the Secretary of the Commission pursuant to the Company’s
application requesting confidential treatment under Rule 406 of the Securities Act.

17

 

	 	 	 	in the investigation of any claim, demand, action or other proceeding covered by this
Section 13.
	 
	 	13.3	 	Insurance. Aptamera shall maintain insurance with respect to the
research, development and commercialization of Products by Aptamera in such amount as
Aptamera customarily maintains with respect to the research, development and
commercialization of its similar products. Aptamera shall maintain such insurance for
so long as it continues to research, develop or commercialize any Products, and
thereafter for so long as Aptamera customarily maintains insurance covering the
research, development or commercialization of its similar products.

	14	 	MISCELLANEOUS

	 	14.1	 	Notices. Any consent, notice or report required or permitted to be
given or made under this Agreement by one of the Parties to the other shall be in
writing and addressed to such other Party at its address indicated below, or to such
other address as the addressee shall have last furnished in writing to the addressor,
and shall be effective upon receipt by the addressee.

	 	 	 	 	 
	 

	 	If to Archemix:
	 	1 Hampshire St
	 

	 	 	 	Cambridge, MA 02139
	 

	 	 	 	Attention: EVP, Corporate Development
	 
	 	 	 	 
	 

	 	If to Aptamera:
	 	640 S. Fourth Street, Suite 400
	 

	 	 	 	Louisville, KY 40202
	 

	 	 	 	Attention: Chief Executive Officer

	 	14.2	 	Assignment. Except as otherwise expressly provided under this
Agreement neither this Agreement nor any right or obligation hereunder may be assigned
or otherwise transferred (whether voluntarily, by operation of law or otherwise),
without the prior express written consent of the other Party; provided, however, that
either Party may, without such consent, assign this Agreement and its rights and
obligations hereunder in connection with the transfer or sale of all or substantially
all of its business, or in the event of its merger, consolidation, change in control or
similar transaction or in the case of Aptamera in connection with any sale or transfer
of rights to any of the Products. Any permitted assignee shall assume all obligations
of its assignor under this Agreement. Any purported assignment or transfer in
violation of this Section 14.2 shall be void.
	 
	 	14.3	 	Applicable Law. This Agreement shall be governed by and construed in
accordance with the laws of the State of Delaware, without regard to the conflicts of
law principles thereof.

Portions of this Exhibit were omitted and
have been filed separately with the Secretary of the Commission pursuant to the Company’s
application requesting confidential treatment under Rule 406 of the Securities Act.

18

 

	 	14.4	 	Entire Agreement. This Agreement contains the entire understanding of
the Parties with respect to the subject matter hereof. All express or implied
representations, agreements and understandings, either oral or written, heretofore made
are expressly superseded by this Agreement.
	 
	 	14.5	 	Independent Contractors. Each Party hereby acknowledges that the
Parties shall be independent contractors and that the relationship between the parties
shall not constitute a partnership, joint venture or agency. Neither Party shall have
the authority to make any statements, representations or commitments of any kind, or to
take any action, which shall be binding on the other Party, without the prior consent
of the other Party to do so.
	 
	 	14.6	 	Waiver. The waiver by a Party of any right hereunder, or of any
failure to perform or breach by the other Party hereunder, shall not be deemed a waiver
of any other right hereunder or of any other breach or failure by the other party
hereunder whether of a similar nature or otherwise.
	 
	 	14.7	 	Force Majeure. Neither Party shall be held liable or responsible to the
other Party nor be deemed to have defaulted under or breached this Agreement for
failure or delay in fulfilling or performing any term of this Agreement to the extent,
and for so long as, such failure or delay is caused by or results from causes beyond
the reasonable control of the affected Party including but not limited to fire, floods,
embargoes, war, acts of war (whether war be declared or not), insurrections, riots,
civil commotions, strikes, lockouts or other labor disturbances, acts of God or acts,
omissions or delays in acting by any governmental authority or the other Party.
	 
	 	14.8	 	Counterparts. This Agreement may be executed in two or more
counterparts, each of which shall be deemed an original, but all of which together
shall constitute one and the same instrument.

         IN WITNESS WHEREOF, the Parties have executed this Agreement as of the Effective Date.

	 	 	 	 	 	 	 
	 	 	Archemix Corp.	 	 
	 
	 	 	 	 	 	 
	 

	 	By	 	/s/ Martin Stanton	 	 
	 

	 	 	 	 	 	 
	 
	 

	 	Title	 	EVP, Corporate Development 	 	 
	 

	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 	 	Aptamera Inc.	 	 
	 
	 	 	 	 	 	 
	 

	 	By	 	/s/ Terry Mintor 	 	 
	 

	 	 	 	 	 	 
	 
	 

	 	Title	 	President and CFO 	 	 
	 

	 	 	 	 	 	 

Portions of this Exhibit were omitted and
have been filed separately with the Secretary of the Commission pursuant to the Company’s
application requesting confidential treatment under Rule 406 of the Securities Act.

19

 

Schedule A. Archemix Patents and Patent Applications 

	 	 	 	 	 	 	 	 	 	 	 
	MATTER NO	 	CTRY	 	SERIALNO	 	PATENTNO	 	TITLE	 	STATUS
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]

Portions of this Exhibit were omitted and
have been filed separately with the Secretary of the Commission pursuant to the Company’s
application requesting confidential treatment under Rule 406 of the Securities Act.

20

 

	 	 	 	 	 	 	 	 	 	 	 
	MATTER NO	 	CTRY	 	SERIALNO	 	PATENTNO	 	TITLE	 	STATUS
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]

Portions of this Exhibit were omitted and
have been filed separately with the Secretary of the Commission pursuant to the Company’s
application requesting confidential treatment under Rule 406 of the Securities Act.

21

 

	 	 	 	 	 	 	 	 	 	 	 
	MATTER NO	 	CTRY	 	SERIALNO	 	PATENTNO	 	TITLE	 	STATUS
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]

Portions of this Exhibit were omitted and
have been filed separately with the Secretary of the Commission pursuant to the Company’s
application requesting confidential treatment under Rule 406 of the Securities Act.

22

 

	 	 	 	 	 	 	 	 	 	 	 
	MATTER NO	 	CTRY	 	SERIALNO	 	PATENTNO	 	TITLE	 	STATUS
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]

Portions of this Exhibit were omitted and
have been filed separately with the Secretary of the Commission pursuant to the Company’s
application requesting confidential treatment under Rule 406 of the Securities Act.

23

 

	 	 	 	 	 	 	 	 	 	 	 
	MATTER NO	 	CTRY	 	SERIALNO	 	PATENTNO	 	TITLE	 	STATUS
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]

Portions of this Exhibit were omitted and
have been filed separately with the Secretary of the Commission pursuant to the Company’s
application requesting confidential treatment under Rule 406 of the Securities Act.

24

 

	 	 	 	 	 	 	 	 	 	 	 
	MATTER NO	 	CTRY	 	SERIALNO	 	PATENTNO	 	TITLE	 	STATUS
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]

Portions of this Exhibit were omitted and
have been filed separately with the Secretary of the Commission pursuant to the Company’s
application requesting confidential treatment under Rule 406 of the Securities Act.

25

 

	 	 	 	 	 	 	 	 	 	 	 
	MATTER NO	 	CTRY	 	SERIALNO	 	PATENTNO	 	TITLE	 	STATUS
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]

Portions of this Exhibit were omitted and
have been filed separately with the Secretary of the Commission pursuant to the Company’s
application requesting confidential treatment under Rule 406 of the Securities Act.

26

 

	 	 	 	 	 	 	 	 	 	 	 
	MATTER NO	 	CTRY	 	SERIALNO	 	PATENTNO	 	TITLE	 	STATUS
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]

Portions of this Exhibit were omitted and
have been filed separately with the Secretary of the Commission pursuant to the Company’s
application requesting confidential treatment under Rule 406 of the Securities Act.

27

 

	 	 	 	 	 	 	 	 	 	 	 
	MATTER NO	 	CTRY	 	SERIALNO	 	PATENTNO	 	TITLE	 	STATUS
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]

Portions of this Exhibit were omitted and
have been filed separately with the Secretary of the Commission pursuant to the Company’s
application requesting confidential treatment under Rule 406 of the Securities Act.

28

 

	 	 	 	 	 	 	 	 	 	 	 
	MATTER NO	 	CTRY	 	SERIALNO	 	PATENTNO	 	TITLE	 	STATUS
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]

Portions of this Exhibit were omitted and
have been filed separately with the Secretary of the Commission pursuant to the Company’s
application requesting confidential treatment under Rule 406 of the Securities Act.

29

 

	 	 	 	 	 	 	 	 	 	 	 
	MATTER NO	 	CTRY	 	SERIALNO	 	PATENTNO	 	TITLE	 	STATUS
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]

Portions of this Exhibit were omitted and
have been filed separately with the Secretary of the Commission pursuant to the Company’s
application requesting confidential treatment under Rule 406 of the Securities Act.

30

 

	 	 	 	 	 	 	 	 	 	 	 
	MATTER NO	 	CTRY	 	SERIALNO	 	PATENTNO	 	TITLE	 	STATUS
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]

Portions of this Exhibit were omitted and
have been filed separately with the Secretary of the Commission pursuant to the Company’s
application requesting confidential treatment under Rule 406 of the Securities Act.

31

 

	 	 	 	 	 	 	 	 	 	 	 
	MATTER NO	 	CTRY	 	SERIALNO	 	PATENTNO	 	TITLE	 	STATUS
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]

Portions of this Exhibit were omitted and
have been filed separately with the Secretary of the Commission pursuant to the Company’s
application requesting confidential treatment under Rule 406 of the Securities Act.

32

 

	 	 	 	 	 	 	 	 	 	 	 
	MATTER NO	 	CTRY	 	SERIALNO	 	PATENTNO	 	TITLE	 	STATUS
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]

Portions of this Exhibit were omitted and
have been filed separately with the Secretary of the Commission pursuant to the Company’s
application requesting confidential treatment under Rule 406 of the Securities Act.

33

 

Schedule B. Work Plan for AGRO100 and AGRO100 Derivatives

     Technology Development

          a. Regarding AGRO100

	 	i.	 	Aptamera [***] and [***], and will be [***] for
[***].
	 
	 	ii.	 	Further development work on AGRO100 will primarily
involve:

	 	1.	 	[***] and [***]

	 
	 	2.	 	[***] that will [***] the [***] for [***]
	 
	 	3.	 	[***] of [***] from [***] and [***] of
[***] and [***].

	 	iii.	 	The parties [***] an [***] AGRO100 [***] within
[***] in which Archemix will [***] Aptamera that is [***] Aptamera [***]
AGRO100 [***]. Further [***] of the [***] will [***] AGRO100 [***] as
[***] as is [***].

          b. Regarding AGRO100 Derivatives

	 	i.	 	[***] an [***] to be [***] Archemix [***] will
[***] the [***] of [***], and [***] for the AGRO100 Derivatives [***].
	 
	 	ii.	 	[***], it is [***] Archemix will [***] at no [***]
Aptamera:

	 	1.	 	[***] in an [***] or [***] AGRO100
Derivatives and the [***] AGRO100 Derivatives [***] AGRO100 [***]
Aptamera
	 
	 	2.	 	[***] and [***] in an [***] or [***]
	 
	 	3.	 	[***] and [***] and [***] or [***] as it
[***] to its [***] in [***] and [***] when not [***] with [***] with
[***]
	 
	 	4.	 	[***] the [***] of [***] and [***] to
[***]

	 	c.	 	Aptamera will [***] AGRO100 and AGRO100 Derivatives. [***], through
[***], the [***] that the [***] of certain [***], and [***] to [***] the [***]
AGRO100 and AGRO100 Derivatives may be [***] Archemix [***] Aptamera at [***].
Aptamera [***] for [***] and [***] AGRO100 and AGRO100 Derivatives.

Portions of this Exhibit were omitted and
have been filed separately with the Secretary of the Commission pursuant to the Company’s
application requesting confidential treatment under Rule 406 of the Securities Act.

34

 

Schedule C. List of [***]

MISCELLANEOUS [***] I

[***]

[***]

[***]

[***]

      [***]

[***]

US Patent No. [***] — available on the Patents Referenced in Misc. [***] CDROM

[***]

Reexamination Certificate – US Patent No. [***] (dated April 7, 1998)

US Patent No. [***] (dated August 11, 1998)

US Patent No. [***] (dated November 14, 1995)

US Patent No. [***] (dated November 11, 1997)

US Patent No. [***] (dated February 8, 2000)

[***]

US Patent No. [***] — available on the Patents Referenced in Misc. [***] CDROM

[***]

[***];

            [***]

[***];

            [***]

[***]   [***]

[***]

            [***]

[***]

[***]

            [***]

US Patents [***]; [***] [***] and [***] are available on the

      Patents Referenced in Misc. [***] CDROM

[***]

[***]

US Patents [***]; [***]; [***]; [***] and [***] are available on the

Portions of this Exhibit were omitted and
have been filed separately with the Secretary of the Commission pursuant to the Company’s
application requesting confidential treatment under Rule 406 of the Securities Act.

35

 

      Patents Referenced in Misc. [***] CDROM

[***]

[***]

[***]

[***]

            [***]

[***]

            [***]

[***]

European Patent No. [***] in both German and English

      (Application dated September 14, 1993)

[***]

WO [***] (EP Patent Application No. [***]) is available on the Patents Referenced

      in Misc. [***] CDROM

[***]

[***]

[***]

[***].

[***].

MISCELLANEOUS [***] 2

[***]

Third New Divisional Application

[***]

[***]

January 22, 2001

March 27, 2000

January 26, 2000

March 9, 1999

January 19, 1999

February 18, 1998

Portions of this Exhibit were omitted and
have been filed separately with the Secretary of the Commission pursuant to the Company’s
application requesting confidential treatment under Rule 406 of the Securities Act.

36

 

October 2, 1997

September 12, 1997

July 28, 1997

July 17, 1997

February 19, 1997

February 9, 1996

February 8, 1996

January 26, 1996

[***]

[***]

[***]

List of 6 pages

Portions of this Exhibit were omitted
and have been filed separately with the Secretary of the Commission pursuant to the Company’s
application requesting confidential treatment under Rule 406 of the Securities Act.

37exv10w44

Exhibit 10.44

 

RESEARCH AND LICENSE AGREEMENT

BETWEEN

EYETECH PHARMACEUTICALS, INC.

AND

ARCHEMIX CORP.

Dated
April 8, 2004

 

Confidential

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.

 

 

	 	 	 	 	 
	ARTICLE 1 DEFINITIONS
	 	 	2	 
	ARTICLE 2 RESEARCH PROGRAM
	 	 	21	 
	ARTICLE 3 LICENSE OPTION
	 	 	28	 
	ARTICLE 4 LICENSES; DEVELOPMENT AND COMMERCIALIZATION
	 	 	35	 
	ARTICLE 5 PAYMENTS
	 	 	49	 
	ARTICLE 6 CONFIDENTIALITY
	 	 	58	 
	ARTICLE 7 INDEMNIFICATION
	 	 	60	 
	ARTICLE 8 INTELLECTUAL PROPERTY OWNERSHIP, PROTECTION AND RELATED MATTERS
	 	 	64	 
	ARTICLE 9 TERM AND TERMINATION
	 	 	75	 
	ARTICLE 10 REPRESENTATIONS AND WARRANTIES
	 	 	80	 
	ARTICLE 11 MISCELLANEOUS PROVISIONS
	 	 	82	 

Confidential

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.

i

 

RESEARCH AND LICENSE AGREEMENT

     This Research and License Agreement (the “Agreement”) is made and entered into as of this 8th
day of April 2004 (the “Effective Date”) between Archemix Corp., a Delaware corporation with
offices at One Hampshire Street, Cambridge, MA 02139 (“ARCHEMIX”), and Eyetech Pharmaceuticals,
Inc., a Delaware corporation with offices at 500 Seventh Avenue, 18th Floor, New York,
New York 10018 (“EYETECH”).

WITNESSETH:

     WHEREAS, ARCHEMIX has developed expertise to undertake the identification and optimization of
Aptamers using the SELEX Process and owns or holds licenses covering the use of Aptamers other than
the Aptamer known as NX1838 for treating, preventing or delaying human diseases or conditions;

     WHEREAS, EYETECH is engaged in the research and development of pharmaceutical compounds that
are safe and effective in treating, preventing or delaying the progress of ophthalmologic diseases
and conditions;

     WHEREAS, both Parties desire to enter into a research program the objective of which will be
for ARCHEMIX to identify and optimize Aptamers against Targets that fulfil certain criteria in
order to be developed and marketed by EYETECH for the prevention and treatment of ophthalmologic
diseases or conditions;

     WHEREAS, ARCHEMIX would like to license to EYETECH Aptamers so identified by ARCHEMIX, and to
provide EYETECH with samples of such Aptamers, and EYETECH would like to accept and receive such
licenses and samples for purposes of pre-clinical and clinical testing and (if appropriate)
commercial use, all under the terms and conditions of this Agreement.

     WHEREAS, EYETECH desires the right to obtain licenses to Aptamers so identified by ARCHEMIX.

Confidential

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.

1

 

     WHEREAS, the Parties each are parties to agreements with Gilead under which they have certain
rights or are subject to certain restrictions concerning Aptamers against VEGF and wish to
individually negotiate, or jointly if mutually agreed upon, certain changes in such agreements with
Gilead with respect to VEGF and to grant each other certain licenses with respect to Aptamers
against VEGF, all under the terms and conditions of this Agreement.

     NOW THEREFORE, in consideration of the mutual covenants set forth in this Agreement, the
Parties agree as follows:

ARTICLE 1 DEFINITIONS

     For the purpose of this Agreement, the following terms, whether used in singular or plural
form, shall have the respective meanings set forth below:

          1.1 “Affiliate”. Affiliate shall mean, with respect to any Person, any other Person,
which directly or indirectly, by itself or through one or more intermediaries, controls, or is
controlled by, or is under direct or indirect common control with, such Person. As used in this
Section 1.1 only, the term “control” means the possession, direct or indirect, of the power to
direct or cause the direction of the management and policies of a Person, whether through the
ownership of voting securities, by contract or otherwise. Control will be presumed if one Person
owns, either of record or beneficially, more than 50% of the voting stock or other equity interest
of any other Person.

          1.2  “Annual Research Plan”. Annual Research Plan shall mean the research and
development plan for the Research Program to be developed and approved by the JRC for each Contract
Year.

          1.3 “Aptamer”. Aptamer shall mean an oligonucleotide identified through the SELEX
Process.

          1.4 “Aptamer Equivalent”. Aptamer Equivalent shall mean any structural variations,
modifications, derivatives, homologs, analogs, or mimetics of an Aptamer having a different
chemical composition than the original Aptamer, including without limitation changes in the

Confidential

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.

2

 

base sequence composition or backbone and conjugations that affect pharmacokinetics. The
Parties acknowledge that the required difference in chemical composition for an Aptamer to become
an Aptamer Equivalent is intended to avoid a finding by the FDA or other Regulatory Authority that
an Aptamer and its Aptamer Equivalent constitute the same drug for regulatory purposes. Each Party
shall consider such intention at the time it commences activities to develop or commercialize an
Aptamer Equivalent to an Aptamer being developed or commercialized by the other Party. If a Party
in good faith determines that an Aptamer is an Aptamer Equivalent with respect to the original
Aptamer, then such Aptamer shall constitute an Aptamer Equivalent with respect to the original
Aptamer even if the FDA or other Regulatory Authority subsequently finds that such Aptamer
Equivalent and the original Aptamer constitute the same drug for regulatory purposes; provided that
the Aptamer Equivalent meets the criteria set forth in the first sentence of this Section with
respect to the original Aptamer.

          1.5 “ARCHEMIX Additional Compound”. ARCHEMIX Additional Compound shall have the
meaning set forth in Section 3.2.

          1.6 “ARCHEMIX Early Decision Initial Compound”. ARCHEMIX Early Decision Initial
Compound shall have the meaning set forth in Section 3.2.

          1.7  “ARCHEMIX Initial Compound”. ARCHEMIX Initial Compound shall have the meaning
set forth in Section 3.2.

          1.8 “ARCHEMIX Know-How”. ARCHEMIX Know-How shall mean all Know-How Controlled by
ARCHEMIX, whether disclosed in a pending patent application or not, as of the Effective Date or
during the Research Term relating to a Compound or the use thereof, ARCHEMIX Proprietary Targets
or the use thereof or the SELEX Process, excluding ARCHEMIX Program Technology and ARCHEMIX’s
interest in Joint Program Technology.

          1.9 “ARCHEMIX Patents”. ARCHEMIX Patents shall mean any Patents Controlled by
ARCHEMIX as of the Effective Date or during the Collaboration Term, claiming a Compound or the use
thereof, ARCHEMIX Proprietary Targets, or the SELEX Process, excluding ARCHEMIX Program Patents and
ARCHEMIX’s interest in Joint Program Patents.

Confidential

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.

3

 

Provided, however, that ARCHEMIX Patents shall not include Patents claiming ARCHEMIX
Proprietary Targets discovered, reduced to practise or obtained after the Research Term.

          1.10 “ARCHEMIX Program Patents”. ARCHEMIX Program Patents shall mean Patents claiming
ARCHEMIX Program Technology.

          1.11 “ARCHEMIX Program Technology”. ARCHEMIX Program Technology shall mean all
Program Technology other than formulations and methods of use relating (A) solely to ARCHEMIX
Technology or ARCHEMIX Proprietary Targets; or (B) solely to Aptamers, Aptamer Equivalents, or the
SELEX Process.

          1.12 “ARCHEMIX Proprietary Target”. ARCHEMIX Proprietary Target shall mean a Target
the use of which to select an Aptamer, or the use of which as a target for therapeutic and
preventive intervention, is covered by an ARCHEMIX Valid Claim or pending patent application.

          1.13 “ARCHEMIX Technology”. ARCHEMIX Technology shall mean all ARCHEMIX Patents and
ARCHEMIX Know-How.

          1.14 “ARCHEMIX Valid Claim”. ARCHEMIX Valid Claim shall mean a claim of an issued and
unexpired ARCHEMIX Patent, ARCHEMIX Program Patent or Joint Program Patent, which has not been
revoked or held permanently unenforceable or invalid by a decision of a court or other governmental
agency of competent jurisdiction, which decision is unappealable or unappealed within the time
allowed for appeal, and which has not been admitted to be invalid or unenforceable through re-issue
or disclaimer or otherwise.

          1.15 “Back-Up”. Back-Up shall have the meaning set forth in Section 3.5.1 hereof.

          1.16 “Bankruptcy Code”. Bankruptcy Code shall have the meaning set forth in Section
4.9.1.

          1.17  “Collaboration Term”. Collaboration Term shall mean the Term of this Agreement
that commences on the Effective Date and continues until the end of the Royalty Term as defined in
Section 9.2.

Confidential

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.

4

 

          1.18 “Collaborator”. Collaborator shall mean any third party who has been granted a
sublicense by ARCHEMIX under Section 4.3.2 of this Agreement for the development and/or
commercialization of Refused Candidates and Aptamer Equivalents of Compounds outside the Field and
Aptamers against VEGF outside the Field and the Local Delivery Field.

          1.19  “Commercialization” or “Commercialize”. Commercialization or Commercialize
shall mean any and all activities directed to commercial scale manufacturing (including assays
and validation, testing development and manufacturing scale-up), marketing, promoting,
distributing, importing and selling a product.

          1.20 “Compound”. Compound shall mean any ARCHEMIX Initial Compound, Program Compound,
ARCHEMIX Additional Compound or Back-Up, it being understood that all the aforementioned categories
of Compounds can include compounds against VEGF, so long as the Parties obtain any necessary rights
covering VEGF from Gilead, unless and until it becomes a Refused Candidate pursuant to Section 3.7,
4.5, or 4.8.1 hereof.

          1.21 “Compound Candidate”. Compound Candidate shall mean a Program Compound that (A)
fulfils the Early Selection Criteria for such Program Compound with respect to a Target or (B)
which is selected by EYETECH, through written notice to ARCHEMIX, to be a Compound Candidate
pursuant to Section 3.4.

          1.22 “Compound Product”. Compound Product shall mean a finished form of product that
comprises, contains or is a Compound and which (i) the manufacture, use or sale of which would
infringe any ARCHEMIX Valid Claim; and/or (ii) embodies ARCHEMIX Know How or ARCHEMIX Program
Technology.

          1.23 “Confidential Information”. Confidential Information shall mean all Know-How or
other information, including, without limitation, proprietary information and materials (whether or
not patentable) regarding a Party’s technology, products, business information or objectives, which
is designated as confidential in writing by the disclosing Party, whether by letter or by the use
of an appropriate stamp or legend, prior to or at the time any such material, trade secret or other
information is disclosed by the disclosing Party to the other Party. Notwithstanding anything in
the foregoing to the contrary, materials, know-how or other

Confidential

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.

5

 

information which is orally, electronically or visually disclosed by a Party, or is disclosed
in writing without an appropriate letter, stamp or legend, shall constitute Confidential
Information of a Party if the disclosing Party, within [***] business days after such disclosure,
delivers to the other Party a written document or documents describing the materials, know-how or
other information and referencing the place and date of such oral, visual, electronic or written
disclosure and the names of the persons to whom such disclosure was made. Notwithstanding the
foregoing, EYETECH Know-How or ARCHEMIX Know-How, as the case may be, that is disclosed to the
other Party in the course of the Research Program shall constitute Confidential Information of a
Party whether or not designated as confidential in writing.

          1.24  “Contract Year”. Contract Year shall mean the period beginning on the Effective
Date and ending on December 31, 2004 (the “First Contract Year”), and each succeeding twelve (12)
month period thereafter during the Research Term (referred to as the “Second Contract Year,” “Third
Contract Year,” etc.).

          1.25 “Controlled”. Controlled shall mean the legal authority or right of a Party
hereto or an Affiliate of a Party to grant a license or sublicense of intellectual property rights
to the other Party hereto which is consistent with the terms of this Agreement, or to otherwise
disclose proprietary or trade secret information to such other Party, without breaching the terms
of any agreement with a Third Party.

          1.26 “Damages”. Damages shall mean any and all costs, losses, claims, liabilities,
fines, penalties, damages and expenses, court costs, and reasonable fees and disbursements of
counsel, consultants and expert witnesses incurred by a Gilead Indemnitee (as defined in Section
7.2(b)) (including any interest payments which may be imposed in connection therewith).

          1.27 “Development” or “Develop”. Development or Develop shall mean any activity with
respect to a Lead Compound, including without limitation, preclinical and clinical drug development
activities, including test method development and stability testing, toxicology, formulation,
quality assurance/quality control development, statistical analysis, clinical studies and
regulatory affairs, product approval and registration.

Confidential

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.

6

 

          1.28 “Development Compound”. Development Compound shall mean a Lead Compound for
which EYETECH has completed all the activities described in Appendix 3 hereof, as such appendix may
be amended or updated by JRC or by the provisions of the Annual Research Plan.

          1.29 “Development Information”. Development Information shall have the meaning set
forth in Section 3.2(d).

          1.30 “Diligent Efforts”. Diligent Efforts shall mean efforts at least equal to those
normally used by a Party for a compound or product owned by it or to which it has rights, which is
of similar market potential, at a similar stage in its product life, taking into account the
competitiveness of the marketplace, the regulatory structure involved, the profitability of the
applicable products and other relative factors.

          1.31 “Early Selection Criteria” or “ESC”. Early Selection Criteria or
ESC shall mean guideline selection criteria for identifying Compounds which are sufficiently
promising to warrant Development set forth in Appendix 1 hereof, as such Appendix
shall be adjusted by mutual agreement of the Parties with respect to each individual Target to be
included in the Research Program before any activities with respect to such Target are initiated.
The specific ESC for each Target must be consistent with the guidelines in Appendix 1 and be
adopted by the formal written resolution of the JRC duly signed by the Program Director of each
Party.

          1.32  “Excluded Aptamers”. Excluded Aptamers shall mean (a) [***], (b) [***], and (c)
any Aptamer or Aptamer Equivalent directed to any of the following targets:

	 	i.	 	[***];
	 
	 	ii.	 	[***];
	 
	 	iii.	 	[***];
	 
	 	iv.	 	[***];
	 
	 	v.	 	[***];

Confidential

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.

7

 

	 	vi.	 	[***];
	 
	 	vii.	 	[***];
	 
	 	viii.	 	[***];
	 
	 	ix.	 	[***];
	 
	 	x.	 	[***];
	 
	 	xi.	 	[***]; or
	 
	 	xii.	 	[***].

          1.33 “Executive Officers”. Executive Officers shall mean the Chief Executive Officer
of EYETECH (or an executive officer of EYETECH designated by such Chief Executive Officer and the
Chief Executive Officer of ARCHEMIX (or an executive officer of ARCHEMIX designated by such Chief
Executive Officer).

          1.34 “Exercise Notice”. Exercise Notice shall have the meaning set forth in Section
3.4.

          1.35 “EYETECH Development Program”. EYETECH Development Program shall mean the
product development program to be undertaken by EYETECH during or after the Research Term to
develop Lead Compounds into Compound Products.

          1.36 “EYETECH Development Program Technology”. EYETECH Development Program Technology
shall mean all Know-How conceived, reduced to practice or developed by EYETECH during and in the
conduct of the EYETECH Development Program specifically relating to any Compound, ARCHEMIX
Proprietary Target or EYETECH Proprietary Target or methods of use of any Compound, ARCHEMIX
Proprietary Target or EYETECH Proprietary Target.

          1.37 “EYETECH Development Program Patents”. EYETECH Development Program Patents shall
mean Patents claiming EYETECH Development Program Technology.

Confidential

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.

8

 

          1.38 “EYETECH Diligence Goal”. EYETECH Diligence Goal shall have the meaning set
forth in Section 2.4(b)(iii).

          1.39 “EYETECH Know-How”. EYETECH Know-How shall mean all Know-How Controlled by
EYETECH, whether disclosed in a pending patent application or not, as of the Effective Date or
during the Research Term relating to a Compound or the use thereof or an EYETECH Proprietary
Target or the use thereof, excluding EYETECH Program Technology and EYETECH’s interest in Joint
Program Technology.

          1.40  “EYETECH Patents”. EYETECH Patents shall mean any Patents Controlled by EYETECH
as of the Effective Date or during the Research Term, claiming a Compound or the use thereof or a
Target or the use thereof, excluding EYETECH Program Patents and EYETECH’s interest in Joint
Program Patents.

          1.41 “EYETECH Program Patents”. EYETECH Program Patents shall mean Patents claiming
EYETECH Program Technology.

          1.42 “EYETECH Program Technology”. EYETECH Program Technology shall mean all Program
Technology relating (A) solely to EYETECH Proprietary Targets or EYETECH Technology, and/or (B)
solely to formulations or methods of use of any Compound. Notwithstanding anything to the contrary
herein, any methods of use of any Compound discovered or reduced to practise during the course of
the Research Term shall be deemed to be EYETECH Program Technology.

          1.43 “EYETECH Proprietary Target”. EYETECH Proprietary Target shall mean a Target the
use of which to select an Aptamer, or the use of which as a target for therapeutic intervention, is
covered by an EYETECH Valid Claim or pending patent application.

          1.44 “EYETECH Technology”. EYETECH Technology shall mean all EYETECH Patents and
EYETECH Know-How.

          1.45 “EYETECH Valid Claim”. EYETECH Valid Claim shall mean a claim of an issued and
unexpired EYETECH Patent, EYETECH Program Patent or Joint Program Patent

Confidential

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.

9

 

which has not been revoked or held permanently unenforceable or invalid by a decision of a
court or other governmental agency of competent jurisdiction, which decision is unappealable or
unappealed within the time allowed for appeal, and which has not been admitted to be invalid or
unenforceable through re-issue or disclaimer or otherwise.

          1.46 “FDA”. FDA shall mean the United States Food and Drug Administration.

          1.47 “Field”. Field shall mean the treatment, prevention and/or delay of any and all
opthamological diseases and conditions in humans, including, without limitation, diseases and
conditions of the eye and/or the ocular adnexa (orbit and its contents, eyelids and lacrimal
system).

          1.48 “First Commercial Sale”. First Commercial Sale shall mean, for each Compound
Product or VEGF Product, the first commercial sale in a country as part of a nationwide
introduction by EYETECH or its Affiliates, or for a VEGF Product by ARCHEMIX or its Affiliates.
Sales for test marketing, clinical trial purposes or compassionate or similar use shall not be
considered to constitute a First Commercial Sale.

          1.49 “Force Majeure”. Force Majeure shall have the meaning set forth in Section 11.9
hereof.

          1.50 “FTE”. FTE shall mean a full time (meaning a total of at least [***] hours per
year) equivalent employee (which may consist of hours spent by more than one person) dedicated to
scientific, technical or managerial work on or directly related to the Research Program with a
Bachelor of Science or greater qualifications, as contemplated in Section 2.4(a)(i) hereof;
provided that, in no event shall such FTEs be responsible for any overhead, laboratory operational
or other non-scientific functions unrelated to the Research Program.

          1.51  “FTE Rate”. FTE Rate shall mean an annual rate of $[***] during the first
Contract Year, and thereafter will mean such rate increased at the beginning of each subsequent
Contract Year to reflect any increase in the Consumer Price Index for Boston, Massachusetts during
the prior Contract Year.

Confidential

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.

10

 

          1.52 “Gilead”. Gilead shall mean Gilead Sciences, Inc.

          1.53 “Gilead-Archemix License”. Gilead-Archemix License shall mean that certain
license agreement dated October 23, 2001, as amended, between ARCHEMIX and Gilead.

          1.54 “Gilead-Eyetech License”. Gilead-Eyetech License shall mean that certain license
agreement dated March 30, 2000, as amended, between EYETECH and Gilead.

          1.55 “Gilead-Eyetech Patent Portfolio”. Gilead-Eyetech Patent Portfolio shall mean
those patent applications and patents licensed to EYETECH under the Gilead-Eyetech License,
including without limitation those listed on Appendix 5 attached hereto.

          1.56 “IND”. IND shall mean an application submitted to a Regulatory Authority to
initiate human clinical trials, including (a) an Investigational New Drug application or any
successor application or procedure filed with the FDA of the United States, (b) except where
otherwise specifically provided in this Agreement, any foreign equivalent of a U.S. Investigational
New Drug application, and (c) all supplements and amendments that may be filed with respect to the
foregoing.

          1.57 “Indication”. Indication shall mean any human indication, disease or condition
(i) in the Field with respect to Compound Products, (ii) in the Field and/or the Local Delivery
Field for Aptamers against VEGF developed or commercialized for or by EYETECH, and (iii) outside
the Field and the Local Delivery Field for Aptamers against VEGF developed or commercialized for or
by ARCHEMIX which can be treated, prevented, cured or the progression of which can be delayed.

          1.58 “Invalidity Claim”. Invalidity Claim shall have the meaning set forth in Section
8.5 hereof.

          1.59 “In Vitro Diagnostics”. In Vitro Diagnostics shall mean the use of Aptamers or
Aptamer Equivalents in the assay, testing or determination outside of a living organism, of a
substance in a test material.

Confidential

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.

11

 

          1.60 “In Vivo Diagnostic Agent”. In Vivo Diagnostic Agent shall mean any product
containing one or more Aptamers or Aptamer Equivalents that is used for any human in vivo
diagnostic purpose related to, inter alia, the identification, quantification or monitoring of the
propensity toward, or actual existence of, any disease state.

          1.61 “Joint Program Patents”. Joint Program Patents shall mean Patents claiming Joint
Program Technology.

          1.62 “Joint Program Technology”. Joint Program Technology shall mean all Program
Technology conceived, reduced to practice or developed jointly by employees, agents, consultants or
subcontractors of both Parties during, and in the conduct of, the Research Program that is neither
ARCHEMIX Program Technology nor EYETECH Program Technology.

          1.63 “JRC”. JRC shall have the meaning set forth in Section 2.1 hereof.

          1.64 “Know-How”. Know-How shall mean all proprietary material and information,
including data, technical information, know-how, experience, inventions, discoveries, trade
secrets, compositions of matter and methods, whether existing at the Effective Date or developed or
obtained during the Research Term and whether or not patentable or confidential, that are
Controlled by a Party to this Agreement and that relate to the discovery, development, utilization,
manufacture or use of any Compound, Compound Product, SELEX Process or Target, including but not
limited to processes, techniques, methods, products, materials and compositions.

          1.65  “Lead Compound”. Lead Compound shall mean a Compound for which EYETECH has
exercised the License Option as set forth in Section 3.4 hereof.

          1.66 “Lead Compound Equivalent”. Lead Compound Equivalent shall mean any Aptamer
directed to the same Target or Target Binding Partner as a Lead Compound.

          1.67 “License Option”. License Option shall have the meaning set forth in Section 3.1
hereof.

Confidential

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.

12

 

          1.68 “Local Delivery Field”. Local Delivery Field shall mean any delivery of an
Aptamer whose intended mode of action is solely to treat tissue in the proximity of the delivery
site of such Aptamer, for example by topical application to treat the skin at the point of
application, or injection into or in proximity of a joint or tumor to treat only that joint or
tumor.

          1.69 “Loss”. Loss shall have the meaning set forth in Section 7.1 hereof.

          1.70 “NDA”. NDA shall mean an application submitted to a Regulatory Authority for
marketing approval of a product, including (a) a New Drug Application, Product License Application
(as defined in Title 21 of the United States Code of Federal Regulations, as amended from time to
time) or Biologics License Application (as defined in Title 21 of the United States Code of Federal
Regulations, as amended from time to time) filed with the FDA or any successor applications or
procedures, (b) except where otherwise specifically provided in this Agreement, any foreign
equivalent of a U.S. New Drug Application, Product License Application or Biologics License
Application, and (c) all supplements and amendments that may be filed with respect to the
foregoing.

          1.71 “Net Sales”. Net Sales shall mean the gross amount received by a Party, its
Affiliates and/or its Sublicensees on Sales of Compound Products or VEGF Products in the case of
EYETECH or VEGF Products only in the case of ARCHEMIX less the following deductions:

               (a) Trade, cash and/or quantity discounts actually allowed and taken with respect to such
sales to wholesalers, hospitals or other buying institutions, as reflected in the amount invoiced;

               (b) Excises, sales taxes, value-added taxes or other taxes imposed upon and paid directly with
respect to the production, sale, delivery or use of the Compound Product or VEGF Product (excluding
national, state or local taxes based on such Party’s or its Affiliates’ income), as reflected in
the amount invoiced;

               (c) Import and export duties paid by a Party or its Affiliates or Sublicensees;

Confidential

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.

13

 

               (d) Amounts repaid or credited by reason of rejections, defects, recalls or returns or because
of governmental charges, chargebacks, refunds, rebates or retroactive price reductions; and

               (e) Freight, insurance and other transportation charges incurred in shipping Compound Product
or VEGF Product to Third Parties, as reflected in the amount invoiced.

Such amounts shall be determined from the books and records of the relevant Party, its Affiliates,
and/or its Sublicensees maintained in accordance with U.S. generally accepted accounting
principles, consistently applied. In the case of any sale of Compound Products or VEGF Products
for consideration other than cash, such as barter or counter-trade, Net Sales shall be calculated
on the fair market value of the consideration received.

In the event the Compound Product or VEGF Product is sold as part of a Combination Product (as
defined below), the Net Sales from the Combination Product or VEGF Product, for the purposes of
determining royalty payments, shall be determined by multiplying the Net Sales of the Combination
Product, during the applicable royalty reporting period, by the fraction, [***], where [***] is the
[***] of the Compound Product or VEGF Product when sold [***] in finished form and [***] is the
[***] of the other product(s) having independent and/or synergistic efficacy in the Indication for
which the product is sold included in the Combination Product when sold [***] in finished form, in
each case in the same country as the Combination Product during the applicable royalty reporting
period or, if sales of both the Compound Product or VEGF Product and such other product(s) did not
occur in the same country as the Combination Product in such period, then in the most recent
royalty reporting period in which sales of both occurred in the same country as the Combination
Product. In the event that such average sale price cannot be determined for both the Compound
Product or VEGF Product and all such other products(s) included in the Combination Product, Net
Sales for the purposes of determining royalty payments shall be calculated by multiplying the Net
Sales of the Combination Product by the fraction, [***], where [***] is the [***] of the Compound
Product or VEGF Product and [***] is the [***] of all other pharmaceutical product(s) having
independent and/or synergistic efficacy in the Indication for which the product is sold included in
the Combination Product. In such event, the Party not selling the product shall in good faith make
a determination of the

Confidential

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.

14

 

respective [***] of the Compound Product or VEGF Product and all other such pharmaceutical products
included in the Combination Product, and shall notify the other Party of such determination and
provide the other Party with data to support such determination. The other Party shall have the
right to review such determination and supporting data, and to notify the Party not selling the
product if it disagrees with such determination. If the other Party does not agree with such
determination and if the Parties are unable to agree in good faith as to such respective [***],
then such matter shall be referred to the Executive Officers for determination.

As used above, the term “Combination Product” means any pharmaceutical product, which consists of a
Compound Product or VEGF Product and other active compounds and/or active ingredients having
independent efficacy and/or synergistic benefit in the Indication for which the product is sold
together in one package. For avoidance of doubt, if a Combination Product is comprised of a
Compound Product and a VEGF Product the royalties shall be calculated separately for the Compound
Product and the VEGF Product each pursuant to the formula set forth above and the royalty rates set
forth in Sections 5.2.1 and 5.2.2.

          1.72  “Option Period”. Option Period shall have meaning set forth in Section 3.3.1.

          1.73 “NX1838”. NX1838 shall mean the anti-VEGF aptamer known as NX1838, together with
all anti-VEGF Aptamers comprising a sequence identity greater than [***]% over the entire length of
NX1838, whether or not such Aptamers incorporate [***], or have [***], including without limitation
[***] to alter the pharmacokinetic properties of the molecule.

          1.74 “Party”. Party shall mean either ARCHEMIX or EYETECH, as applicable, and
“Parties” shall mean both ARCHEMIX and EYETECH.

          1.75 “Patent Prosecution”. Patent Prosecution shall mean the filing, prosecution,
maintenance or extension of a Patent, including without limitation, interferences, nullity suits
and re-examinations.

          1.76 “Patents”. Patents shall mean all patents and patent applications existing at
the Effective Date and all patent applications hereafter filed during the Term, including any
continuation, continuation-in-part, division, provisional or any substitute applications, any
patent

Confidential

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.

15

 

issued with respect to any such patent applications, any reissue, re-examination, black box
application, renewal or extension (including any supplementary protection certificate) of any such
patent, and any confirmation patent or registration patent or patent of addition based on any such
patent, and all foreign counterparts of any of the foregoing.

          1.77 “Person”. Person shall mean any individual, corporation, partnership, limited
liability company, association, joint-stock company, trust, unincorporated organization, other
business entity or government or political subdivision thereof.

          1.78  “Phase 1 Clinical Study”. Phase 1 Clinical Study shall mean a study of a
Compound in human volunteers or patients with the endpoint of determining initial tolerance, safety
and/or pharmacokinetic information in a single dose, single ascending dose, multiple dose and/or
multiple ascending dose regimen.

          1.79 “Phase 2 Clinical Study”. Phase 2 Clinical Study shall mean a study of a
Compound in patients to determine additional safety information and initial efficacy and dose range
finding.

          1.80 “Phase 3 Clinical Study”. Phase 3 Clinical Study shall mean a clinical study in
patients, conducted in accordance with a protocol designed to ascertain efficacy and safety of a
Compound for the purpose of preparing and submitting an NDA to the competent Regulatory Authorities
in the Territory.

          1.81 “Program Compound”. Program Compound shall mean any Aptamer (other than Excluded
Aptamers), including, without limitation, an Aptamer which has not yet met the Early Selection
Criteria, that has been demonstrated to have an affinity for, to bind to, inhibit or otherwise
modulate the activity of any Target that is being investigated in the Research Program.

          1.82 “Program Director”. Program Director shall mean a research executive appointed
by each Party to serve as such Party’s principal coordinator and liaison for the Research Program.
The Program Director appointed by EYETECH is referred to as the EYETECH Program Director, and the
Program Director appointed by ARCHEMIX is referred to as the ARCHEMIX Program Director.

Confidential

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.

16

 

          1.83 “Program Patent Rights”. Program Patent Rights shall mean ARCHEMIX Program
Patents, EYETECH Program Patents or Joint Program Patents.

          1.84 “Program Technology”. Program Technology shall mean all Know-How (whether or not
patentable and whether or not copyrightable) conceived, reduced to practice or developed by a Party
or jointly by the Parties during, and in the conduct of, the Research Program.

          1.85  “Radio Therapeutic”. Radio Therapeutic shall mean any product for human
therapeutic use that contains one or more Aptamers or Aptamer Equivalents that target specifically
any diseased tissue, cells or disease-specific molecules or any tissue or cells which are affected
by a disease or located in the close neighborhood of a disease process and is linked to or
incorporates (a) radio nucleotides or (b) any structure or elements which develop therapeutic
effects similar to the effect of linking or incorporating radio nucleotides after submission of any
kind of radiation.

          1.86 “Refused Candidate”. Refused Candidate shall have the meaning set forth in
Sections , 3.7, 4.5, and 4.8.1 hereof.; provided that notwithstanding anything to the contrary in
the aforesaid Sections, Compounds that ARCHEMIX has not disclosed to EYETECH pursuant to Section
3.2 and compounds which ARCHEMIX discovers following termination or expiration of this Agreement
shall not constitute, or be deemed to be Refused Candidates for any purposes under this Agreement,
including without limitation for purposes of Section 8.7.6.

          1.87 “Refused Target”. Refused Target shall mean any Target or proposed Target that
becomes a Refused Target as set forth in Section 2.5, 3.7, 4.2.5.3, 4.5, or 4.8.1 other than VEGF
and its two (2) Target Binding Partners (FLT1 and KDR). 

          1.88 “Regulatory Approval”. Regulatory Approval shall mean, with respect to any
country, all authorizations by the appropriate governmental entity or entities necessary for
commercial sale of a Compound Product or VEGF Product in that country (or in the case of the
European Union, group of countries) including, without limitation and where applicable, approval of
labelling, and manufacturing. “Regulatory Approval” in the United States shall mean final approval
of an NDA pursuant to United States Code as published at 21 USC 355 and

Confidential

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.

17

 

corresponding regulations at 21 CFR Part 314, permitting marketing of the applicable Compound
Product or VEGF Product in interstate commerce in the United States. “Regulatory Approval” in the
European Union shall mean marketing authorization for the applicable Compound Product or VEGF
Product pursuant to Council Directive 2001/83/EC, as amended, or Council Regulation 2309/93/EEC, as
amended.

          1.89 “Regulatory Authority”. Regulatory Authority shall mean any federal, national,
supranational, state, provincial or local regulatory agency, department, bureau or other
governmental entity with authority over the testing, manufacture, use, storage, import, promotion,
marketing and sale of a therapeutic product in a country or countries, including, but not limited
to, the FDA.

          1.90 “Regulatory Filings”. Regulatory Filings shall have the meaning set forth in
Section 9.7 hereof.

          1.91 “Research Program”. Research Program shall mean all research and discovery
activities undertaken by the Parties under this Agreement according to an Annual Research Plan,
associated with the identification and design of Compounds, Compound Candidates for Indications as
provided herein, including Compounds directed against VEGF in the Field and/or the Local Delivery
Field; including but not limited to identification and initial testing of Program Compounds;
selection of Compound Candidates from Compounds and preparation for preclinical assessment of such
Compounds. For purposes of clarity, the Research Program does not include any Development
activities performed in the course of the EYETECH Development Program.

          1.92 “Research Program Data”. Research Program Data shall mean all data and
information pertaining to Compounds, Compound Candidates, Back-Ups, Lead Compounds, Development
Compounds, including Compounds directed against VEGF in the Field or the Local Delivery Field
obtained by the Parties in the course of the Research Program.

          1.93 “Research Term”. Research Term shall have the meaning set forth in Section 9.1
hereof.

Confidential

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.

18

 

          1.94 “Royalty Term”. Royalty Term shall have the meaning set forth in Section 9.2
hereof.

          1.95  “Sales”. Sales shall mean with respect to a Compound Product or a VEGF Product,
the gross amounts invoiced by either Party or its Affiliates or sublicensees (including, but not
limited to, transfers to wholesale distributors but excluding subsequent sales by such
distributors) on account of sales or use of such Compound Product or a VEGF Product.

          1.96 “Sales Report”. Sales Report shall mean a written report or written reports
showing each of (i) the Net Sales of each Compound Product or VEGF Product in each country in the
Territory during the reporting period by EYETECH or ARCHEMIX and each of their respective
Affiliates and Sublicensees; (ii) the royalties, payable in US Dollars, which shall have accrued
under Section 5.2 hereof in respect of such sales and the basis of calculating those
royalties; (iii) withholding taxes, if any, required by law to be deducted in respect of any such
sales; (iv) the exchange rates used in converting into US Dollars, from the currencies in which
sales were made, any payments due which are based on Net Sales; and (v) dispositions of Compound
Products or VEGF Products other than pursuant to sale to a Third Party exclusively for cash.

          1.97 “SELEX Portfolio”. SELEX Portfolio shall mean those patent applications and
patents licensed by Gilead to ARCHEMIX pursuant to the Gilead-Archemix License, including without
limitation those set forth in Appendix _5___attached hereto.

          1.98 “SELEX Process”. SELEX Process shall mean any process for identification or use
of a nucleic acid, which process is disclosed in or falls within the claimed scope of U.S. Patent
Nos. [***] or [***], including any continuations, divisionals continuations-in-part, or any
substitute applications, any patent issued with respect to any such patent applications, any
reissue, re-examination, black box application, renewal or extension (including any supplementary
protection certificate) or foreign equivalents.

          1.99 “Service Providers”. Service Provider shall mean Third Parties who execute a
confidentiality agreement with a Party that is at least as restrictive as the provisions hereof and
who provide assistance, consultation, advice, guidance, recommendation, and training to a Party

Confidential

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.

19

 

for the purpose of improving or enhancing the Party’s ability to meet the objectives of this
Agreement.

          1.100 “Sublicensee”. Sublicensee shall mean a Third Party to whom EYETECH or ARCHEMIX
grants a sublicense of any or all of the rights granted hereunder to it by the other Party or from
Gilead in respect of VEGF.

          1.101 “Target”. Target shall mean any non-intracellular enzyme, receptor, transducer,
transcription factor or other molecule approved by the JRC or proposed by EYETECH unless the JRC
determines that there is a compelling scientific reason for refusing the Target proposed by
EYETECH, for use in identifying Compounds meeting the ESC for use in the Field under the Research
Program. For avoidance of doubt, Target shall not include any intracellular target, but shall
include extra-cellular and membrane-bound targets.

          1.102 “Target Binding Partner”. Target Binding Partner shall mean the primary natural
ligand that binds to a Target, as designated pursuant to Section 2.5. However, the Parties
acknowledge that in some cases the Target Binding Partner will be comprised of two primary ligands
(for example with respect to VEGF the primary natural ligands are FLT1 and KDR).

          1.103 “Target Criteria”. Target Criteria shall mean the criteria set forth on
Appendix 4 hereto.

          1.104 “Term”. Term shall have the meaning set forth in Section 9.3 hereof.

          1.105 “Territory”. Territory shall mean worldwide.

          1.106 “Third Party”. Third Party shall mean any person or entity, which is not a
Party or an Affiliate of any Party.

          1.107 “USD” or “US Dollars”. USD or US Dollars shall mean the legal tender in the
United States of America.

Confidential

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.

20

 

          1.108 “URC License Agreement”. URC License Agreement shall mean the Restated
Assignment and License Agreement, dated July 17, 1991, by and between University Research
Corporation and Gilead, as successor in interest to NeXstar (as defined therein).

          1.109 “UTC”. UTC shall mean the University Technology Corporation, the successor to
the University Research Corporation (as defined there).

          1.110 “VEGF”. VEGF shall mean vascular endothelial growth factor.

          1.111 “VEGF Product”. VEGF Product shall mean a finished dosage form usable for
administration to a patient as a pharmaceutical containing, as an active ingredient, an Aptamer
against VEGF that is not NX1838.

ARTICLE 2  RESEARCH PROGRAM

          2.1 Joint Research Committee (JRC).

               (a) Composition; Responsibilities. The Parties shall establish a joint research
committee (the “JRC”), comprised of [***] representatives of ARCHEMIX (including the ARCHEMIX
Program Director) and [***] representatives of EYETECH (including the EYETECH Program Director).
Each Party shall make its designation of its representatives prior to the Effective Date. The JRC
shall meet within [***] days after the Effective Date and, thereafter, at least [***] during the
Research Term to (i) subject to Section 2.5, select Targets and develop the ESC for each such
Target and the activities to be set forth in Appendix 3 which will establish that an Aptamer
against such Target is a Development Compound, (ii) review the efforts of the Parties in the
conduct of the Research Program, (iii) review and approve amendments to the Annual Research Plan,
(iv) address such other matters as either Party may bring before the JRC, (v) perform such other
tasks and undertake such other responsibilities as may be set forth in this Agreement, and (vi)
attempt to resolve any disputes relating to this Agreement that may arise between the Parties. For
purposes of clarity, (i) the JRC shall not review, oversee or have any jurisdiction with respect to
Development of Lead Compounds and the EYETECH Development Program and (ii) the JRC may request but
shall not have the right to require ARCHEMIX to perform any work on an Aptamer after it becomes a
Lead Compound.

Confidential

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.

21

 

               (b) Administrative Matters. The JRC shall appoint [***] co-chairpersons, [***] from
among the representatives of EYETECH and [***] from among the representatives of ARCHEMIX (the
“Chairpersons”). The Chairpersons shall be responsible for calling meetings of the JRC and for
leading the meetings at their respective facilities. A JRC member of the Party hosting a meeting
of the JRC shall serve as secretary of that meeting. The secretary of the meeting shall prepare
and distribute to all members of the JRC minutes of the meeting within [***] days following the
meeting to allow adequate review and comment. Such minutes shall provide a description in
reasonable detail of the discussions held at the meeting and a list of any actions, decisions or
determinations approved by the JRC. Minutes of each JRC meeting shall be approved or disapproved,
and revised as necessary, at the next meeting.

               (c) The location of meetings of the JRC shall alternate between ARCHEMIX’s principal place of
business and EYETECH’s principal place of business, or as otherwise agreed by the Parties. The JRC
may also meet by means of a telephone conference call or videoconference. Each Party may change
any one or more of its representatives to the JRC at any time upon notice to the other Party. Each
Party shall use reasonable efforts to cause its representatives to attend the meetings of the JRC.
If a representative of a Party is unable to attend a meeting, such Party may designate an alternate
to attend such meeting in place of the absent representative. In addition, each Party may, at its
discretion, invite non-voting employees, and, with the consent of the other Party, consultants or
scientific advisors, to attend the meetings of the JRC to, among other things, review and discuss
the Research Program and its results. Either Party may convene a special meeting of the JRC for
the purpose of resolving disputes.

               (d) Decision Making. Until the time a Compound becomes a Lead Compound, the goal of
all decision making as to such Compound shall be to achieve consensus, recognizing ARCHEMIX’s
expertise in the identification and optimization of Aptamers and EYETECH’s right to select Targets
for consideration by the JRC. Prior to the Lead Compound designation each Party (acting through
its designated members) shall have one vote on the JRC to be cast by its Co-Chairperson and
unanimous agreement shall be required for any action, except as set forth in Section 2.5.

               (e) Term. The JRC shall function during the Research Term.

Confidential

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.

22

 

          2.2 Management of Research Program.

               (a) Program Directors. ARCHEMIX and EYETECH shall each appoint a Program Director
prior to the Effective Date. Each Party shall have the right, after consultation with the other
Party, to designate a different Program Director. The Program Directors shall jointly oversee the
conduct of the Research Program, shall report to the JRC and shall be responsible for recommending
to the JRC any changes to the Annual Research Plan.

               (b) Project Teams. The Program Directors shall appoint one or more appropriate
Project Teams, in each case consisting of representatives from ARCHEMIX and EYETECH, to facilitate
the conduct of elements of the Research Program in (i) the areas set forth in the Annual Research
Plan and (ii) such other areas as may be agreed upon by the Program Directors.

               (c) Dispute Resolution. The Program Directors shall decide matters appropriate to the
scope of their responsibilities on a consensus basis. In the event that the Program Directors are
unable to reach agreement on any matter within [***] business days after the matter is first
considered by them, the issue may be referred to the JRC by either Program Director for resolution
thereby.

          2.3 Annual Research Plan. 

               (a) Annual Research Plan. The JRC shall prepare and approve the Annual Research Plan
for first Contract Year within [***] days of the Effective Date. Thereafter the JRC shall prepare
and approve the Annual Research Plan for each Contract Year during the Research Term (other than
the First Contract Year) at least [***] days prior to the commencement of such Contract Year. At
EYETECH’s request, the JRC shall include in the Annual Research Plan a plan to discover and develop
Compounds against the Targets PDGF and VEGF, so long as the Parties obtain any necessary rights
covering VEGF from Gilead. In the event the JRC fails to approve an Annual Research Plan due to a
dispute over the contents of such Annual Research Plan, each Party shall have the right to refer
such dispute to resolution pursuant to Section 11.2.

Confidential

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.

23

 

               (b) Updates and Amendments. The JRC shall review and approve updates and amendments,
as appropriate, to the current Annual Research Plan during the course of the applicable Contract
Year.

               (c) Content. Each Annual Research Plan shall be consistent with the other terms and
conditions of this Agreement. Each Annual Research Plan shall specify, among other things, (i)
specific research objectives and priorities, (ii) specific activities to be performed, (iii) the
Party responsible for performance of an activity, (iv) the number and types of FTEs expected to be
assigned to specific activities by each Party, (v) timelines for performance and (vi) specific
deliverables. The Annual Research Plan shall not require ARCHEMIX to perform any research other
than the identification and optimization of Aptamers using the SELEX Process but ARCHEMIX agrees to
reasonably consider requests to perform such other work related to the identification of Lead
Compounds as may be requested by EYETECH. The number of FTEs to be provided by ARCHEMIX may not be
increased without at least [***] months prior notice to ARCHEMIX and may never be reduced below
[***] and for any reduction ARCHEMIX must be given at least [***] months prior written notice.

               (d) Implementation. The Parties shall undertake the Research Program in accordance
with the Annual Research Plan.

          2.4 Obligations under the Research Program

               (a) ARCHEMIX Obligations and Restrictions. Subject to the oversight of the JRC,
during the Research Term, ARCHEMIX agrees that:

                    (i) with respect to the Annual Research Plan, (A) ARCHEMIX shall undertake the
responsibilities assigned to it, as set forth in the Annual Research Plan, and (B) ARCHEMIX shall
make available for the conduct of the Research Program, as needed, those resources to be provided
by ARCHEMIX as set forth in the Annual Research Plan;

                    (ii) as of the Effective Date, ARCHEMIX shall have disclosed to EYETECH all ARCHEMIX Initial
Compounds; and

Confidential

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.

24

 

                    (iii) during the Research Term ARCHEMIX shall use Diligent Efforts to perform the activities
assigned to ARCHEMIX in the Annual Research Plan in a professional and timely manner(the “ARCHEMIX
Diligence Goal”). In the event ARCHEMIX fails to meet the ARCHEMIX Diligence Goal within a [***]
month period, EYETECH shall have no obligation to meet its Diligence Goal pursuant to Section 2.4
(b) (iii) within such period.

               (b) EYETECH Obligations. Subject to the oversight of the JRC, EYETECH agrees that:

                    (i) during the Research Term, to pay the FTE Rate per FTE per annum, quarterly in advance
based on the number of FTEs set forth in the Annual Research Plan for the quarter;

                    (ii) with respect to the Annual Research Plan, EYETECH shall undertake the responsibilities
assigned to it in the Annual Research Plan, including, but not limited to, the dedication of
resources to such efforts as set forth in the Annual Research Plan; and

                    (iii) during the Research Term, EYETECH shall use Diligent Efforts to meet the EYETECH
Diligence Goal. The “EYETECH Diligence Goal” shall be to (A) approve at least [***] Lead Compound
(in accordance with Section 3.4) which is ARC127 in its pegylated or non-pegylated form, a Compound
against VEGF, a Program Compound that was not originally an ARCHEMIX Initial Compound or an
ARCHEMIX Additional Compound or a Program Compound that was originally an ARCHEMIX Initial Compound
or an ARCHEMIX Additional Compound but which was designated as a Program Compound prior to
achieving the ESC in each [***] month period, (B) move at least one such Lead Compound to
Development Compound status in each [***] month period and (C) commence at least [***] IND for a
Development Compound which is ARC127, a Compound against VEGF, a Program Compound that was not
originally an ARCHEMIX Initial Compound or an ARCHEMIX Additional Compound or a Program Compound
that was originally an ARCHEMIX Initial Compound or an ARCHEMIX Additional Compound but which was
designated as a Program Compound Prior to achieving the ESC in each [***] year period, except,
without limitation in each of (A), (B) and

Confidential

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.

25

 

(C), for any delays caused by ARCHEMIX’s failure to meet the ARCHEMIX Diligence Goal, an
inconsequential delay by EYETECH or Force Majeure. In addition, in the event of a deadlock of the
JRC continuing for more than [***] months with respect to inclusion of a target in the Research
Program, and the dispute is resolved in EYETECH’s favour, then EYETECH’s diligence requirement in
(A) shall be extended by the duration of the deadlock and dispute resolution.

               (c) Failure to meet Diligence Goals. ARCHEMIX may terminate the Research Program, but
not this Agreement and the licenses granted hereunder, if EYETECH fails to achieve any aspect of
the EYETECH Diligence Goal, provided, that such failure is not caused by ARCHEMIX’ failure to meet
the ARCHEMIX Diligence Goal; provided, however, that (i) EYETECH Diligence Goal “A” shall be waived
for any [***]-month period in which EYETECH has paid for [***] FTEs per year at ARCHEMIX; (ii)
EYETECH Diligence Goal “B” shall be waived for any [***]-month period in which EYETECH has paid for
[***] FTEs per year at ARCHEMIX during the entire period; and (iii) EYETECH Diligence Goal “C”
shall be waived for any [***] year period for which EYETECH has paid for [***] FTEs per year at
ARCHEMIX during the entire period.

          2.5 Target Selection. The JRC shall determine which Targets shall be utilized for
identification of Compounds under the Research Program; provided that in no event will any
of the targets listed in Section 1.32 be utilized as a Target under this Agreement except as set
forth in Section 8.7.2. ARCHEMIX and EYETECH each may propose Targets to be used for
identification of Compounds under the Research Program. If any Target is presented by either
Party, the JRC will consider such Target and such Target may be included in the Research Program,
or deferred for later consideration until the Parties agree in writing that such Target shall
become a Refused Target; provided, however that Targets proposed by EYETECH shall be included in
the Research Program unless there is a compelling scientific reason to exclude such Target. In the
event the JRC refuses to accept, or can not reach consensus on the acceptance of a proposed Target
for inclusion into the Research Program and EYETECH believes there exists no compelling scientific
reason for excluding such Target from inclusion into the Research Program, then EYETECH shall have
the right to refer such matter to dispute resolution pursuant

Confidential

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.

26

 

to Section 11.2. If the JRC determines that such Target does not have potential utility in
the Field, such Target shall be a Refused Target. Once a Target is selected, (i) the JRC will
promptly develop the ESC for such Target and the activities which will establish that an Aptamer
against such Target is a Development Compound to be set forth in Appendix 3, and (ii) EYETECH will
propose a molecule to be designated as the Target Binding Partner for such Target and will present
to the JRC the data supporting such designation and the JRC will determine the Target Binding
Partner for such Target. For the avoidance of doubt, nothing in this Agreement shall give ARCHEMIX
any right to utilize any EYETECH Proprietary Target, (excluding any Target that is within the
definition of EYETECH Proprietary Target solely because it is covered by claims in a Joint Program
Patent), for any purpose other than in the performance of its obligations or the exercise of its
rights under this Agreement and nothing in this Agreement shall give EYETECH any right to utilize
any ARCHEMIX Proprietary Target, (excluding any Target that is within the definition of ARCHEMIX
Proprietary Target solely because it is covered by claims in a Joint Program Patent), for any
purpose other than in the performance of its obligations or the exercise of its rights under this
Agreement.

          2.6 Compliance with Laws. Each Party agrees to use commercially reasonable efforts to
carry out all work assigned to such Party in the Annual Research Plan in material compliance with
all applicable federal, supranational, state or local laws, regulations and guidelines governing
the conduct of such work, including, without limitation, all applicable export and import control
laws.

          2.7 Product Labelling. All Compound Products and all VEGF Products sold by a Party
shall carry that Party’s name and logo. A Party shall have no rights to have its name and logo
incorporated on the label or otherwise associated with the other Party’s Compound Products or VEGF
Products (as applicable). 

          2.8 Progress Reports. Within [***] business days after the end of each calendar
quarter, each Party shall provide to the other Party a written report summarizing the activities
undertaken by the reporting Party during the preceding calendar quarter in connection with the
Research Program. ARCHEMIX’s report shall include details on the number of FTEs dedicated

Confidential

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.

27

 

to and actually working on the Research Program, and ARCHEMIX shall maintain adequate records
to verify such work.

          2.9 Research Records. ARCHEMIX shall maintain complete and accurate records, in
sufficient detail and in good scientific manner appropriate for patent and regulatory purposes,
that fully and properly reflect in all material respects all work done and results achieved in the
performance of the Research Program. Such records shall include, but not be limited to, as
appropriate in the particular circumstances, all books, reports, research notes, charts, graphs,
comments, computations, analyses, recordings, photographs, computer programs, databases, and
documentation thereof, samples of materials and other graphic, written or tangible data or material
generated in connection with the Research Program, including any data required to be maintained
pursuant to all requirements of applicable laws and regulations, and records of the number,
qualifications and job responsibilities of FTEs working on the Research Program. All of such books
and records related to the Research Program shall be subject to audit by EYETECH. EYETECH shall
have the right, during normal business hours and with reasonable notice, to inspect and copy all
such records of ARCHEMIX. Notwithstanding the foregoing, EYETECH shall not have the right to audit
or copy any materials that relate to Aptamers that do not, or have been determined not to, have
utility in the Field or that become Refused Candidates or are ARCHEMIX Initial Compounds or
ARCHEMIX Additional Compounds that have not been designated as Program Compounds.

ARTICLE 3  LICENSE OPTION

          3.1 Exclusive Option.  During the Option Period, EYETECH shall have the exclusive
right and option to select for further Development and Commercialization hereunder (the “License
Option”) (i) Program Compounds based on its own analysis of information provided by ARCHEMIX
hereunder, and/or (ii) Compound Candidates.

          3.2 Process for Determining Compound Candidate.

               (a) ARCHEMIX Initial Compounds. As of the Effective Date, ARCHEMIX shall have
disclosed in writing to EYETECH and the JRC all Aptamers (other than Excluded Aptamers) Controlled
by ARCHEMIX including without limitation, ARC 127 in its

Confidential

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.

28

 

pegylated and non-pegylated variations (“ARCHEMIX Initial Compounds”). Of the ARCHEMIX
Initial Compounds, ARCHEMIX will identify up to [***] ARCHEMIX Initial Compounds against up to
[***] targets for immediate consideration by the JRC (“ARCHEMIX Early Decision Initial Compounds”).
If the JRC elects to have any such Aptamer included in the Research Program, which the JRC
cannot refuse to do for ARCHEMIX Initial Compounds selected by EYETECH for up to [***] Initial
Compounds per target, unless there exists a compelling scientific basis for such refusal, the JRC
will modify the Annual Research Plan accordingly and will establish the ESC and activities to be
set forth in Appendix 3 for such Aptamer, and such Aptamer shall thereafter be a Program Compound
hereunder. If the JRC does not select an ARCHEMIX Initial Compound for inclusion in the Research
Program within [***] days, or an ARCHEMIX Early Decision Initial Compound on or before April 26,
2004, such Aptamer will not be a Program Compound, but ARCHEMIX may request the JRC to establish
ESC for no more than [***] ARCHEMIX Initial Compounds per [***] and the JRC will do so within [***]
days. At any time during the Research Term upon EYETECH’S request, ARCHEMIX shall provide updates
to EYETECH with respect to the development status of the ARCHEMIX Initial Compounds which have not
become Program Compounds, and EYETECH and ARCHEMIX may, at ARCHEMIX’s sole option, agree through
the JRC to include into the Program such ARCHEMIX Initial Compounds. In addition at any time during
the Research Term, EYETECH shall have the right to request the JRC to include into the Research
Program an effort to discover Aptamer Equivalents of ARCHEMIX Initial Compounds that have not
become Program Compounds, and the JRC shall approve the inclusion of such Aptamer Equivalents which
then becomes a Program Compound unless there exists a compelling scientific reason to refuse such
approval.

               (b) Program Compounds. Within [***] business days of the end of each calendar quarter
(ending each March 31, June 30, September 30 and December 31) during the Research Term ARCHEMIX
will notify EYETECH and the JRC of each Program Compound identified in such calendar quarter.

               (c) Archemix Additional Compounds. In addition, ARCHEMIX may, in its sole discretion,
notify EYETECH of any Aptamer identified by ARCHEMIX outside the

Confidential

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.

29

 

Research Program believed by ARCHEMIX to have potential application in the Field and for
Aptamers against VEGF in the Field (“ARCHEMIX Additional Compounds”). If the JRC elects to have
any ARCHEMIX Additional Compound included in the Research Program, the JRC will modify the Annual
Research Plan accordingly and will establish the ESC and activities to be set forth in Appendix 3
for such Aptamer and such Aptamer shall thereafter be a Program Compound hereunder. If the JRC
does not elect to have an ARCHEMIX Additional Compound included in the Research Program within
[***] days after disclosure thereof, such Aptamer will not be a Program Compound, but ARCHEMIX may
then request the JRC to establish ESC for such Aptamer and the JRC will do so within [***] days.
The JRC shall not be obligated to consider more than [***] ARCHEMIX Additional Compounds for
inclusion in the Research Program per calendar quarter.

                    (d) Development Information. ARCHEMIX will provide EYETECH and the JRC on a quarterly
basis during the Research Term, with notice of all material information applicable to the Field
known to ARCHEMIX about any Program Compound (the “Development Information”), including analysis
results and raw data which the JRC should reasonably require to assess whether a given Program
Compound meets the Early Selection Criteria or which EYETECH should reasonably require in order for
EYETECH (i) to exercise its rights under this Agreement, and (ii) to decide, in EYETECH’s sole
discretion, whether to exercise the License Option with respect to such Program Compound or
Compound Candidate, as applicable. The Development Information shall also include any previously
undisclosed information with respect to ARCHEMIX Technology, which is important for a scientific
and commercial evaluation of the Program Compound. EYETECH expects to utilize evaluation criteria
such as those set forth on Appendix 1, without limitation, in its assessment of whether to
license Program Compounds or Compound Candidates.

                    (e) In addition to the Development Information, at the request of EYETECH given within [***]
days of the notice under Section 3.2(b) hereof, ARCHEMIX shall supply EYETECH with up to [***] of
the Program Compound or Compound Candidate (the “Material”) at ARCHEMIX’s direct manufacturing cost
of production (which includes (i) direct and indirect labor (salaries, wages and employee benefits)
and (ii) direct and indirect materials)

Confidential

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.

30

 

thereof for EYETECH’s use in connection with determining whether to exercise the License
Option with respect to such Program Compound or Compound Candidate (the “Evaluation”). ARCHEMIX
will use commercially reasonable efforts to deliver the Material to EYETECH no later than [***]
days following EYETECH’s request and shall be accompanied by a document setting forth the sequence
of the Program Compound or Compound Candidate and any analytic information with respect thereto
which ARCHEMIX has available. ARCHEMIX shall make no warranty. At the request of EYETECH,
ARCHEMIX will provide additional quantities of the Material at ARCHEMIX’s fully loaded cost of
production thereof. EYETECH’s use of the Material shall be subject to the following provisions:

                    (i) EYETECH agrees to use the Material only for non-commercial internal research in the
conduct of the Evaluation. EYETECH shall not (i) provide access to or distribute the Material to
any third party other than employees of EYETECH who are working on the Evaluation and who are bound
by the requirements of this Agreement, (ii) otherwise use such Material in research outside of the
Evaluation, nor (iii) modify or change in any way the Material, in any case without the express
prior written consent of ARCHEMIX. Any Material delivered pursuant to this Agreement (x) is
understood to be experimental in nature and may have hazardous properties (and EYETECH agrees to
handle the Material accordingly), (y) is supplied solely for use in animals used exclusively for
testing and/or in vitro testing, and (z) is not to be used for in vivo testing in humans. If the
relevant License Option is not exercised in accordance with its terms, then upon expiration
thereof, EYETECH shall at the instruction of ARCHEMIX either destroy or return any unused Material;

                    (ii) EYETECH shall use the Material only in compliance with all applicable Federal, state, and
local laws, regulations and guidelines; and

                    (iii) EYETECH acknowledges and agrees that, subject to EYETECH’s rights following exercise of
the relevant License Option, all Material is and shall be owned by ARCHEMIX and EYETECH has no
right to ownership of the Material and ARCHEMIX reserves all intellectual property rights therein
and thereto.

Confidential

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.

31

 

               (f) If ARCHEMIX reasonably believes any Program Compound, or any ARCHEMIX Additional Compound
or ARCHEMIX Initial Compound that has been presented by ARCHEMIX but has not become a Program
Compound has met the ESC and thus should be designated as a Compound Candidate, ARCHEMIX shall
notify the JRC and EYETECH in writing (the “Compound Candidate Notice”), and shall provide to the
JRC the data and information demonstrating that the Program Compound, ARCHEMIX Initial Compound or
ARCHEMIX Additional Compound satisfies the relevant ESC. At the request of the JRC, ARCHEMIX shall
provide the JRC with such additional data as the JRC shall reasonably request. Within [***] days
after its receipt of the Compound Candidate Notice, or (as applicable) its receipt of the requested
additional data, the JRC shall (i) review the data and information using the relevant ESC, (ii)
determine whether such Program Compound, ARCHEMIX Initial Compound or ARCHEMIX Additional Compound
satisfies such ESC and (iii) notify the Parties in writing of such determination. If the
determination is positive, such Program Compound, ARCHEMIX Initial Compound or ARCHEMIX Additional
Compound shall be deemed to have been so designated as a Compound Candidate as of the date of the
Compound Candidate determination. Any negative determination shall be accompanied by a detailed
explanation of the reasons therefor.

          In the Event that the JRC fails to determine if the Program Compound, ARCHEMIX Initial
Compound or ARCHEMIX Additional Compound is a Compound Candidate within such [***] day period, the
matter will be resolved in accordance with Section 11.2.1 hereof.

          If it is determined by the JRC or under Section 11.2.1 hereof that the Program Compound,
ARCHEMIX Initial Compound or ARCHEMIX Additional Compound does not meet the ESC, the JRC may amend
the Annual Research Plan to add performance by ARCHEMIX, as a part of the Research Program and
using the resources set forth in the Annual Research Plan, any activities, identified by the JRC as
necessary and reasonable to determine if the Program Compound, ARCHEMIX Initial Compound or
ARCHEMIX Additional Compound fulfils the ESC, that are susceptible of being performed and resubmit
the resulting information to the JRC, whereupon the procedure set forth above shall again apply.

Confidential

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.

32

 

     3.3 Option and Review Periods.

          3.3.1 Option Period. The option period (the “Option Period”) for each Compound
Candidate and its Back-Up, as applicable, commences when it is determined that the Compound is a
Compound Candidate and ends, on a Compound Candidate -by-Compound Candidate basis, upon the later
of (i) [***] days in the case of a Program Compound identified in the Research Program, and [***]
days in the case of a Program Compound that was initially an ARCHEMIX Initial Compound or an
ARCHEMIX Additional Compound, after the date of the relevant Compound Candidate determination or
the determination pursuant to Section 11.2.1 hereof that a Program Compound meets the ESC and (ii)
[***] days after the date of receipt by EYETECH of the initial quantity of Material and all of the
Development Information that has been developed as of the date of delivery of the initial quantity
of Material for that Compound Candidate or Back-Up, as applicable, contemplated in Section 3.2
above.

     3.4 Exercise of Option. EYETECH may exercise a License Option and accept a Program
Compound for further Development and Commercialization, either for itself or on behalf of any of
its Affiliates, by delivery to ARCHEMIX, within the relevant Option Period for such License Option,
of a written notice of exercise (an “Exercise Notice”), specifying the Program Compound as to which
such License Option is being exercised and by paying (i) the entire payment for Milestone (A) set
forth in Section 5.3.1 for each Exercise Notice; it being understood that for VEGF Products the
Milestones and Payments set forth in Section 5.4.1 shall apply. In addition, EYETECH may designate
a Program Compound as a Compound Candidate at any time and may exercise its License Option with
respect to an ARCHEMIX Initial Compound that has become a Program Compound, Program Compound, or
ARCHEMIX Additional Compound that has become a Program Compound at any time before the Option
Period begins, regardless of whether the Compound meets the ESC, unless it has become a Refused
Candidate or is directed to a Refused Target.

     3.5 Back-Ups.

          3.5.1 Delivery of a Back-Up for each Compound Candidate. As directed by the JRC, for
each Compound Candidate provided to EYETECH by ARCHEMIX, ARCHEMIX will

Confidential

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.

33

 

use diligent and commercially reasonable efforts, consistent with those customary in the
industry, to deliver to EYETECH an Aptamer in addition to the Compound Candidate as a follow-up
Aptamer against the Target, which is distinct in chemical structure from the Compound Candidate
(“Back-Up”). ARCHEMIX’s activities to identify a Back-Up shall be performed as a part of the
Research Program using the resources set forth therein and the Annual Research Plan shall be
amended accordingly. The rights and obligations of the Parties relating to a Back-Up shall be
identical to those applicable to the accompanying Compound Candidate, except as otherwise expressly
provided herein.

          3.6 Back-Up Notices. EYETECH shall notify ARCHEMIX in writing in the event EYETECH
chooses to replace a Compound Candidate, Lead Compound or Development Compound with the applicable
Back-Up or to develop the Back-Up in addition to the Compound Candidate, Lead Compound or
Development Compound. Subsequent to such notice, as applicable, any reference to the Compound
Candidate, Lead Compound or Development Compound shall be deemed to include or to be made to the
Back-Up for the purposes of this Agreement.

          3.7 Refused Candidate. If EYETECH does not exercise its License Option with respect
to a particular Compound Candidate or its Back-Up within the Option Period for such Compound
Candidate, then the applicable License Option shall expire and such Compound Candidate and its
Back-Up shall be a Refused Candidate, and ARCHEMIX will thereafter, subject to its obligations
under Sections 4.2.3 and 4.2.5.1, be free to exercise all of its rights with respect to the Refused
Candidate at is own costs and expense; provided, however, that nothing contained in this Section
3.7 shall be deemed to constitute a license under any EYETECH Technology or EYETECH Program
Technology. In addition, if there are no other Program Compounds directed to the Target against
which the Refused Candidate is directed and Aptamers against such Target are not the subject of
activities in the Research Program or the EYETECH Development Program, then the Target against
which the Refused Candidate is directed shall be a Refused Target without further action by the
Parties. However, Refused Candidates directed against VEGF can only be used by Archemix outside of
the Field and the Local Delivery Field.

Confidential

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.

34

 

Nothing in this Agreement shall provide Archemix with the right, and ARCHEMIX hereby covenants
not to use Aptamers directed against VEGF in the Field or in the Local Delivery Field.

ARTICLE 4  LICENSES; DEVELOPMENT AND COMMERCIALIZATION

     4.1 Evaluation License to EYETECH. Solely for the purpose of evaluating the efficacy
of Compounds for Indications, during the Research Term, ARCHEMIX hereby grants to EYETECH a
non-exclusive, royalty-free license, sublicensable only to its Affiliates and Service Providers, in
the Territory under the ARCHEMIX Technology, ARCHEMIX Program Technology, ARCHEMIX Program Patents,
ARCHEMIX’s interest in the Joint Program Technology and Joint Program Patents, and any ARCHEMIX
Valid Claim covering an ARCHEMIX Proprietary Target to which such Compounds are directed, to use
and practice the ARCHEMIX Technology, ARCHEMIX Program Technology, Joint Program Technology,
ARCHEMIX Proprietary Target and manufacture or have manufactured such Compounds,; provided,
however, that no license is granted to EYETECH (i) under any ARCHEMIX Valid Claim relating
to any ARCHEMIX Proprietary Target, except as expressly provided in this Section 4.1 or (ii) to use
or practice the SELEX Process.

     4.2 Development and Commercialization License Grants to EYETECH; Exclusivity.

          4.2.1 License. Effective upon each exercise of a License Option by EYETECH
for a Program Compound or Compound Candidate hereunder, ARCHEMIX hereby grants to EYETECH an
exclusive, royalty-bearing (during the applicable Royalty Term only) license in the Territory, with
the right to grant sublicenses as set forth in Section 4.2.2 below, under the ARCHEMIX Technology,
ARCHEMIX Program Technology, ARCHEMIX Program Patents and ARCHEMIX’s interest in the Joint Program
Technology and Joint Program Patents, and under any ARCHEMIX Valid Claim covering an ARCHEMIX
Proprietary Target to which such Lead Compound is directed, to Develop, modify, manufacture, have
manufactured, export, import, use, sell and offer to sell, Compound Products in the Field
incorporating such Lead Compound and all Back Ups relating to such Lead Compound; provided,
however, that no license is granted to EYETECH under any claim of any ARCHEMIX Patent or ARCHEMIX
Program Patent (i) under any ARCHEMIX Valid Claim relating to any ARCHEMIX Proprietary

Confidential

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.

35

 

Target, except as expressly provided in this Section 4.2.1 or (ii) to use or practice the
SELEX Process. The foregoing license is granted for an unlimited number of Lead Compounds for
which the License Option is duly exercised and an unlimited number of instances during the Term.
Upon each exercise of a License Option by EYETECH, ARCHEMIX will provide a complete list of all
patents it controls that, but for the grant of the license, would be infringed by the manufacture,
use, sale, offer for sale or import of the anticipated Compound Products in the Field to which such
Lead Compound is directed. ARCHEMIX shall provide updates to such list as requested by EYETECH.

          4.2.2 Sublicense Rights. Subject to the terms of this Agreement, EYETECH shall have
the right to grant sublicenses solely under the license granted pursuant to Section 4.2.1 above and
Section 4.13.1 below. EYETECH shall give ARCHEMIX prompt written notice of each sublicense under
this Agreement along with a true, correct and complete copy of such sublicense promptly following
execution thereof by the parties thereto with financial and other information redacted that is not
required to enable ARCHEMIX to fulfill its reporting obligations to Gilead under the
Gilead-Archemix License. Any such sublicense shall contain provisions for the assignment to
ARCHEMIX of EYETECH’s interest therein upon termination of this Agreement, subject to the last
sentence of this Section 4.2.2, unless the termination of this Agreement arises out of the action
or inaction of such Sublicensee or the Sublicensee is then in breach of its obligations under such
sublicense, in which case ARCHEMIX, at its option, may terminate such sublicense. Each sublicense
shall also contain provisions which obligate such Sublicensee to comply with terms, conditions,
agreements and obligations that are consistent with the terms, conditions, agreements and
obligations to which EYETECH is subject under this Agreement. ARCHEMIX hereby agrees to accept
such assignment and that such sublicense, as assigned, will remain in full force and effect,
provided that ARCHEMIX shall have no obligation thereunder except to maintain the continued
effectiveness of the sublicense.

          4.2.3 Exclusivity for Compounds. ARCHEMIX hereby agrees that (A) neither ARCHEMIX nor
its Affiliates will use, make, have made, offer to sell, sell, import, license or otherwise
distribute any Compound Candidate, Lead Compound or Back-Ups anywhere in the Territory, regardless
of whether inside or outside the Field unless the same shall have become a

Confidential

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.

36

 

Refused Candidate, (B) so long as EYETECH meets or is excused from making Diligent Efforts to
Develop and Commercialize a Development Compound or Compound Product under Section 4.8.1, neither
ARCHEMIX nor its Affiliates will at any time during the Collaboration Term, even if this Agreement
has been terminated, use, license, import, manufacture, have manufactured, offer to sell or sell
any Lead Compound Equivalent to such Development Compound or Compound Product, which was in its
Control on the Effective Date or over which it later obtains Control, in the Field, unless such
Development Compound or Compound Product has become a Refused Candidate and (C) neither ARCHEMIX
nor its Affiliates will at any time use, make, have made, offer to sell, sell, import, license or
otherwise distribute NX1838. Nothing contained in this Agreement shall restrict ARCHEMIX from
using, licensing, importing, making, selling or otherwise dealing with (i) any Aptamer Equivalent
of any Compound or Back-Up outside the Field, (ii) any Aptamer or Aptamer Equivalent in the Field
directed to a Refused Target or its ligands, subject to EYETECH’s enforcement rights set forth in
Section 8.3.1 or (iii) Aptamers against a target that has been deferred by EYETECH for inclusion in
the Research Program and its ligands for any indication in the Field if EYETECH confirms in writing
that it is contractually restricted from researching, Developing or Commercializing Aptamers
directed to such target, which written confirmation shall be provided by EYETECH upon ARCHEMIX’s
request without undue delay, subject to EYETECH’s enforcement rights set forth in Section 8.3.1.

          4.2.4 Negative Covenant. Without limiting any of the other terms, conditions or
limitations contained herein, EYETECH shall not (a) develop, modify, manufacture, have
manufactured, export, import, use, sell or offer to sell any products containing any Excluded
Aptamer (other than NX1838), (b) develop, modify, manufacture, have manufactured, export, import,
use, sell or offer to sell any Excluded Aptamer (other than NX1838), or (c) develop, modify,
manufacture, have manufactured, export, import, use, sell or offer any Aptamer for In Vitro
Diagnostics, as In Vivo Diagnostic Agents or as Radio Therapeutics or (d) develop, modify,
manufacture, have manufactured, export, import, use, sell or offer to sell any Aptamer outside the
Field, except for a VEGF Product in the Local Delivery Field. For the avoidance of any doubt,
nothing in this Section 4.2.4 shall limit EYETECH’s ability to develop, modify, manufacture, have
manufactured, import, use, sell or offer to sell any products (other than VEGF

Confidential

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.

37

 

Products outside the Field and the Local Delivery Field) for which EYETECH has obtained rights
from a third party under the SELEX Portfolio.

          4.2.5 Exclusivity between the Parties in the Field. In addition to the restrictions
set forth in Sections 2.5, 3.2(a), 4.2.3 and 4.2.4:

               4.2.5.1 ARCHEMIX Obligation. During the Research Term and so long as EYETECH meets or
is excused from meeting the EYETECH Diligence Goal and is fulfilling its obligations under Section
4.8.1, (A) ARCHEMIX shall not commence a research program (other than as contemplated by the
Research Program) in collaboration with any Third Party involving the identification, optimization,
research, development, licensing or sale of Aptamers in the Field, and (B) ARCHEMIX shall not grant
rights in the Field to any Third Party with respect to Aptamers directed to a target that is not a
Refused Target and (C) ARCHEMIX shall not grant rights in the Field to any Third Party with respect
to Aptamers directed to a Target that is selected for work in the Research Program or its Target
Binding Partner as long as any Aptamer against such Target, or efforts to identify such Aptamer,
is included in the Research Program. During the Collaboration Term and thereafter for as long as
EYETECH is under a current obligation to pay royalties to ARCHEMIX, or is making Diligent Efforts
to Develop a Lead Compound, Development Compound or Compound Product which if Commercialized would
result in a future obligation to pay royalties to ARCHEMIX, if EYETECH meets or is excused from
making Diligent Efforts to Develop and Commercialize a Lead Compound, Development Compound or
Compound Product under Section 4.8.1, ARCHEMIX shall not, alone or in collaboration with Third
Parties, Develop or Commercialize or grant rights to Third Parties to Develop or Commercialize any
Aptamers in the Field directed against the same Target or Target Binding Partner against which such
Lead Compound, Development Compound or Compound Product is directed. The preceding sentence of this
Section 4.2.5.1 shall survive the termination or expiration of this Agreement.

               4.2.5.2 EYETECH Obligation. Except as set forth in Section 4.2.5.3, during the
Research Term EYETECH will not conduct any research in the Field or enter into any agreement in the
Field with a Third Party with respect to research, development or commercialization of any
Alternate Therapy (defined below) directed to a prospective Target

Confidential

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.

38

 

unless EYETECH has first presented such Target to the JRC pursuant to Section 2.5 and
ARCHEMIX’s representatives to the JRC have elected not to include such Target in the Research
Program. For purposes of this Section 4.2.5.2, an Alternate Therapy is any molecule or combination
of molecules directed to a Target other than VEGF, including, without limitation, any antibody and
antibody fragment.

               4.2.5.3 Exceptions to EYETECH Obligations. Notwithstanding the foregoing, EYETECH may
conduct research or enter into an agreement in the Field with a Third Party (i) to develop any
molecule against any potential target that JRC determines is a target not amenable to intervention
using an Aptamer, or (ii) to develop any molecule against any potential Target proposed by EYETECH
and refused by ARCHEMIX for inclusion in the Research Program pursuant to Section 2.5 or (iii) to
develop a small molecule compound against any potential Target, or (iv) to license any molecule
against any potential Target if EYETECH reasonably believes that such molecule is at least a year
closer to the filing of an NDA than any Aptamer against such potential Target being researched or
Developed in the Research Program or the EYETECH Development Program (it being understood that a
lead compound candidate against a target available for licensing shall be deemed a year closer to
NDA filing if no Lead Compound against the same target has been entered into the Research Program),
or (v) if EYETECH has established an internal research program against a target as of the Effective
Date provided however, that if EYETECH takes any action described in the preceding clauses (i),
(iii), (iv) and (v), EYETECH will notify ARCHEMIX of the potential Target involved and the
indication for which EYETECH is developing or licensing such molecule and (a) the potential Target
involved and the ligands that bind to it will become a Refused Target, and (b) ARCHEMIX will be
free to discover, develop and commercialize any Aptamer for such indication against such potential
Target and its Target Binding Partner, notwithstanding any other provision of this Agreement, all
without any further action of the Parties. In addition, if EYETECH confirms in writing that it is
contractually restricted from researching, Developing or Commercializing Aptamers directed to such
target which written confirmation shall be provided upon ARCHEMIX’s request without undue delay,
then the target of such Aptamer and ligands that bind to it shall become a Refused Target.

Confidential

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.

39

 

               4.2.6 Technology Transfer. During the Term, promptly after the effectiveness of the
applicable licenses under Section 4.2.1, ARCHEMIX shall disclose to EYETECH all ARCHEMIX Technology
which is necessary or useful for EYETECH and licensed to EYETECH under Section 4.2.1 relating to
the Compound Candidate, as applicable, whether in human or machine readable form, all such
information to be included in the ARCHEMIX Technology; provided that the information to be
disclosed shall not include the SELEX Process or any ARCHEMIX Patents, ARCHEMIX Know-How or
ARCHEMIX Program Patents covering or embodied in the SELEX Process. ARCHEMIX acknowledges that the
information that EYETECH desires to receive pursuant to this Section 4.2.6 is information that
would be necessary or useful to EYETECH in maximizing the value of the Compound Candidate, Lead
Compound and the resulting Compound Products.

          4.3 Grant to ARCHEMIX.

               4.3.1 Research License. EYETECH hereby grants to ARCHEMIX a non-exclusive,
royalty-free, license, sublicensable solely to its Affiliates and Service Providers, in the
Territory under the ARCHEMIX Technology that is exclusively licensed to EYETECH hereunder and a
royalty-free, non-exclusive license in the Territory under the EYETECH Technology, EYETECH Program
Technology, EYETECH Program Patents and any EYETECH interest in the Joint Program Technology and
Joint Program Patents to use and practice the EYETECH Technology, EYETECH Program Technology and
Joint Program Technology, in each case only in the Field and solely to perform ARCHEMIX’S
obligations and responsibilities under this Agreement during the Research Term.

               4.3.2 ARCHEMIX Option. Subject to the restrictions of Section 4.2.3 hereof, EYETECH hereby
grants to ARCHEMIX: (1) an option for a royalty-free, non-exclusive license (the “ARCHEMIX
License Option”) in the Territory, with the right to grant sublicenses to Collaborators,
under the EYETECH Program Technology, EYETECH Program Patents, any EYETECH interest in the
Joint Program Technology and Joint Program Patents, the EYETECH Development Program
Technology and the EYETECH Development Program Patents to make, use, sell, offer to sell
and import Refused Candidates and Aptamer Equivalents of Compounds outside the Field and
Aptamer Equivalents of Compounds against

Confidential

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.

40

 

VEGF outside the Field and the Local Delivery Field. Notwithstanding the foregoing,
EYETECH shall have no obligation to disclose EYETECH Development Program Technology that is not
covered by EYETECH Development Program Patents to ARCHEMIX.

          4.3.3 Exercise of Option. ARCHEMIX may exercise an ARCHEMIX License Option by
delivery to EYETECH of a written notice of exercise (an “Exercise Notice”), specifying the Refused
Candidate or Aptamer Equivalent of a Compound or Aptamer Equivalents of Compounds against VEGF
outside the Field and Local Delivery Field as to which such License Option is being exercised. In
the event ARCHEMIX will be responsible for any payment to EYETECH pursuant to the last two
sentences of Section 4.3.4 or under the last sentence of Section 4.13.2, Eyetech will so notify
ARCHEMIX in writing within ten (10) days of receipt of the Exercise Notice, including the details
of all said payments and the technology to which it pertains, and ARCHEMIX will have the option to
exclude any technology subject to such payment from the license grant by written notice to EYETECH
given within thirty (30) days of EYETECH’s notice to ARCHEMIX. Eyetech shall only grant a
sublicense to ARCHEMIX under any Third Party license to the extent the grant of such sublicense is
permitted under EYETECH’s license.

          4.3.4 Payment. ARCHEMIX shall make the following payments to EYETECH in
consideration of the licenses obtained through exercise of options under Section 4.3.3: (1) a
one-time payment of U.S. $[***] upon the first exercise of such option; (2) U.S. $[***] annual
maintenance fee upon each anniversary of the first license grant until the first commercial sale
of the first product covered by any such license; and (3) U.S. $[***] upon the first commercial
sale of the first product covered by any such license. ARCHEMIX hereby agrees to pay to EYETECH in
full any and all Third Party royalties and all other payments which EYETECH owes to its licensors
with respect to any license or sublicense granted by EYETECH to ARCHEMIX under this Agreement.
Such payments shall be due and payable by ARCHEMIX on or before the date they are payable by
EYETECH.

     4.4 Commencement of the Development Program. As soon as practicable after the
effectiveness of a license under Section 4.2 hereof relating to a Lead Compound, but in no event
later than [***] days thereafter, EYETECH shall commence an EYETECH Development

Confidential

Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company’s application requesting
confidential treatment under Rule 406 of the Securities Act.

41

 

Program with respect to such Lead Compound. EYETECH will have sole authority and
responsibility for, and bear the cost of, conducting the EYETECH Development Program with respect
to the Lead Compound. The Parties will agree on reasonable and appropriate measures by which
manufacturing or synthesis, if any, of the Lead Compound previously being undertaken by ARCHEMIX
shall be transitioned to EYETECH following the effective date of such license. The objective of
both Parties will be to accomplish a smooth and timely transition. At ARCHEMIX’s fully loaded cost
determined in accordance with ARCHEMIX’s normal accounting practices and United States generally
accepted accounting principles (“GAAP”), and upon EYETECH’s request ARCHEMIX shall provide all or
part of the amounts of such Lead Compound substance then in its possession accompanied by a
document setting forth the sequence of the Lead Compound and any analytic information with respect
thereto which ARCHEMIX has available. ARCHEMIX shall make no warranty other than as expressly set
forth in such document.

     4.5 Abandonment of a Lead Compound. EYETECH shall have the right to abandon a Lead
Compound and/or all of its Back-up Compounds, in which event its licenses thereto shall
automatically terminate. In such case, no further milestone or other payments shall be due and
payable with respect to that Lead Compound and/or its Back-ups, as applicable, hereunder and such
Lead Compound and/or its Back-ups shall collectively become a Refused Candidate. For clarity,
unless EYETECH abandons the Lead Compound as well as all of its Back-ups none of the aforesaid
Compounds shall become a Refused Candidate. The provisions of Section 9.7 shall apply to any Lead
Compound and its Back-ups for which EYETECH’s license is terminated, except that the license grant
for EYETECH Technology shall not be free of charge, and instead shall be on commercially reasonable
terms to be agreed upon. In addition, if there are no other Program Compounds directed to the
Target of the Refused Candidate and Aptamers against such Target are not the subject of activities
in the Research Program or the EYETECH Development Program, then the Target of the Refused
Candidate shall be a Refused Target without further action by the Parties.

     4.6 Registration Dossiers for Regulatory Approvals; ARCHEMIX Data. EYETECH shall be
solely responsible for and authorized to prepare and submit registration dossiers for

Confidential

Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company’s application requesting
confidential treatment under Rule 406 of the Securities Act.

42

 

Regulatory Approval of the Lead Compound (and any resulting Development Compound and/or
Compound Product). ARCHEMIX shall provide EYETECH with all information in its Control relating to
such Lead Compound and EYETECH shall have the right to use and reference that information in
connection with preparation and submission of regulatory dossiers. All Regulatory Approvals shall
be held by and in the name of EYETECH, and EYETECH shall own all submissions in connection with
them and such submissions shall constitute the Confidential Information of EYETECH regardless of
the absence of any markings thereon.  

          4.6.1 Principal Interface. All formulary or marketing approvals shall be obtained by
and in the name of EYETECH, and EYETECH will be the principal interface with and will otherwise
handle all interactions with Regulatory Authorities concerning any Development Compound and/or
Compound Product including, to the extent legally possible, being the sole contact with such
agencies.

          4.6.2 Regulatory Meetings. EYETECH will have sole control as to the regulatory
strategy and regulatory decision-making for any Development Compound and/or Compound Product.

     4.7 Manufacturing and Supply. EYETECH is exclusively authorized and responsible for
the manufacture and supply of all Development Compound and/or Compound Product as necessary for the
conduct of the EYETECH Development Program and for all commercial purposes in the Territory.
Further, EYETECH is exclusively authorized and responsible for formulation, packaging and labeling
including but not limited to package inserts and leaflets for Compound Products.

     4.8 Diligence in Development and Commercialization.

          4.8.1 Diligence. EYETECH shall use Diligent Efforts to Develop, obtain Regulatory
Approval, and Commercialize each Lead Compound in all commercially significant parts of the
Territory, including, without limitation maintaining sufficient facilities, resources and
personnel to fulfil its obligations under this Agreement. Without limiting the generality of the
foregoing, EYETECH will diligently conduct the activities set forth in Appendix 3, as amended from
time-to-time, and will notify ARCHEMIX when such activities are completed.

Confidential

Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company’s application requesting
confidential treatment under Rule 406 of the Securities Act.

43

 

If EYETECH abandons the Development or Commercialization of a Lead Compound, it will so
notify ARCHEMIX, whereupon the license for such Lead Compound will terminate and, unless EYETECH
is pursuing a Back-up, such Lead Compound will become a Refused Candidate for all purposes of this
Agreement and the provisions of Section 9.7 shall apply to any Lead Compound and its Back-ups for
which a license is terminated; except that the license grant for EYETECH Technology shall not be
free of charge, and instead shall be on commercially reasonable terms to be agreed upon . In
addition, if there are no other Program Compounds directed to the Target of the Refused Candidate
and Aptamers against such Target are not the subject of activities in the Research Program or the
EYETECH Development Program, then the Target of the Refused Candidate shall be a Refused Target
without further action by the Parties, unless the Target is VEGF, in which event VEGF will not
become a Refused Target. Nothing in this Section 4.8.1 shall be deemed to give ARCHEMIX any
rights in the Field or the Local Delivery Field to Refused Candidates directed against VEGF.

          4.8.2 Gilead Reversion of Rights. EYETECH acknowledges and agrees that under the URC
License Agreement and the Gilead-Archemix License, ARCHEMIX’s rights in the ARCHEMIX Technology
may revert to Gilead or the UTC if ARCHEMIX, its Affiliates and all assignees and sublicensees
cease reasonable efforts to develop the commercial applications of products and services utilizing
the technology licensed to ARCHEMIX under the Gilead-Archemix License, including, the ARCHEMIX
Technology.

          4.8.3 Reporting. EYETECH shall keep ARCHEMIX fully informed with respect to its
diligence obligations, including without limitation, thorough reports to ARCHEMIX as described
below, providing ARCHEMIX with copies of all Regulatory Filings and by meeting with ARCHEMIX at
ARCHEMIX’s request, but no more than once semi-annually. On or before February 15 and August 15,
commencing August 15, 2004, EYETECH shall provide a semi-annual progress report to ARCHEMIX, each
report covering the [***] month period preceding the due date of the report. Each report shall
describe the progress made by EYETECH, its Affiliates or Sublicensees toward the commercial
development of any Compound Products. Such report shall include at a minimum, information
reasonably sufficient to enable ARCHEMIX to satisfy its reporting obligations to Gilead under the
Gilead-

Confidential

Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company’s application requesting
confidential treatment under Rule 406 of the Securities Act.

44

 

Archemix License with respect to this Agreement, including any reporting obligations of the
U.S. Government, and to assess the progress made by EYETECH toward meeting the diligence
requirements of this Section 4.8

     4.9 Section 365(n) of the Bankruptcy Code. 

          4.9.1 Intellectual Property; Embodiments. All rights and licenses granted under or
pursuant to any Section of this Agreement, including this Article 4, are rights to “intellectual
property” as defined in Section 101(35A) of Title 11 of the United States Code, as amended (such
Title 11, the “Bankruptcy Code”). Each Party hereby acknowledges that (i) copies of research
data, (ii) laboratory samples, (iii) product samples, (iv) formulas, (v) laboratory notes and
notebooks, (vi) data and results related to clinical trials, (vii) regulatory filings and
approvals, (viii) rights of reference in respect of regulatory filings and approvals, (ix)
pre-clinical research data and results, and (x) marketing, advertising and promotional materials,
in each case, that relate to such intellectual property, constitute “embodiments” of such
intellectual property pursuant to Section 365(n) of the Bankruptcy Code, and each Party hereby
grants to the other a right of access and right to obtain possession of and to benefit from such
embodiments in the event of any rejection of this Agreement in any proceeding by or against such
Party under the Bankruptcy Code. Each such Party agrees not to interfere with the other’s
exercise, pursuant to Section 365(n) of the Bankruptcy Code, of rights and licenses to
intellectual property licensed hereunder and embodiments thereof and agrees to use reasonable
efforts, at the other’s expense, to assist the other to obtain such intellectual property and
embodiments thereof in the possession or control of Third Parties as reasonably necessary for the
other to exercise, pursuant to Section 365(n) of the Bankruptcy Code, such rights and licenses.

          4.9.2 Royalty Payments. The Parties acknowledge and agree that the royalty payments
payable by EYETECH and ARCHEMIX under Sections 5.2.1 and 5.2.2 and the milestone payments payable
under Sections 5.3 and 5.4 constitute “royalty payments” under Section 365(n) of Title 11 of the
United States Code with respect to the licenses granted by ARCHEMIX to EYETECH under Sections 4.1,
4.2 and 4.13 and by EYETECH to ARCHEMIX pursuant to Section 4.13 and that such licenses are
otherwise royalty-free. All

Confidential

Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company’s application requesting
confidential treatment under Rule 406 of the Securities Act.

45

 

other payments due from EYETECH to ARCHEMIX hereunder, for purposes of Section 365(n) of the
Bankruptcy Code, constitute payments in consideration of ARCHEMIX’s performance of its obligations
hereunder.

     4.10 Use of Compound Supplied by ARCHEMIX. Notwithstanding any other provision of
this Agreement, EYETECH acknowledges that any Compound supplied by ARCHEMIX, including without
limitation the Materials, hereunder will not have been manufactured under cGMP or cGLP. The
restrictions under of Section 3.2(e) hereof pertaining to Materials, will also govern EYETECH’s use
of any Compound provided by ARCHEMIX.

     4.11 URC License. The Parties acknowledge and agree that, in the event of any
termination of the URC License Agreement, the licenses granted to EYETECH hereunder shall remain in
full force and effect in accordance with Section 3.4 of the URC License Agreement, provided that
EYETECH is not then in breach of this Agreement and EYETECH agrees to be bound to UTC as the
licensor under the terms and conditions of this Agreement.

     4.12 Gilead-Archemix License. The Parties further acknowledge and agree that, in the
event of any termination of the Gilead-Archemix License, the licenses granted to EYETECH hereunder
shall remain in full force and effect in accordance with Section 2.3 of the Gilead-Archemix License
provided that EYETECH agrees to be bound to Gilead as the licensor under the terms and conditions
of this Agreement and provided that if the termination of the Gilead-Archemix License arises out of
the action or inaction of EYETECH, Gilead, at its option, may terminate such license.

     4.13 Cross Licenses for VEGF. The Parties agree that, as between them, EYETECH shall
have the exclusive right to Develop and Commercialize Aptamers against VEGF in the Field and in the
Local Delivery Field, and that ARCHEMIX shall have the exclusive right to Develop and Commercialize
Aptamers (other than NX1838) against VEGF in all other fields. To achieve this agreement:
Furthermore, the Parties agree that the licenses granted under this Section 4.13 shall not be
subject to any diligence requirement (including without limitation any obligation to use Diligent
Efforts to develop or commercialize any Product) otherwise set forth in this Agreement.

Confidential

Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company’s application requesting
confidential treatment under Rule 406 of the Securities Act.

46

 

          4.13.1 To the extent that ARCHEMIX has, as of the Effective Date, or acquires during the
Term of this Agreement the right to do so, ARCHEMIX shall and hereby does grant to EYETECH an
exclusive, royalty-bearing (during the applicable Royalty Term only) license in the Territory,
with the right to grant sublicenses, under the ARCHEMIX Patents, ARCHEMIX Program Patents and
ARCHEMIX’s interest in Joint Program Patents to discover, Develop, modify, manufacture, have
manufactured, export, import, use, sell and offer to sell, VEGF Products in the Field and the
Local Delivery Field. For the avoidance of doubt, 1) the royalty due to ARCHEMIX on any EYETECH
VEGF Product will be independent of the extent of ARCHEMIX’s specific contribution to such VEGF
Product and 2) the prohibition on the use of the SELEX Process set forth in Section 4.1 and 4.2.1
do not apply to this Section 4.13.1. EYETECH hereby agrees to pay to ARCHEMIX in full any and all
Third Party royalties and all other payments which ARCHEMIX owes to its licensors with respect to
any license or sublicense granted by ARCHEMIX to EYETECH under this Agreement. Such payments shall
be due and payable by EYETECH on or before the date they are payable by ARCHEMIX.

          4.13.2 To the extent that EYETECH has, as of the Effective Date, or acquires during the Term
of this Agreement the right to do so, EYETECH shall and hereby does grant to ARCHEMIX an
exclusive, royalty-bearing (during the applicable Royalty Term only) license in the Territory,
with the right to grant sublicenses, under the EYETECH Patents, EYETECH Program Patents and
EYETECH’s interest in Joint Program Patents to discover, Develop, modify, manufacture, have
manufactured, export, import, use, sell and offer to sell, VEGF Products outside the Field and the
Local Delivery Field, excluding NX1838. For the avoidance of doubt, the royalty due to EYETECH on
any ARCHEMIX VEGF Product will be independent of the extent of EYETECH’s specific contribution to
such VEGF Product. ARCHEMIX hereby agrees to pay to EYETECH in full any and all Third Party
royalties and all other payments which EYETECH owes to its licensors with respect to any license
or sublicense granted by EYETECH to ARCHEMIX under this Agreement. Such payments shall be due and
payable by ARCHEMIX on or before the date they are payable by EYETECH.

Confidential

Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company’s application requesting
confidential treatment under Rule 406 of the Securities Act.

47

 

          4.13.3 To the extent that it has or acquires the right to do so, EYETECH hereby grants to
ARCHEMIX a non-exclusive, non-royalty bearing, research license, sublicensable only to its
Affiliates and Service Providers, solely to discover and optimize VEGF Aptamers, excluding NX1838,
for use in the Field and the Local Delivery Field as directed by the JRC.

          4.13.4 In order to assure the exclusivity of the rights granted in Sections 4.13.1 and
4.13.2, ARCHEMIX agrees it will not develop or sell any VEGF Product for use in the Field or the
Local Delivery Field and EYETECH agrees it will not develop or sell any VEGF Product, excluding
NX1838, unless such VEGF Product is for use in the Field or in the Local Delivery Field.

Confidential

Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company’s application requesting
confidential treatment under Rule 406 of the Securities Act.

48

 

ARTICLE 5 PAYMENTS

     5.1 Up-front Fees. Within ten (10) business days of the Effective Date, EYETECH
shall deliver to ARCHEMIX One Million and five hundred thousand U.S. Dollars ($1,500,000).

5.2 Royalties.

          5.2.1 Royalty Rates for Compound Products. During the Royalty Term applicable to a
Compound Product that is not a VEGF Product, EYETECH shall pay to ARCHEMIX the following royalties
on Net Sales of such Compound Product, other than VEGF Products, during each Contract Year:

	 	 	 
	Range of Net Sales applicable to such	 	Royalty Percentage
	Compound Product in such Contract Year	 	applicable to such Range
	[***]

	 	[***] percent ([***]%)
	 
	 	 
	[***]

	 	[***] percent ([***]%)
	 
	 	 
	[***]

	 	[***] percent ([***]%)

          For example, if worldwide Net Sales in a Contract Year totaled $[***] for Compound Product A
and $[***] for Compound Product B, EYETECH would pay ARCHEMIX (A) $[***] in royalties for Compound
Product A arising in that Contract Year (calculated as $[***] multiplied by [***], plus $[***]
million multiplied by [***], plus $[***] multiplied by [***]) and (B) $[***] in royalties for
Compound Product B arising in that Contract Year (calculated as $[***] multiplied by [***]). The
same calculation would be performed again for the subsequent Contract Years.

          Royalty payments under this Section 5.2.1 shall continue on a country-by-country basis for the
applicable Royalty Term; provided, however, that the royalty payments otherwise payable under this
Section 5.2.1 as to such country shall be reduced by [***] percent ([***]%) during portions of any
Royalty Term in which (1) no ARCHEMIX Valid Claim exists with

Confidential

Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company’s application requesting
confidential treatment under Rule 406 of the Securities Act.

49

 

respect to (i) the use of the SELEX Process necessary to identify such Compound Product in the
country in which such Compound Product is manufactured or sold; or (ii) the use, manufacture, sale
or import of a Compound Product in the country in which such Compound Product is manufactured or
sold and (2) there exists no pending claim of an ARCHEMIX Patent, ARCHEMIX Program Patent or Joint
Program Patent, with respect to (i) the use of the SELEX Process necessary to identify such
Compound Product in the country in which such Compound Product is manufactured or sold; or (ii) the
use, manufacture, sale or import of such Compound Product in the country in which such Compound
Product is manufactured or sold that has been pending for less than [***] years since the earliest
priority date of the patent application containing such claim. In no event shall such a pending
claim extend the Royalty Term beyond [***] years from the earliest priority date of the application
in which such claim is pending.

          5.2.2 Royalty Rates for VEGF Products. During the Royalty Term applicable to a VEGF
Product,

               (a) EYETECH shall pay to ARCHEMIX the following royalties on Net Sales of such VEGF Product
during each Contract Year:

	 	 	 
	[***]

	 	[***]
percent 
([***]%)        
	 
	 	 
	[***]

	 	[***] percent
 ([***]%)        

               (b) ARCHEMIX shall pay to EYETECH the following royalties on Net Sales of such VEGF Product
during each Contract Year:

	 	 	 
	[***]

	 	[***]
percent
 ([***]%)        

Confidential

Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company’s application requesting
confidential treatment under Rule 406 of the Securities Act.

50

 

          Royalty payments under this Section 5.2.2 shall continue on a country-by-country basis for the
applicable Royalty Term; provided, however, that the royalty payments otherwise payable under this
Section 5.2.2 as to such country shall be reduced by [***] percent ([***]%) during portions of any
Royalty Term in which no ARCHEMIX Valid Claim exists with respect to the use, manufacture, sale or
import of a VEGF Product in the country in which such VEGF Product is manufactured or sold and
there exists no pending claim of an ARCHEMIX Patent, ARCHEMIX Program Patent or Joint Program
Patent, with respect to the use, manufacture, sale or import of such VEGF Product in the country in
which such VEGF Product is manufactured or sold that has been pending for less than [***] years
since the earliest priority date of the patent application containing such claim.

          5.2.3 Third Party Royalties. Each of EYETECH and ARCHEMIX, at is respective sole
expense, shall pay all royalties or fees owing to any Third Party that such Party determines, in
its reasonable business judgment, are necessary in order to exercise its rights hereunder to
develop, modify, manufacture, have manufactured, export, import, use, sell and offer to sell,
Compound Products or VEGF Products as set forth herein. Each Party shall obtain and pay for any
Third Party licenses necessary to practice the rights granted to it herein [***] milestone
payments or royalties payable hereunder. Notwithstanding the above, (A) ARCHEMIX shall obtain or
pay for any Third Party licenses which, in its sole discretion, it believes are specifically
necessary to perform the SELEX Process as required to carry out its obligations under the Research
Program, including paying any royalty payments due to the University of Colorado resulting from
payments made by EYETECH to ARCHEMIX, (B) subject to EYETECH’s notice obligation under Section
4.3.3, ARCHEMIX hereby agrees to pay to EYETECH in full any and all Third Party royalties which
EYETECH owes to its licensors with respect to any sublicense granted by EYETECH to ARCHEMIX
pursuant to

Confidential

Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company’s application requesting
confidential treatment under Rule 406 of the Securities Act.

51

 

Section 4.3 above and (C) EYETECH hereby agrees to pay to ARCHEMIX in full any and all Third
Party royalties which ARCHEMIX owes to its licensors with respect to any sublicense granted by
ARCHEMIX to EYETECH for ARCHEMIX Proprietary Targets under licenses granted to ARCHEMIX after the
Effective Date. Archemix shall only grant a sublicense to EYETECH under any Third Party license
to the extent the grant of such sublicense is permitted under ARCHEMIX’s license.

     In the event EYETECH will be responsible for any payment to ARCHEMIX pursuant to the preceding
sentence or the last sentence of Section 4.13.1, ARCHEMIX will so notify EYETECH in writing within
[***] days of the proposal of the relevant ARCHEMIX Proprietary Target pursuant to Section 2.5,
including the details of all said payments and the technology to which it pertains, and EYETECH
will have the option to exclude any technology subject to such payment from the license granted
under Sections 4.1 and 4.2 by written notice to ARCHEMIX given within thirty (30) days of
ARCHEMIX’s notice to EYETECH.

          5.2.4 Sales Reports. During the Royalty Term for a Compound Product or VEGF Product,
the licensed Party shall furnish or cause to be furnished to the licensing Party on a [***] basis
a sales report covering sales by the licensed Party, its Affiliates and its Sublicensees during
each calendar quarter (each such calendar quarter being sometimes referred to herein as a
“reporting period”) and including the gross amount received and an itemization of deductions
permitted by Section 1.71 on a country-by-country basis. With respect to Sales of the Compound
Products or VEGF Products invoiced in US Dollars, the Net Sales amounts and the amounts due to the
licensing Party hereunder shall be expressed in US Dollars. With respect to sales of the Compound
Products or VEGF Products invoiced in a currency other than US Dollars, the Net Sales and amounts
due to the licensing Party hereunder shall be expressed in the currency in which they are
invoiced, together with the US Dollar equivalent of the amount payable to the licensing Party,
calculated using the licensed Party’s

Confidential

Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company’s application requesting
confidential treatment under Rule 406 of the Securities Act.

52

 

then-current standard exchange rate methodology for the translation of foreign currency sales
into US Dollars. In each Sales Report, the methodology will be disclosed and will be identical to
that employed by the licensed Party, generally, in its external financial reporting, as reviewed
and approved by its independent auditors and will be in accordance with U.S. generally accepted
accounting standards (GAAP) as consistently applied at the licensed Party. The licensed Party
shall furnish to the licensing Party appropriate evidence of payment of any tax or other amount
required by applicable laws or regulations to be deducted from any royalty payment, including any
tax or withholding levied by a foreign taxing authority in respect of the payment or accrual of
any royalty. The licensed Party shall not make any other deduction from such payment. Sales
Reports shall be due on the [***] day following the close of each reporting period. Each Sales
Report will be accompanied by payment of all royalties due.

          5.2.5 Recordkeeping. Each Party, as licensed Party, shall keep, and shall cause its
Affiliates and Sublicensees to keep, complete and accurate records of Net Sales and other data
relating to Sales Reports and payments required under this Article 5. The licensing Party may, at
its own expense, except as specified below, have an independent, certified public accountant,
selected by it and reasonably acceptable to the licensed party, review any such records of the
licensed Party and its Affiliates and Sublicensees, in the location(s) where such records are
maintained by the licensed party or its Affiliates or Sublicensees, upon reasonable notice and
during regular business hours and under obligations of confidence, [***] per entity per [***]
month period, for the sole purpose of verifying the basis and accuracy of payments made under this
Article 5 within the prior [***] month period. If the review of such records reveals that any of
the licensed Party, its Affiliates or its Sublicensees has failed to accurately report information
pursuant to this Section 5.2, then the licensed Party shall promptly pay to

Confidential

Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company’s application requesting
confidential treatment under Rule 406 of the Securities Act.

53

 

the licensing Party any corresponding unpaid amounts due under this Article 5, together with
interest calculated in the manner provided in Section 5.6 below and if the error exceeds the
lesser of $[***] or [***]% of the amount reported by the licensed Party, then the licensed Party
shall reimburse the licensing Party for the cost of the audit. Nothing contained herein is
intended to waive or limit the licensed Party’s right to contest the accuracy of any review
undertaken by the licensing Party.

5.3 Development Milestone Payments by EYETECH for Compounds. 

          5.3.1 Milestones and Payments. EYETECH will make the following payments to ARCHEMIX
upon the first achievement of the following milestone events with respect to each Compound or
Back-Up, other than Compounds or Back-ups against VEGF:

	 	 	 	 	 
	 	 	Payment
	Milestone	 	(in U.S. Dollars)
	(A) [***].
	 	$	[***]	 
	 
	 	 	 	 
	(B) [***]
	 	$	[***]	 
	 
	 	 	 	 
	(C) [***]
	 	$	[***]	 
	 
	 	 	 	 
	(D) [***]
	 	$	[***]	 
	 
	 	 	 	 
	(E) [***]
	 	$	[***]	 
	 
	 	 	 	 
	(F) [***] [***]
	 	$	[***]	 
	 
	 	 	 	 
	(G) [***]
	 	$	[***]	 
	 
	 	 	 	 
	(H) [***]
	 	$	[***]	 

Confidential

Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company’s application requesting
confidential treatment under Rule 406 of the Securities Act.

54

 

          EYETECH shall immediately notify ARCHEMIX of the achievement of the above milestone events
with respect to each Compound; provided that if a payment is made for Milestone (B), (C), (D), (E)
or (F) with respect to a Compound and any of the preceding Milestone payments were not made with
respect to such Compound, such earlier Milestone payments shall be made concurrently therewith
(e.g. if Milestone (F) is achieved, but Milestone (E) was never achieved or paid, the payments for
Milestone (E) and (F) shall be made concurrently). For the avoidance of doubt, in no event shall
any of the foregoing milestones be paid more than once for any Compound, even if such Compound is
approved or utilized for different Indications than first approved or utilized.

          5.3.2 Attainment of Milestones for Development Compounds. The milestone payments
specified above shall be payable at the first achievement of a milestone by each Compound. Except
as provided in Section 5.3.3 below, multiple payments for achieving the milestone events specified
above shall be payable if EYETECH develops both the Lead Compound and a Back-Up; provided,
however, that (i) EYETECH shall pay [***] milestone payment upon the occurrence of the
milestone event specified in [***] of Section 5.3.1 above with respect to any Lead Compound and
all of the Back-Ups related thereto; and (ii) if EYETECH develops both the Lead Compound and a
Back-Up, EYETECH shall pay [***] of the milestone payments specified above until such time as the
second of the Lead Compound or the Back-Up achieves the milestone event specified in [***] of
Section 5.3.1 above, at which time EYETECH shall pay [***] for such [***] Compound to the extent
those payments were not previously made or applicable and subsequently pay the [***] for such
second Compound, as those milestones are satisfied with respect to such second Compound.

          5.3.3 Abandonment of a Compound; Effect on Back-Up Milestone Payments. If the
Development or Commercialization of a Compound is abandoned during the Term for any reason (in
which event, the provisions of Section 4.5 hereof would apply) after any one or more of the
foregoing milestone payments are made, and a Back-Up is developed to replace the abandoned
Compound, then no milestone payment shall be required with respect to the Back-Up to the extent
that that milestone payment has already been made with respect to the abandoned Compound.

Confidential

Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company’s application requesting
confidential treatment under Rule 406 of the Securities Act.

55

 

     5.4 Development Milestone Payments for VEGF Products.

          5.4.1 Milestones and Payments. EYETECH and ARCHEMIX will each make the following
payments to the other upon the first achievement by it of the following milestone events with
respect to each VEGF Product :

	 	 	 	 	 
	 	 	Payment
	Milestone	 	(in US Dollars)
	(a) [***]
	 	$	[***]	 
	 
	 	 	 	 
	(b) [***]
	 	$	[***]	 
	 
	 	 	 	 
	(c) [***]
	 	$	[***]	 
	 
	 	 	 	 
	(d)[***]
	 	$	[***]	 
	 
	 	 	 	 
	(e)[***]
	 	$	[***]	 
	 
	 	 	 	 
	(f) [***]
	 	$	[***]	 

          The Party developing the VEGF Product shall immediately notify the other Party of the
achievement of the above milestone events with respect to each VEGF Product; provided that if a
payment is made for Milestone (b), (c), (d), (e) or (f) with respect to a VEGF Product and any of
the preceding Milestone payments were not made with respect to such VEGF Product, such earlier
Milestone payments shall be made concurrently therewith (e.g., if Milestone (d) is achieved, but
Milestone (c) was never achieved or paid, the payments for Milestone (c) and (d) shall be made
concurrently). For the avoidance of doubt, in no event shall any of the foregoing milestones be
paid [***] by either Party for any VEGF Product, even if such VEGF Product is approved or utilized
for different Indications than first approved or utilized.

          5.4.2 Attainment of Milestones for VEGF Products. The milestone payments specified
above shall be payable by a Party at the first achievement of a milestone by each

Confidential

Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company’s application requesting
confidential treatment under Rule 406 of the Securities Act.

56

 

VEGF Product. Except as provided in Section 5.4.3 below, multiple payments for achieving the
milestone events specified above shall be payable if a Party develops both the Lead Compound and a
Back-Up; provided, however, that if the Party develops both the Lead Compound and
a Back-Up, the Party shall pay to the other Party [***] of the milestone payments specified above
until such time as the second of the Lead Compound or the Back-Up achieves the milestone event
specified in [***] of Section 5.4.1 above, at which time the Party shall pay to the other Party
[***] of milestones (a), (b) and (c) for [***] Compound to the extent those payments were not
previously made or applicable and subsequently pay the [***] for such second Compound, as those
milestones are satisfied with respect to such second Compound.

          5.4.3 Abandonment of a VEGF Product. If the Development or Commercialization of a
VEGF Product is abandoned by a Party during the Term for any scientific, medical or commercial
reason after any one or more of the foregoing milestone payments are made, and another Aptamer
against VEGF for use in the same indication is developed to replace the abandoned VEGF Product,
then no milestone payment shall be required with respect to the replacement Aptamer to the extent
that that milestone payment has already been made with respect to the abandoned VEGF Product.

          5.4.4 Equity Investment Option. On or after the Effective Date, ARCHEMIX and EYETECH
agree that it is their mutual intent that EYETECH will purchase [***] dollars ($[***]) of Stock
of ARCHEMIX on terms that are pari passu with terms granted to other investors in the first round
of financing to occur following September 1, 2004; provided, however, that neither Party shall
have any obligation with respect to such obligation unless it is mutually agreed at the time.

     5.5 Currency. All payments shall be made in the United States in US Dollars,
regardless of the country in which products are sold.

     5.6 Invoices; Late Payments. Payments of milestones shall be due within [***]
business days of the achievement of the milestone. In case of any delay in payment by either Party
to the other Party not occasioned by Force Majeure or a good faith dispute regarding the

Confidential

Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company’s application requesting
confidential treatment under Rule 406 of the Securities Act.

57

 

amount due, interest on the unpaid amount at the lesser of (i) the Prime Rate in effect at the
close of business on the date the applicable payment was due, as reported in The Wall Street
Journal, plus [***] percent ([***]%), compounded annually, or (ii) the highest rate permitted by
applicable law shall be payable by the paying Party from the due date through the date of payment
in full.

ARTICLE 6 CONFIDENTIALITY

     6.1 Confidential Information. All Confidential Information disclosed by a Party to
the other Party during the Term of this Agreement shall not be used by the receiving Party except
in connection with the activities contemplated by this Agreement, shall be maintained in confidence
by the receiving Party (except to the extent reasonably necessary for Regulatory Approval of
products developed by EYETECH or ARCHEMIX or any of their respective Affiliates or for Patent
Prosecution), and shall not otherwise be disclosed by the receiving Party to any other person,
firm, or agency, governmental or private, without the prior written consent of the disclosing
Party, except to the extent that the Confidential Information (as determined by competent
documentation):

          (a) was known or used by the receiving Party prior to its date of disclosure to the receiving
Party; or

          (b) either before or after the date of the disclosure to the receiving Party is lawfully
disclosed to the receiving Party by sources other than the disclosing Party without such source
violating its confidentiality obligations, if any, to the disclosing Party; or

          (c) either before or after the date of the disclosure to the receiving Party becomes published
or generally known to the public (including information known to the public through the sale of
products in the ordinary course of business) through no fault or omission on the part of the
receiving Party; or

          (d) is independently developed by or for the receiving Party without reference to or reliance
upon the Confidential Information.

Confidential

Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company’s application requesting
confidential treatment under Rule 406 of the Securities Act.

58

 

     6.2 Permitted Disclosures 

          (a) The provisions of Section 6.1 shall not preclude a Party or its Affiliates from disclosing
Confidential Information to the extent such Confidential Information is required to be disclosed by
such Party or its Affiliates to comply with applicable law or legal process, including without
limitation the rules or regulations of the United States Securities and Exchange Commission or
similar regulatory agency in a country other than the United States or of any stock exchange,
including without limitation Nasdaq, or to defend or prosecute litigation, provided that such Party
provides prior written notice of such disclosure to the disclosing Party and takes reasonable and
lawful actions to avoid and/or minimize the degree of such disclosure.

          (b) Subject to Sections 6.2(c) and 11.10, the Parties agree that the material financial terms
of this Agreement will be considered Confidential Information of both Parties. Notwithstanding the
foregoing, (a) either Party may disclose such terms to bona fide potential or actual sublicensees,
as reasonably necessary in connection with a permitted sublicense under the licenses granted in
this Agreement, and (b) either Party may disclose the material financial terms of this Agreement to
bona fide potential or actual investors, lenders, investment bankers, acquirors, acquirees, merger
partners or other potential financial partners, and to such Party’s consultants and advisors, as
reasonably necessary in connection with a proposed equity or debt financing of such Party or as
reasonably necessary in connection with a proposed acquisition or business combination. In
connection with any permitted disclosure of Confidential Information pursuant to this Section
6.2(b), each Party agrees to use all reasonable efforts to inform each disclosee of the
confidential nature of such information and cause each disclosee to treat such information as
confidential.

          (c) Notwithstanding any provision to the contrary in this Agreement, either Party may disclose
to any and all Persons, without limitation of any kind, the United States federal tax treatment and
tax structure of the transactions set forth in this Agreement and all materials of any kind
(including opinions or other tax analyses) that are provided to the Parties relating to such tax
treatment and tax structure.

Confidential

Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company’s application requesting
confidential treatment under Rule 406 of the Securities Act.

59

 

     6.3 Employee and Advisor Obligations. EYETECH and ARCHEMIX each agree that they shall
provide Confidential Information received from the other Party only to their respective employees,
consultants and advisors, and to the employees, consultants and advisors of such Party’s
Affiliates, who have a need to know and have an obligation to treat such information and materials
as confidential. 

     6.4 Term. All obligations of confidentiality imposed under this Article 6 shall
expire [***] years following termination or expiration of this Agreement.  

     6.5 Publications. Neither ARCHEMIX nor EYETECH shall publish any Research Program
Data or any other information regarding the Research Program without the other’s prior written
consent, provided, however, that nothing in this Agreement shall restrict EYETECH’s right to
publish information and data regarding Lead Compounds. ARCHEMIX shall not publish information
regarding Compound Candidates, Back-Ups, Lead Compounds or Development Compounds without EYETECH’s
prior written consent. The foregoing restriction on ARCHEMIX shall not apply to Refused
Candidates.

ARTICLE 7 INDEMNIFICATION

     7.1 Indemnification by ARCHEMIX. ARCHEMIX will indemnify and hold EYETECH and its
Affiliates, and their employees, officers and directors (each, an “EYETECH Indemnitee”) harmless
against any loss, damages, action, suit, claim, demand, liability, cost or expense (including
reasonable fees and expenses of legal counsel) (a “Loss”), including, without limitation, product
liability claims, that results from a Third Party claim, other than any claim of patent
infringement, that is based on or arises out of the Development, testing, production, manufacture,
use, Commercialization, import or sale of any Aptamer Equivalent to a Compound Product, Refused
Candidate or VEGF Product which is used, manufactured or sold by ARCHEMIX or any of its Affiliates
or sublicensees; provided, however, that the foregoing indemnification of EYETECH and the EYETECH
Indemnitees shall not apply to any Loss to the extent such Loss is caused by the negligent or
wilful misconduct of EYETECH and its Affiliates, and their employees, officers and directors or as
to which EYETECH is obligated to indemnify ARCHEMIX pursuant to Section 7.2.

Confidential

Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company’s application requesting
confidential treatment under Rule 406 of the Securities Act.

60

 

     7.2 Indemnification by EYETECH.

          (a) ARCHEMIX Indemnitees. EYETECH will indemnify and hold ARCHEMIX, and its
Affiliates, and their employees, officers and directors (each, an “ARCHEMIX Indemnitee“) harmless
against any loss, damages, action, suit, claim, demand, liability, cost or expense (including
reasonable fees and expenses of legal counsel) (a “Loss”), including, without limitation, product
liability claims, that results from a Third Party claim, other than any claim of patent
infringement, that is based on or arises out of the Development, testing, production, manufacture,
Commercialization, use, import or sale of any Compound, Compound Product or VEGF Product which is
used, manufactured or sold by EYETECH or any of its Affiliates or sublicensees; provided,
however, that the foregoing indemnification of ARCHEMIX and the ARCHEMIX Indemnitees shall
not apply to any Loss to the extent such Loss is caused by the negligent or wilful misconduct of
ARCHEMIX and its Affiliates, and their employees, officers and directors or as to which ARCHEMIX is
obligated to indemnify EYETECH pursuant to Section 7.1.

          (b) Gilead Indemnitees. EYETECH will indemnify and hold Gilead Sciences, Inc., its
Affiliates and UTC and any of their respective directors, officers, employees and agents (each, a
“Gilead Indemnitee”) from and against any Damages that are incurred by a Gilead Indemnitee as a
result of Third Party claims, demands, actions or proceedings (collectively, the “Claims”) to the
extent such Claims arise out of:

               (i) the breach or alleged breach of any representation or warranty by EYETECH hereunder;

               (ii) failure to perform any of EYETECH’s covenants or undertakings under this Agreement,
including, without limitation EYETECH’s covenants in Sections 4.2.4 and 4.12 hereof; and

               (iii) the possession, research, Development, manufacture, use, offer for sale, sale or other
Commercialization, distribution, administration, storage or transport, by EYETECH or its Affiliates
or Sublicensees of any Aptamer sublicensed from ARCHEMIX,

Confidential

Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company’s application requesting
confidential treatment under Rule 406 of the Securities Act.

61

 

or product developed by EYETECH relating to the ARCHEMIX Technology, including any Compound
Product or VEGF Product, sublicensed from ARCHEMIX.

     7.3 Claims Procedures as to Third Party Claims. Each EYETECH Indemnitee or ARCHEMIX
Indemnitee entitled to be indemnified by EYETECH or ARCHEMIX (an “Indemnified Party”) pursuant to
Section 7.1 or 7.2 hereof shall give written notice to EYETECH or ARCHEMIX, as the case may be (an
“Indemnifying Party”) promptly after such Indemnified Party has actual knowledge of any threatened
or asserted Third Party claim as to which indemnity may be sought, and shall permit the
Indemnifying Party to assume the defense of any such claim or any litigation resulting therefrom;
provided that:  

          (a) The Indemnifying Party may so assume the defense of any such claim or any litigation
resulting therefrom only if it shall give written notice to the Indemnified Party of the
Indemnifying Party’s decision to so assume such defense within thirty (30) days after the date of
the written notice from the Indemnified Party of the Third Party claim as to which indemnity is
sought;

          (b) Counsel for the Indemnifying Party, who shall conduct the defense of such claim or any
litigation resulting therefrom (if such defense is assumed by the Indemnifying Party), shall be
approved by the Indemnified Party (whose approval shall not unreasonably be withheld) and the
Indemnified Party may participate in such defense with the Indemnified Party’s own counsel at the
Indemnified Party’s own expense (unless (i) the employment of counsel by such Indemnified Party has
been authorized by the Indemnifying Party; (ii) the Indemnified Party shall have reasonably
concluded that there may be a conflict of interest between the Indemnifying Party and the
Indemnified Party in the defense of such action; or (iii) the Indemnifying Party shall have failed
to assume the defense as provided herein, in each of which cases the Indemnifying Party shall pay
the reasonable fees and expenses of one law firm serving as counsel for the Indemnified Party,
which law firm shall be subject to approval, not to be unreasonably withheld, by the Indemnifying
Party);

Confidential

Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company’s application requesting
confidential treatment under Rule 406 of the Securities Act.

62

 

          (c) The failure of any Indemnified Party to give notice as provided herein shall not relieve
the Indemnifying Party of its obligations under this Agreement to the extent that the failure to
give notice did not result in prejudice to the Indemnifying Party;

          (d) No Indemnifying Party, in the defense of any such claim or litigation, shall, except with
the express written consent of each Indemnified Party, consent to entry of any judgment or enter
into any settlement which (i) would result in injunctive or other relief being imposed against the
Indemnified Party; or (ii) does not include as an unconditional term thereof the giving by the
claimant or plaintiff to such Indemnified Party of a release from all liability in respect to such
claim or litigation; provided that the Indemnifying Party is otherwise free to enter into any
settlement in its sole discretion so long as such settlement does not affect the Indemnified Party;

          (e) If the Indemnifying Party assumes the defense of the Third Party claim or litigation, each
Indemnified Party shall furnish such information regarding itself or the claim in question as an
Indemnifying Party may reasonably request in writing in connection with the defense of such claim
and litigation resulting therefrom;

          (f) If the Indemnifying Party assumes the defense of the Third Party claim or litigation, the
Indemnified Party shall not settle or agree to a judgment with respect to such claim or litigation
without the consent of the Indemnifying Party; and

          (g) If the Indemnifying Party does not assume the defense of the Third Party claim or
litigation, the Indemnified Party shall apprise the Indemnifying Party on at least an annual basis
of major developments relating to such claim or litigation; provided, however, that
the Indemnified Party shall not be required to disclose any information to the Indemnifying Party
that would entail a waiver of, or otherwise jeopardize, the attorney-client privilege.

Confidential

Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company’s application requesting
confidential treatment under Rule 406 of the Securities Act.

63

 

     7.4 Compliance. The Parties shall comply with all applicable laws and regulations in
connection with their respective activities under this Agreement.

ARTICLE 8 INTELLECTUAL PROPERTY OWNERSHIP, PROTECTION AND RELATED MATTERS

     8.1 Ownership of Program Technology and Data Retention. 

          8.1.1 Ownership of Program Technology. Except as otherwise set forth herein, all
inventions and discoveries acquired or developed solely by agents, employees, consultants or
subcontractors of a Party during the Research Term (“Sole Inventions”) shall be the property of
such Party. Regardless of inventorship, EYETECH shall own all EYETECH Program Technology and
EYETECH Development Program Technology and ARCHEMIX shall own all ARCHEMIX Program Technology.
Joint Program Technology shall be jointly owned by the Parties, with no duty to account or pay
royalties relating thereto, except as specifically set forth herein. Each Party’s right to
practice and license Joint Program Technology and Joint Program Patents is set forth in Section 4
hereof. Each Party agrees to negotiate in good faith with the other Party upon request for a
non-exclusive license (in the Field for licenses requested by EYETECH and outside the Field for
licenses requested by ARCHEMIX) to such Party’s Sole Inventions. Each Party shall execute such
assignments and other instruments reasonably requested by the other Party in order to effectuate
all filings of patent applications pursuant to this Section 8.1.1.

          8.1.2 Determination of Program Technology Ownership. Either Party (the “Notifying
Party”) may give notice (the “Prosecution Notice”) to the other Party that it believes Patent
Prosecution should be sought for any Program Technology at any time during the Term, which in any
event will be prior to either Party filing a patent application claiming such Program Technology.
The Prosecution Notice will state the opinion of the Notifying Party as to whether the Program
Technology belongs in the ARCHEMIX Program Technology, EYETECH Program Technology or Joint Program
Technology category of ownership and will provide all relevant information reasonably available to
the Notifying Party with regard to such opinion. The Notifying Party will also provide all
additional information, available to such

Confidential

Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company’s application requesting
confidential treatment under Rule 406 of the Securities Act.

64

 

Notifying Party, with respect thereto that is reasonably requested by the other Party.
Within [***] days of receipt of the Prosecution Notice, the other Party shall provide a written
response (the “Response”) stating its ownership category opinion to the Notifying Party.

               (a) If the other Party fails to provide the Response within the [***] day period or if the
other Party provides the Response and affirms the Notifying Party’s opinion of ownership, then the
relevant Program Technology will be deemed to belong to the category asserted in the Prosecution
Notice and the Party responsible for Patent Prosecution in that category shall promptly take action
with regard thereto.

               (b) If the other Party provides a Response within the [***] day period and states that it does
not agree with the Notifying Party’s opinion of ownership category, then the Parties will in good
faith seek to resolve the disagreement for a period of up to [***] days from the date of receipt of
the Response. If the Parties agree that the Program Technology is Joint Program Technology, the
Party responsible pursuant to Section 8.2.3 hereof shall promptly take action with regard thereto.
If the Parties fail to agree upon an ownership category within such [***] day period, then the
Parties will retain a mutually acceptable patent attorney who has not represented either Party on
any matter to determine the ownership category.

               (c) Each Party shall execute such assignments and other instruments reasonably requested by
the other Party in order to effectuate all determinations of ownership made under this Section
8.1.2.

          8.1.3 Data Retention Policy. In order to protect the Parties’ rights in Program
Technology under United States law, each Party agrees to maintain a policy which requires its
employees and consultants to record and maintain all data and information developed during the
Research Program or EYETECH Development Program, as applicable, in such a manner as to enable the
Parties to use such records to establish the earliest date of invention and/or diligence to
reduction to practice. At a minimum, the policy shall require such individuals to record all
inventions generated by them in standard laboratory notebooks, which are dated and corroborated by
non-inventors on a regular, contemporaneous basis.

     8.2 Prosecution and Maintenance of Patents.

Confidential

Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company’s application requesting
confidential treatment under Rule 406 of the Securities Act.

65

 

          8.2.1 EYETECH. EYETECH shall have the exclusive right and option to undertake the
Patent Prosecution of any EYETECH Program Patents and EYETECH Development Program Patents, keeping
ARCHEMIX reasonably informed with respect to EYETECH Program Patents and any EYETECH Development
Program Patents licensed to ARCHEMIX.

          8.2.2 ARCHEMIX. ARCHEMIX shall have the exclusive right and option to undertake the
Patent Prosecution of any ARCHEMIX Program Patents, keeping EYETECH reasonably informed.
Specifically with regard to ARCHEMIX Program Patents, in each case wherein EYETECH has exercised a
License Option for a Lead Compound, ARCHEMIX agrees to use diligent efforts in: (1) maintaining
until expiration any issued Patents; (2) considering in good faith the reasonable comments or
requests from EYETECH; (3) providing EYETECH with at least [***] days written notice of its
intention, in the exercise of diligence, to cease their Patent Prosecution efforts. In this event,
EYETECH, at its sole discretion and expense, shall have the right, but not the obligation, to
assume responsibility for such Patent Prosecution. Should EYETECH elect to assume responsibility
for Patent Prosecution under this section, EYETECH shall notify ARCHEMIX in writing of its
decision within [***] days of receipt of notice. ARCHEMIX shall assist EYETECH in the Patent
Prosecution at EYETECH’s sole expense. If EYETECH shall thereafter decide to cease Patent
Prosecution of any such Patent, EYETECH will give ARCHEMIX [***] days notice thereof, and
ARCHEMIX, at its sole discretion and expense, shall have the right, but not the obligation, to
reassume responsibility for such Patent Prosecution.

          8.2.3 Joint Program Technology. Within [***] days after it is determined pursuant to
Section 8.1.2 that any particular Program Technology is Joint Program Technology, the Parties will
determine whether one Party or the other (the “Controlling Party”) should undertake the Patent
Prosecution of Joint Program Patents with respect thereto, based on the relative utility of such
Program Technology to, and the respective expertise of, the Parties. If the Parties fail to agree,
then Patent Prosecution of such Joint Program Patents shall be alternately assigned to each Party
beginning with ARCHEMIX. The Controlling Party shall keep the other Party reasonably informed of
the status of such activities, including, without

Confidential

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

66

 

limitation, (A) by providing the other Party
with copies of all communications received from or filed in patent offices with respect to such
filing, and (B) by providing the other Party, a reasonable time prior to taking or failing to take
any action that would affect the scope or validity of any such filing (including the substantially
narrowing, cancellation or abandonment of any claims without retaining the right to pursue such
subject matter in a separate application, or the failure to file or perfect the filing of any
claims in any country), with prior written notice of such proposed action or inaction so that the
other Party has a reasonable opportunity to review and comment. The non-Controlling Party shall
have a right to control Patent Prosecution of Joint Program Patents if the Controlling Party
decides to abandon such Patent Prosecution.

     8.2.4 Each Party agrees that for all Program Technology for which it assumes responsibility
under Section 8.2 for Patent Prosecution of, it will give good faith consideration to all comments
from the other Party with regard thereto and will use commercially reasonable efforts to obtain
claims with application both inside and outside the Field.

     8.2.5 Costs and Expenses. Except as expressly stated herein to the contrary, each
Party shall bear its own costs and expenses of the Patent Prosecution of ARCHEMIX Patents,
ARCHEMIX Program Patents, EYETECH Patents and EYETECH Program Patents and the Controlling Party
shall be reimbursed by the other Party for [***] percent ([***]%) of the costs and expenses
incurred by the Controlling Party in Patent Prosecution of Joint Program Patents. The
non-Controlling Party shall have the right to elect not to pay such costs and expenses in which
case the non-Controlling Party shall assign its rights to the Joint Program Patents to the
Controlling Party.

     8.2.6 Cooperation. Each Party agrees to cooperate with the other with respect to
Patent Prosecution pursuant to this Section 8.2, including, without limitation:

               (a) the execution of all documents and instruments reasonably necessary to carry out such
Patent Prosecution;

Confidential

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

67

 

               (b) the performance of such acts as may be reasonably necessary in order to permit the other
Party to continue any Patent Prosecution that such Party has elected not to pursue, as provided for
in Section 8.2.2 and 8.2.3, as applicable;

               (c) making its employees, agents and consultants reasonably available to the other Party (or
to the other Party’s authorized attorneys, agents or representatives), to the extent reasonably
necessary to enable the prosecuting Party to undertake Patent Prosecution;

               (d) to provide the other Party with copies of all material correspondence pertaining to Patent
Prosecution of Program Patent Rights with the United States Patent and Trademark Office or its
foreign counterparts;

               (e) to cooperate, if necessary and appropriate, with the other Party in gaining patent term
extensions wherever applicable to Program Patent Rights; and

               (f) to endeavour in good faith to coordinate its efforts with the other Party to minimize or
avoid interference with the Patent Prosecution of the other Party’s patent applications

     8.3 Third Party Infringement.

          8.3.1 Infringement Action. Each Party shall promptly notify the other if it becomes
aware of any infringement of any (a) ARCHEMIX Program Patents in the Field; (b) ARCHEMIX Patents
in the Field; (c) Joint Program Patents inside the Field; (d) EYETECH Program Patents licensed to
ARCHEMIX outside the Field; or (e) EYETECH Development Program Patents licensed to ARCHEMIX
outside the Field (any of (a), (b), (c), (d) or (e) an “Infringement”). The notice shall set forth
the facts of such Infringement in sufficient detail and the following shall apply:

                    (i) Within [***] days of such notice of an Infringement, the Responsible Party (as defined
below) shall decide whether to institute an infringement suit or take other appropriate action that
it believes is reasonably required to enforce the relevant Patents in the Field. With respect to
infringements described in clauses (a), (b), or (c) if the Responsible

Confidential

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

68

 

Party fails to institute
such suit or take such action within such [***]-day period, then the other Party shall have the
right at its sole discretion to institute such suit or other appropriate action in the name of
either or both Parties. In such event, the Responsible Party shall cooperate with the other Party
to the extent reasonably possible, including the joining of suit if necessary or desirable.
EYETECH shall have the sole right to enforce EYETECH Program Patents and EYETECH Development
Program Patents.

                    (ii) Nothing contained in this Agreement shall in any way limit or be deemed to limit
EYETECH’s rights under Section 6.15 (b) or 6.15 (c) under the Gilead-Eyetech License with
respect to infringing activities inside the Field.

                    (iii) Subject to EYETECH’s rights under Section 6.15 (b) of the Gilead Eyetech License, with
respect to an Infringement described in clause 8.3.1(a) or (b) above, with regard to any ARCHEMIX
Program Patent or ARCHEMIX Patent, EYETECH shall be the Responsible Party and shall have the first
right to decide whether to institute an infringement suit or take other appropriate action that it
believes is reasonably required to cease the Infringement; if, but only if (1) the alleged Third
Party infringer is selling an oligonucleotide directed to the same Target or Target Binding
Partner as a Lead Compound, Development Compound or Compound Product, and (2) (i) in the
reasonable opinion of both Parties there is an ARCHEMIX Program Patent or an ARCHEMIX Patent that
contains claims directed to a specific Aptamer or to Aptamers that bind to a specified Target
species (e.g., “PDGF” but not “proteins”) and that is infringed by the sale of such
oligonucleotide; provided, that in the case of this clause (i), with respect to ARCHEMIX
Patents, EYETECH may only assert infringement of any ARCHEMIX Patent that contains claims directed
to a specific Aptamer or to Aptamers that bind to a specified Target genus (e.g., “PDGF” but not
“protein”); or (ii) in the reasonable opinion of both Parties there is no ARCHEMIX Program Patent
or ARCHEMIX Patent that contains claims directed to a specific Aptamer or to Aptamers that bind to
a specified Target species (e.g., “PDGF” but not “proteins”) and that is infringed by the sale of
such oligonucleotide; provided, that in the case of this clause (ii) EYETECH may only
assert infringement of any ARCHEMIX Patent after consulting with ARCHEMIX regarding assertion of
any such ARCHEMIX Patent and giving good faith consideration to the reasonable requests

Confidential

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

69

 

of ARCHEMIX
regarding assertion of such ARCHEMIX Patents If EYETECH fails to institute such suit or take such
action within such [***]-day period, then ARCHEMIX shall have the right at its sole discretion to
institute such suit or other appropriate action in its own name or that of both Parties.

                    (iv) Notwithstanding any right to do so granted to EYETECH under the Gilead Eyetech License
EYETECH shall in no event, without the prior written consent of ARCHEMIX, institute an infringement
suit or take any other action with respect to its enforcement rights as a Secondary Party (as
defined in the Gilead Eyetech License) under Section 6.15 (c) of the Gilead Eyetech License with
regard to infringement outside the Field and outside the Local Delivery Field of any ARCHEMIX
Patents within the SELEX Portfolio. Notwithstanding the foregoing, nothing contained in this
Agreement shall in any way limit or be deemed to limit EYETECH’s rights under Section 6.15(c) of
the Gilead-Eyetech License regarding infringing activities of any third party outside the Field
that are specific to the manufacture, use, sale, offer for sale or importation of NX1838.

          8.3.2 Responsible Party. Subject to Section 8.3.1(i), (ii) and (iii) above, as used
herein, the term “Responsible Party” means (i) EYETECH, with respect to EYETECH Program Patents,
EYETECH Patents and Joint Program Patents for which EYETECH is the Controlling Party under Section
8.2.3 above; and (ii) ARCHEMIX, with respect to ARCHEMIX Patents, ARCHEMIX Program Patents and
Joint Program Patents for which ARCHEMIX is the Controlling Party under Section 8.2.3 above.

          8.3.3 Costs. Each Party shall assume and pay all of its own out-of-pocket costs
incurred in connection with any litigation or proceedings described in this Section 8.3,
including, without limitation, the fees and expenses of that Party’s counsel.

          8.3.4 Recoveries. Any recovery obtained by any Party as a result of any proceeding
described in this Section 8.3 or from any counterclaim or similar claim asserted in a proceeding
described in Section 8.4, by settlement or otherwise, shall be applied in the following order of
priority:

Confidential

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

70

 

               (a) first, to reimburse each Party for all litigation costs (including attorneys’ fees) in
connection with such proceeding paid by that Party and not otherwise recovered (on a pro rata basis
based on each Party’s respective litigation costs, to the extent the recovery was less than all
such litigation costs); and

               (b) second, the remainder of the recovery shall be paid [***] percent ([***]%) to the Party
bringing the action and [***] percent ([***]%) to the other Party.

          8.3.5 Cooperation; Settlements. In the event that either EYETECH or ARCHEMIX takes
action pursuant to Section 8.3.1 above, the other Party shall cooperate with the Party so acting
to the extent reasonably possible, including the joining of suit if necessary or desirable.
Neither Party shall settle or compromise any claim or proceeding relating to Program Technology or
Program Patent Rights without obtaining the prior written consent of the other Party, EYETECH
shall not settle or compromise any claim or proceeding relating to ARCHEMIX Patents without
obtaining the prior written consent of ARCHEMIX, in either case, such consent not to be
unreasonably withheld.

     8.4 Claimed Infringement. In the event that a Party becomes aware of any claim that
the practice by either Party of ARCHEMIX Technology or Program Technology in the Field infringes
the intellectual property rights of any Third Party, such Party shall promptly notify the other
Party. In any such instance, the Parties shall cooperate and shall mutually agree upon an
appropriate course of action. Each Party shall provide to the other Party copies of any notices it
receives from Third Parties regarding any patent nullity actions, any declaratory judgment actions,
any alleged infringement in the Field of ARCHEMIX Patents or Program Patents or any alleged
misappropriation in the Field of intellectual property with respect to ARCHEMIX Technology or
Program Technology. Such notices shall be provided promptly, but in no event after more than [***]
days following receipt thereof.

     8.5 Patent Invalidity Claim. If a Third Party at any time asserts a claim that any
ARCHEMIX Program Patent, Joint Program Patent or ARCHEMIX Patent covering the manufacture, use,
sale or import of a Compound Product, is invalid or otherwise unenforceable (an “Invalidity
Claim”), either as a defense in an infringement action brought by EYETECH or

Confidential

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

71

 

ARCHEMIX pursuant to
Section 8.3 or in an action brought against EYETECH or ARCHEMIX under Section 8.4, the Parties
shall cooperate with each other in preparing and formulating a response to such Invalidity Claim;
provided, however, if the Parties fail to agree upon such response, Archemix shall
have the right, at its discretion, to assume control of such response and any subsequent action,
including without limitation all aspects of claim construction, with counsel of its own choice.
Neither Party shall settle or compromise any Invalidity Claim without the consent of the other
Party, which consent shall not be unreasonably withheld.

     8.6 Patent Term Extensions. The Parties shall cooperate, if necessary and appropriate, with
each other in gaining patent term extensions wherever applicable to a Program Patent that covers
Compound Products. The Parties shall, if necessary and appropriate, use reasonable efforts to
agree upon a joint strategy relating to patent term extensions, but, in the absence of mutual
agreement with respect to any extension issue, a patent shall be extended if either Party elects to
extend such patent. All filings for such extension shall be made by the Party to whom the patent
is assigned, provided, however, that in the event that the Party to whom the patent is assigned
elects not to file for an extension, such Party shall (i) inform the other Party of its intention
not to file and (ii) grant the other Party the right to file for such extension.

     8.7 Relationship with Gilead with respect to VEGF.

          8.7.1 Acknowledgement of EYETECH. EYETECH acknowledges that the effectiveness of the
rights granted by ARCHEMIX to EYETECH hereunder with respect to Aptamers against VEGF and VEGF
Products may require the Parties to obtain the consent of Gilead with respect to such grants.

          8.7.2 Negotiation with Gilead. ARCHEMIX and EYETECH will individually negotiate with
GILEAD (unless both Parties mutually agree to negotiate jointly) to obtain any necessary consents
and rights from Gilead required for (i) EYETECH to discover, make, use and sell Aptamers against
VEGF in the Field and the Local Delivery Field and (ii) ARCHEMIX to discover, make, use and sell
Aptamers against VEGF for use outside the Field and the Local Delivery Field. Upon obtaining any
necessary rights from Gilead, the definition of Excluded Aptamers hereunder shall be amended,
without further action by the Parties, to delete VEGF

Confidential

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

72

 

from the list of Targets in clause (c) of
such definition. ARCHEMIX hereby covenants that ARCHEMIX will not seek, negotiate or otherwise try
to obtain rights to VEGF from Gilead in the Field and the Local Delivery Field. EYETECH hereby
covenants that EYETECH will not seek, negotiate or otherwise try to obtain rights to VEGF from
Gilead outside the Field or the Local Delivery Field. Each Party agrees to cooperate with the other
Party in the negotiation with Gilead whether such negotiation occurs jointly or individually among
the Parties and Gilead. For purposes of clarification, the rights of each Party as set forth in
this Section 8.7.2 shall be independent of each other and nothing in this Section, or any other
portion of this Agreement, shall be construed to mean that the survival or enforcement of such
rights are dependent upon the outcome of either Party’s negotiations, if any and whether conducted
separately or jointly, with Gilead. For further clarification, other than the rights and
obligations set forth in this Agreement, neither ARCHEMIX nor EYETECH shall be obligated to
negotiate on behalf of the other Party nor shall they be obligated to enter into any agreement with
Gilead to grant the rights for Aptamers against VEGF and VEGF Products.

          8.7.3 Waiver of Rights and Covenants By EYETECH. EYETECH agrees that at any time
after the Effective Date of this Agreement and upon written request by ARCHEMIX it will:

               (a) notify Gilead that it has provided to ARCHEMIX any and all rights it has to discover,
make, use and sell VEGF Aptamers (other than NX1838) outside of the Field and the Local Delivery
Field,

               (b) waives the protections Gilead inserted into the Gilead-Archemix License restricting
ARCHEMIX’s rights to discover, make, use and sell VEGF Aptamers (other than NX1838) outside of the
Field and the Local Delivery Field. Eyetech will request that Gilead remove from the
Gilead-Archemix License all restrictions to ARCHEMIX’s rights to discover, make, use and sell VEGF
Aptamers (other than NX1838) outside of the Field and the Local Delivery Field, including without
limitation the following restrictions with respect to ARCHEMIX’s rights outside the Field and the
Local Delivery Field: the inclusion of VEGF on the “Excluded Aptamer” list (Section 1.11 of the
Gilead-Archemix Agreement), the negative covenant against the use of VEGF Aptamers (other than
NX1838) (Section 2.2 of the Gilead-

Confidential

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

73

 

Archemix Agreement) and restrictions included in the “Licensed
Field” (Section 1.18 of the Gilead-Archemix Agreement),

               (c) at EYETECH’s sole option, EYETECH may request that Gilead remove from the Gilead-Archemix
License any restrictions to ARCHEMIX’s rights to discover, make and use VEGF Aptamers inside of the
Field and the Local Delivery Field as necessary for ARCHEMIX to discover Compounds for EYETECH’s
use in the Field or the Local Delivery Field. For purposes of clarity, a) it is EYETECH’s sole
responsibility to obtain the removal of such restrictions and b) ARCHEMIX will have no obligation
under Section 2.3(a) if EYETECH is unable to obtain the removal of such restrictions, and

               (d) provide to Gilead its consent to enter into direct negotiations with ARCHEMIX regarding
rights to discover, make, use and sell VEGF Aptamers (other NX1838) outside of the Field and the
Local Delivery Field.

          8.7.4 Waiver of Rights by ARCHEMIX. ARCHEMIX agrees that at any time after the
Effective Date of this Agreement and upon written request by EYETECH it will:

               (a) notify Gilead that it has provided to EYETECH any and all rights it has to discover, make,
use and sell VEGF Aptamers in the Field and the Local Delivery Field, and

               (b) provide to Gilead its consent to enter into direct negotiations with EYETECH regarding
rights to discover, make, use and sell VEGF Aptamers in the Field and the Local Delivery Field.

          8.7.5 Waivers of Enforcement Rights Under Gilead-Eyetech License. To the extent that
it does not conflict with any rights EYETECH may have granted to Third Parties as of the Effective
Date, including specifically Pfizer, Inc., EYETECH hereby, except in the event of an intentional
breach committed by ARCHEMIX for the sole purpose of obtaining the rights set forth in this Section
8.7.5, irrevocably waives any and all rights, other than those related to or covering the
development, manufacture, use, sale, offer for sale or import of NX1838, EYETECH may have under the
Gilead-EYETECH License, including without limitation, rights under Section 6.15(c) thereof, to
enforce the Gilead-Eyetech Patent Portfolio solely against

Confidential

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

74

 

ARCHEMIX, its Affiliates, or its
Sublicensees other than (i) in the Field or (ii) in the Local Delivery Field. For the avoidance of
doubt, nothing in this Agreement, including without limitation this Section 8.7.5, shall constitute
or be deemed to constitute a sublicense of any nature whatsoever to any rights held by EYETECH to
NX 1838.

          8.7.6 Waiver of Rights to Challenge Pre-existing Gilead Agreements. ARCHEMIX and
EYETECH each represents and warrants that it has received a copy of the other Party’s agreement
with Gilead (The Gilead-Archemix Agreement and the Gilead-Eyetech Agreement) and hereby agrees to
irrevocably waive the right to challenge the validity of the other Party’s agreement with Gilead
outside the Field and with respect to Refused Candidates inside and outside the Field.. EYETECH
acknowledges that Gilead has properly and validly granted to Archemix under the Gilead-Archemix
agreement the right to discover, develop, manufacture, sell and import Aptamers other than Excluded
Aptamers as defined in the Gilead-Archemix Agreement outside the Field and with respect to Refused
Candidates inside and outside the Field. Nothing in this Section 8.7.6 shall be deemed (i) to
waive on behalf of any Third Party any rights granted to such Third Party before the Effective Date
or (ii) to waive or grant to ARCHEMIX any rights in the Field or the Local Delivery Field to
Refused Candidates directed against VEGF.

ARTICLE 9 . . TERM AND TERMINATION

     9.1 Research Term. Unless the Research Program is terminated earlier in accordance
with this Agreement, the research term (“Research Term”) shall commence on the Effective Date and
continue until the fifth (5th) anniversary thereof; provided that EYETECH may, in its
sole discretion, extend the Research Term for one additional two (2) year period upon written
notice to ARCHEMIX at least one hundred-eighty (180) days prior to the expiration of the
then-current Research Term, so long as EYETECH is in compliance with the EYETECH Diligence Goal at
the end of the Research Term immediately prior to the applicable extension period.  

     9.2 Royalty Term. The royalty term (“Royalty Term”) for a Compound Product or VEGF
Product, on a country-by-country basis, shall commence on the date of First Commercial Sale of such
Compound Product or VEGF Product in the applicable country and expire on the

Confidential

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

75

 

later of (i) the [***]
year anniversary of the First Commercial Sale of such Compound Product or VEGF Product in the
applicable country and (ii) the latest date on which the Compound Product or VEGF Product is
covered by an ARCHEMIX Valid Claim in the country of manufacture or sale, if no ARCHEMIX Valid
Claim exists, a pending claim of an ARCHEMIX Patent, ARCHEMIX Program Patent or Joint Program
Patent in the country in which such Compound Product or VEGF Product is manufactured or sold that
has been pending for less than seven (7) years since the earliest priority date of the patent
application containing such claim.  

     9.3 Term. Unless earlier terminated as set forth in this Article 9, this Agreement
shall be effective as of the Effective Date and shall extend until the end of the Research Term
and, if applicable, thereafter until the later of (A) the Option Period for all Compound Candidates
shall have expired and (B) the Royalty Term shall have expired for each Compound Product and VEGF
Product in all applicable countries, at which time this Agreement shall expire (the “Term”).

     9.4 Termination by EYETECH for Cause. Upon written notice to ARCHEMIX, EYETECH may at
its sole discretion unilaterally terminate this Agreement upon the occurrence of any of the
following events:

               (a) ARCHEMIX shall materially breach any of its material obligations under this Agreement and
(i) shall not have remedied such material breach within [***] days ([***] business days in the case
of any payment breach) after EYETECH sends written notice of breach to ARCHEMIX or (ii) if the
breach is not a payment breach and is of the nature that is susceptible of remedy, but not within
such [***] day period, shall not have initiated within such [***] day period all reasonable steps
to remedy such breach and thereafter diligently continued such steps to remedy until the breach is
remedied in full; or

               (b) ARCHEMIX shall cease to function as a going concern by suspending or discontinuing its
business for any reason except for merger or acquisition or interruptions caused by Force Majeure
(as specified in Section 11.9).

          In the event of any valid termination under this Section 9.4, EYETECH shall have the right
with respect to any Compound Candidate, to exercise the applicable License Option

Confidential

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

76

 

within ten (10) business days of such termination. Notwithstanding the foregoing, any license under Section 4 then
in effect, and all of EYETECH’s payment obligations hereunder relating thereto, shall survive the
termination and continue in full force and effect pursuant to the terms of this Agreement.

     9.5 Termination by ARCHEMIX for Cause. ARCHEMIX may terminate this Agreement upon
written notice to EYETECH upon the occurrence of any of the following events:

               (a) EYETECH shall materially breach any of its material obligations under this Agreement and
(i) shall not have remedied such material breach within [***] days ([***] business days in the case
of any payment breach) after ARCHEMIX sends written notice of breach to EYETECH or (ii) if the
breach is not a payment breach and is of the nature that is susceptible of remedy, but not within
such [***] day period, shall not have initiated within such [***] day period all reasonable steps
to remedy such breach and thereafter diligently continued such steps to remedy until the breach is
remedied in full;

               (b) EYETECH shall cease to function as a going concern by suspending or discontinuing its
business for any reason except for merger or acquisition or interruptions caused by Force Majeure
(as specified in Section 11.9).

     9.6 Termination at Will. EYETECH may terminate the Research Term at any time for any
or no reason upon [***] months prior written notice to ARCHEMIX and payment of a termination fee
equal to the greater of (i) [***] of FTE funding at the FTE level then approved by the JRC or (ii)
[***] dollars $[***].

     9.7 Rights of ARCHEMIX following ARCHEMIX’s termination pursuant to Section 9.5 (cause) or
EYETECH’s termination of the Research Term pursuant to Section 9.6 (at will). If this
Agreement is terminated by ARCHEMIX pursuant to Section 9.5 or the Research Term is terminated by
EYETECH pursuant to Section 9.6, EYETECH shall (a) lose all License Options not exercised as of the
date of termination (b) retain its rights and licenses hereunder with respect to all Lead
Compounds, Development Compounds and Compound Products; provided that EYETECH continues to exercise
commercially reasonable efforts to Develop and/or

Confidential

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

77

 

Commercialize such lead Compounds, Development
Compounds and Compound Products. In the event that EYETECH fails to continue exercising
commercially reasonable efforts to Develop and/or Commercialize any such Lead Compound, Development
Compound or Compound Product other than a VEGF Product or VEGF Aptamer, its rights to such Lead
Compound, Development Compound or Compound Product shall terminate upon [***] days’ prior written
notice from ARCHEMIX; provided that if EYETECH cures such failure within such [***] day notice
period, such rights and licenses shall not terminate, and provided further that if EYETECH disputes
ARCHEMIX’ assertion of failure, such rights and licenses shall not terminate until such time as
such dispute is resolved in accordance with the procedures set forth herein. If EYETECH’s rights
and licenses hereunder to any Lead Compound, Development Compound or Compound Product are
terminated after this Agreement is terminated by ARCHEMIX pursuant to Section 9.5 or the Research
Term is terminated by EYETECH pursuant to Section 9.6, then upon request of ARCHEMIX, EYETECH shall
(a) transfer to ARCHEMIX all of its rights, title and interest in all filings with Regulatory
Authorities (“Regulatory Filings”), including without limitation all INDs and NDAs, and all
Regulatory Approvals then in its name for all such Lead Compound, Development Compound or Compound
Product and all Confidential Information Controlled by it as of the date of termination relating
to such Regulatory Filings and Regulatory Approvals, (b) notify the appropriate Regulatory
Authorities and take any other action reasonably necessary to effect such transfer of ownership (c)
deliver to ARCHEMIX all correspondence between EYETECH and such Regulatory Authorities relating to
such Regulatory Filings and Regulatory Approvals, and (d) unless expressly prohibited by any
Regulatory Authority, transfer control to ARCHEMIX of all clinical trials being conducted as of the
date of termination which relate to the Lead Compound, Development Compound or Compound Product.
EYETECH shall cooperate fully with ARCHEMIX to facilitate an orderly transition of the conduct of
such trials to ARCHEMIX or its designee. To the extent EYETECH has the right, EYETECH shall be
deemed to have granted to ARCHEMIX a worldwide license with the right to grant sublicenses, under
EYETECH Program Technology, EYETECH Program Patents, EYETECH’s interest in Joint Program Patents
and EYETECH Development Program Technology and EYETECH Development Program Patents actually used by
EYETECH for the Development, manufacture or Commercialization of any Lead Compound, Development
Compound or Compound Product

Confidential

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

78

 

with respect to which EYETECH’s rights and licenses hereunder are
terminated after this Agreement is terminated by ARCHEMIX pursuant to Section 9.5 or the Research
Term is terminated by EYETECH pursuant to Section 9.6, and under any product trademark used in the
Commercialization of such lead Compound, Development Compound or Compound Product, solely to
Develop, use, manufacture and Commercialize such Lead Compound, Development Compound or Compound
Product, itself or in collaboration with, or through a license to, Third Parties. Furthermore, to
the extent EYETECH has the right, EYETECH agrees to negotiate in good faith the grant of a license
to EYETECH Technology existing as of the date of termination by ARCHEMIX actually used by EYETECH
for the Development, manufacture or Commercialization of any Lead Compound, Development Compound or
Compound Product to ARCHEMIX on reasonable terms and conditions and, further, EYETECH agrees not to
unreasonably withhold the grant of such license from ARCHEMIX. For the avoidance of any doubt and
notwithstanding anything to the contrary in Section 1.39 or 1.40, the grant by EYETECH to ARCHEMIX
under EYETECH Technology pursuant to the immediately preceding sentence shall include any
technology which would be within the definition of EYETECH Technology if it existed as of the end
of the Research Term actually used by EYETECH for the Development, manufacture or Commercialization
of any Lead Compound, Development Compound or Compound Product existing as of the date of
termination by ARCHEMIX and is not limited to EYETECH Technology existing only at the end of the
Research Term. In the event the Parties fail to agree on such license within [***] days of the
termination, then at the request of either Party the remaining disagreements will be submitted for
binding resolution to a single arbitrator with experience and expertise in biotechnology licensing
mutually agreed upon by the parties (or if the Parties fail to agree, selected by the American
Arbitration Association). Said licenses and the transfer of EYETECH’s Regulatory Filings and
Regulatory Approvals shall be free of charge with the exception that ARCHEMIX hereby agrees to pay
to EYETECH in full any and all Third Party royalties and all other payments which EYETECH owes to
its licensors with respect to any license or sublicense granted by EYETECH to ARCHEMIX under this
Agreement. Such payments shall be due and payable by ARCHEMIX on or before the date they are
payable by EYETECH.. Additionally, EYETECH shall cooperate fully with ARCHEMIX to ensure an
orderly transition of all manufacturing activities.

Confidential

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

79

 

     9.8 Effect of Termination. Termination or expiration of this Agreement for any reason
will not affect the rights and obligations of the parties hereunder with respect to Aptamers
against VEGF, VEGF Products and the enforcement of the Gilead-Eyetech Patent Portfolio. Without
limiting the generality of the foregoing, except where explicitly provided elsewhere herein,
termination of this Agreement for any reason, or expiration of this Agreement, will not affect: (i)
obligations which have accrued as of the date of termination or expiration, (ii) obligations and
rights pursuant to Sections 2.7, 2.9, 4.2.1, 4.2.2, 4.2.3 (with respect to Lead Compounds only),
4.2.4, 4.2.5.1 (last sentence only), 4.3.2, 4.3.3, 4.3.4, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 4.10, 4.11,
4.12, 4.13, 5.2.2, 5.2.3, and 5.2.4 and Articles 6, 7, 8, 9, 10 and 11, and (iii) any other
provision of this Agreement that, by its terms, survives termination or expiration which shall
survive in full force and effect.

ARTICLE 10 REPRESENTATIONS AND WARRANTIES

     10.1 Representations of Authority. EYETECH and ARCHEMIX each represents and warrants
to the other that as of the Effective Date (i) it has full right, power and authority to enter into
this Agreement and to perform its respective obligations under this Agreement, and (ii) that it has
the right to grant to the other Party the licenses and sublicenses granted pursuant to this
Agreement, and that it has, as of the Effective Date, access to and the right to use the technology
necessary to perform its obligations hereunder.

     10.2 Consents. EYETECH and ARCHEMIX each represents and warrants that all necessary
consents, approvals and authorizations of all government authorities and other persons required to
be obtained by such Party in connection with execution, delivery and performance of this Agreement
have been and shall be obtained.

     10.3 No Conflict. EYETECH and ARCHEMIX each represents and warrants that
notwithstanding anything to the contrary in this Agreement, the execution and delivery of this
Agreement, the performance of such Party’s obligations hereunder and the conduct of the Research
Program (a) do not conflict with or violate any requirement of applicable laws or regulations and
(b) do not and will not conflict with, violate or breach or constitute a default or

Confidential

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

80

 

require any consent under, any contractual obligations of such Party, except such consents as shall have been
obtained prior to the Effective Date.

     10.4 Employee Obligations. EYETECH and ARCHEMIX each represents and warrants that, to
the extent required to support such Party’s obligations under this Agreement, all of its employees,
officers, and consultants have executed agreements or have existing obligations under law
requiring, in the case of employees and officers, assignment to such Party of all inventions made
during the course of and as the result of their association with such Party and obligating the
individual to maintain as confidential such Party’s Confidential Information as well as
confidential information of a Third Party which such Party may receive, and ARCHEMIX represents and
covenants that each FTE is or will be subject to similar obligations even if such FTEs are not
employees of ARCHEMIX.

     10.5 Intellectual Property. ARCHEMIX represents that, to the best of its knowledge and
except as disclosed to EYETECH in writing, as of the Effective Date, the practice by ARCHEMIX of
the SELEX Process does not infringe or conflict with the rights of any Third Party in respect of
issued patents owned by such Third Party and there is no claim or demand of any person asserted in
any proceeding which is pending or threatened, that challenges the rights of ARCHEMIX in respect of
ARCHEMIX Technology or ARCHEMIX Patents.

     10.6 Fees Payable. ARCHEMIX and EYETECH each represents and warrants that there are
no broker’s commissions, finder’s fees or other amounts payable with regard to this transaction,
and ARCHEMIX and EYETECH agree to indemnify and hold the other harmless from and against all
liabilities, claims, demands, damages or costs of any kind arising from or connected with any
broker’s or finder’s commission, fee or other amount claimed to be due any person arising from the
indemnitor’s conduct with respect to this Agreement and the transactions contemplated by this
Agreement.

     10.7 No Warranties. EXCEPT AS OTHERWISE EXPRESSLY SET FORTH HEREIN , THE PARTIES MAKE
NO REPRESENTATIONS AND EXTEND NO WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, AND
PARTICULARLY THAT PRODUCTS WILL BE SUCCESSFULLY DEVELOPED HEREUNDER, AND IF

Confidential

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

81

 

DEVELOPED, WILL HAVE
COMMERCIAL UTILITY OR MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR WILL NOT INFRINGE ANY
PATENT, COPYRIGHT, TRADEMARK OR OTHER RIGHTS OF ANY THIRD PARTY.

ARTICLE 11 MISCELLANEOUS PROVISIONS

     11.1 Governing Law. This Agreement, and any disputes between the Parties relating to
the subject matter of this Agreement, shall be construed and the respective rights of the Parties
hereto determined according to the substantive laws of the State of New York notwithstanding the
provisions governing conflict of laws under such State of New York law to the contrary, except
matters of intellectual property law which shall be determined in accordance with the national
intellectual property laws relevant to the intellectual property in question.

11.2 Dispute Resolution. 

          11.2.1 Disputes relating to certain Decisions of the JRC. If the JRC cannot agree on
(i) the ESC, (ii) the inclusion into the Research Program of a proposed Aptamer or target, (iii) an
Annual Research Plan, (iv) the activities to be set forth in Appendix 3 which will establish that
an Aptamer against such Target is a Development Compound, (v) whether a Compound meets the ESC, or
(vi) whether a molecule is designated as the Target Binding Partner for a Target, then such matter
shall be referred to the Executive Officers for attempted resolution by good faith negotiation. If
the Executive Officers cannot resolve any such matter within [***] days, the matter will be
determined by binding arbitration pursuant to this Section 11.2.1 by one (1) independent, neutral
arbitrator who is (i) mutually acceptable to the Parties, and (ii) an expert in the pharmaceutical
or biotechnology industry. If the Parties are unable to agree upon a mutually acceptable
arbitrator, the arbitrator shall be an independent expert as described in the preceding sentence
selected by the AAA office encompassing Boston, Massachusetts. Any arbitration of a Dispute
pursuant to this Section 11.2.1 shall be governed by the Commercial Arbitration Rules and
Supplementary Procedures for Large Complex Disputes of the AAA. The place of arbitration shall be
Boston, Massachusetts, and all proceedings and communications shall be in English.

Confidential

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

82

 

               (a) Either Party may apply to the arbitrator for interim relief until the arbitration award is
rendered or the controversy is otherwise resolved. Either Party also may, without waiving any
remedy under this Agreement, seek from any court having jurisdiction any injunctive or provisional
relief necessary to protect the rights or property of that Party pending the arbitration award.

               (b) The Parties hereby agree that any disputed performance or suspended performances pending
the resolution of the arbitration that the arbitrator determines to be required to be performed by
a Party must be completed within a reasonable time period following the final decision of the
arbitrator.

               (c) The Parties further agree that the decision of the arbitrator shall be the sole, exclusive
and binding remedy between them regarding determination of the matters presented to the arbitrator.

     (d) For arbitration of Disputes subject to this Section 11.2.1, each Party to the arbitration
shall prepare and submit a written proposal setting forth its proposed resolution of the matter
within fifteen (15) business days of the selection of the arbitrator, together with a written
explanation setting forth the reasons for its position. After the arbitrator has received written
proposals from both Parties, the arbitrator shall forward a copy of the other Party’s proposal to
each. Each Party shall have [***] business days to prepare and submit a written rebuttal to such
proposal and may then amend its original proposal. Each Party shall have the right to make oral
presentations or present evidence as determined by the arbitrator during the arbitration
proceeding. The arbitrator shall select the proposal of one of the Parties as his/her decision,
and shall not have the authority to render any substantive decision other than to so select in its
entirety the summary or proposal of one Party or the other. Each Party shall bear its own costs
and expenses and attorneys’ fees. The administrative and arbitrator’s fees shall be paid by the
non-prevailing Party. The arbitrator shall be directed that any arbitration subject to this
Section 11.2.1 shall be completed within [***] business days from the appointment of the
arbitrator. Except to the extent necessary to confirm an award or as may be required by law, the
arbitration proceedings and the decision shall not be made public without the joint consent of the

Confidential

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

83

 

Parties and each Party shall maintain the confidentiality of such proceedings and decision unless
otherwise permitted by the other Party.

          11.2.2 Disputes Not Relating To Decisions Of The JRC. For disputes other than those
relating to certain decisions by the JRC as described in Section 11.2.1. above, the Parties shall
not be bound to arbitrate such disputes, but may agree to do so.

     11.3 Assignment. Neither ARCHEMIX nor EYETECH may assign this Agreement in whole or
in part without the consent of the other, except if such assignment occurs in connection with a
merger or consolidation of such Party or the sale or transfer of all or substantially all of the
business or assets (any such transaction, an “Acquisition”) of ARCHEMIX, on the one hand, or
EYETECH, on the other, to which the subject matter of this Agreement pertains, in which event no
consent shall be required; provided, however, that the Party proposing to engage an Acquisition
shall notify the other Party at least [***] days prior to the expected closing of the Acquisition
and the Party receiving such notice may terminate the Research Program effective upon closing of
the Acquisition by notice to the Party engaging in the Acquisition given within [***] days of its
receipt of the notice. Notwithstanding the foregoing, any Party may assign its rights (but not its
obligations) pursuant to this Agreement in whole or in part to an Affiliate of such Party.

     11.4 Limitation on Liability. EXCEPT AS EXPLICITLY SET FORTH IN THIS AGREEMENT,
NEITHER PARTY WILL BE LIABLE FOR SPECIAL, INCIDENTAL, CONSEQUENTIAL, EXEMPLARY, PUNITIVE, MULTIPLE
OR OTHER INDIRECT DAMAGES, OR FOR LOSS OF PROFITS, LOSS OF DATA OR LOSS OF USE DAMAGES, ARISING OUT
OF THE MANUFACTURE, SALE, SUPPLYING OR FAILURE OR DELAY IN SUPPLYING ANY PRODUCTS OR SERVICES
HEREUNDER, WHETHER BASED UPON WARRANTY, CONTRACT, TORT, STRICT LIABILITY OR OTHERWISE, EVEN IF SUCH
PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES OR LOSSES.

     11.5 Registration of License. EYETECH may, at its expense, register the license
granted under this Agreement in any country where the use, sale or manufacture of a Compound
Product in such country would be covered by an ARCHEMIX Valid Claim. Upon request by EYETECH,
ARCHEMIX agrees promptly to execute any reasonable “short form” licenses

Confidential

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

84

 

submitted to it by EYETECH
required to effect the foregoing registration in such country, but such licenses shall in no way
alter or affect the obligations of the Parties hereunder.

     11.6 Entire Agreement; Amendments. This Agreement constitutes the entire
agreement between the Parties with respect to the subject matter hereof, and supersedes all
previous arrangements with respect to the subject matter hereof, whether written or oral. Any
amendment or modification to this Agreement shall be made in writing signed by both Parties.

     11.7 Notices.

Notices to ARCHEMIX shall be addressed to:

ARCHEMIX Corp.

One Hampshire Street

Cambridge, MA 02139

Attention: Chief Executive Officer

Facsimile No.: (617) 621-9300

with a copy to:

Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.

One Financial Center

Boston, MA 02111

Attention: Jeffrey M. Wiesen, Esq.

Facsimile No.: (617) 542-2241

Notices to EYETECH shall be addressed to:

EYETECH Pharmaceuticals, Inc.

500 Seventh Avenue, 18th floor

New York, New York 10018

Attention: General Counsel

Facsimile No.: (212) 997 9251

          Any Party may change its address by giving notice to the other Party in the manner herein
provided. Any notice required or provided for by the terms of this Agreement shall be in writing
and shall be (a) sent by registered or certified mail, return receipt requested, postage prepaid,
(b) sent via a reputable overnight courier service providing evidence of delivery, or (c) sent by
facsimile transmission confirmed by hard copy sent in accordance with

Confidential

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

85

 

(a) or (b), in each case
properly addressed in accordance with the paragraph above. The effective date of notice shall be
the actual date of receipt by the Party receiving the same.

     11.8 Exports. The Parties acknowledge that the export of technical data, materials or
products is subject to the exporting Party receiving any necessary export licenses and that the
Parties cannot be responsible for any delays attributable to export controls that are beyond the
reasonable control of either Party. The Parties agree not to export or reexport, directly or
indirectly, any information, technical data, the direct product of such data, samples or equipment
received or generated under this Agreement in violation of any governmental regulations that may be
applicable. The Parties agree to obtain similar covenants from their Affiliates, sublicensees and
contractors with respect to the subject matter of this Section.

     11.9 Force Majeure. No failure or omission by the Parties hereto in the performance
of any obligation of this Agreement shall be deemed a breach of this Agreement or create any
liability if the same shall arise from any cause or causes beyond the control of the Parties (such
causes, “Force Majeure”), including, but not limited to, the following: acts of God; acts or
omissions of any government; any rules, regulations or orders issued by any governmental authority
or by any officer, department, agency or instrumentality thereof; fire; storm; flood; earthquake;
accident; war; rebellion; insurrection; riot; and invasion and provided that such failure or
omission resulting from one of the above causes is cured as soon as is practicable after the
occurrence of one or more of the above-mentioned causes. The Party claiming Force Majeure shall
notify the other Party of the Force Majeure event as soon as practicable, but in no event longer
than [***] business days after its occurrence, which notice shall reasonably identify such
obligations under this Agreement and the extent to which performance thereof will be affected. In
such event, the Parties shall meet promptly to determine an equitable solution to the effects of
any such event.

     11.10 Public Announcements.

               (a) Announcements; Publicity. Any announcements or similar publicity with respect to
this Agreement shall be agreed upon between the Parties in advance of such announcement. Once any
item of information has been disclosed in accordance with this

Confidential

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

86

 

Section 11.10, the further
announcement or disclosure thereof shall not require further agreement of the Parties.

               (b) SEC Filings. Notwithstanding anything in Section 11.10 (a) above to the contrary,
either Party may disclose the terms of this Agreement to the extent required, in the reasonable
opinion of such Party’s legal counsel, to comply with applicable laws, including without limitation
the rules and regulations promulgated by the United States Securities and Exchange Commission or by
any stock exchange or interdealer quotation system (such as NASDAQ) on which its securities are
traded. Notwithstanding the foregoing, before disclosing this Agreement or any of the terms hereof
pursuant to this Section 11.10, the Parties will consult with one another on the terms of this
Agreement to be redacted in making any such disclosure. If a Party discloses this Agreement or
any of the terms hereof in accordance with this Section 11.10, such Party agrees, at its own
expense, to seek confidential treatment of portions of this Agreement or such terms, as may be
reasonably requested by the other Party.

     11.11 Independent Contractors. It is understood and agreed that the relationship
between the Parties hereunder is that of independent contractors and that nothing in this Agreement
shall be construed as authorization for either ARCHEMIX or EYETECH to act as agent for or partner
of the other. The Program Directors and members of Project Teams shall remain employees of EYETECH
or ARCHEMIX, as the case may be.

     11.12 No Strict Construction. This Agreement has been prepared jointly and shall not
be strictly construed against any Party.

     11.13 Headings. The captions or headings of the sections or other subdivisions hereof
are inserted only as a matter of convenience or for reference and shall have no effect on the
meaning of the provisions hereof.

     11.14 No Implied Waivers; Rights Cumulative. No failure on the part of either Party
to exercise, and no delay in exercising, any right, power, remedy or privilege under this
Agreement, or provided by statute or at law or in equity or otherwise, shall impair, prejudice or
constitute a waiver of any such right, power, remedy or privilege or be construed as a waiver of
any breach of this Agreement or as an acquiescence therein, nor shall any single or partial

Confidential

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

87

 

exercise of any such right, power, remedy or privilege preclude any other or further exercise
thereof or the exercise of any other right, power, remedy or privilege.

     11.15 Severability. If any provision hereof should be held invalid, illegal or
unenforceable in any respect in any jurisdiction, then, to the fullest extent permitted by law, (a)
all other provisions hereof shall remain in full force and effect in such jurisdiction and shall be
liberally construed in order to carry out the intentions of the Parties as nearly as may be
possible and (b) such invalidity, illegality or unenforceability shall not affect the validity,
legality or enforceability of such provision in any other jurisdiction. To the extent permitted by
applicable law, ARCHEMIX and EYETECH hereby waive any provision of law that would render any
provision hereof prohibited or unenforceable in any respect.

     11.16 Execution in Counterparts. This Agreement may be executed in counterparts, each
of which counterparts, when so executed and delivered, shall be deemed to be an original, and all
of which counterparts, taken together, shall constitute one and the same instrument.  

     11.17 No Third Party Beneficiaries. Except as set forth in Article 7, no person or
entity other than ARCHEMIX, EYETECH and their respective Affiliates and permitted assignees
hereunder shall be deemed an intended beneficiary hereunder or have any right to enforce any
obligation of this Agreement.

*[The remainder of this page is intentionally left blank, signature page to follow]*

Confidential

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

88

 

          IN WITNESS WHEREOF, the Parties hereto have caused this Research and License Agreement to be
executed by their duly authorized representatives in duplicates as of the day, month and year first
above written.

	 	 	 	 	 	 	 
	 

	 	ARCHEMIX CORP.	 	 
	 
	 	 	 	 	 	 
	 

	 	By:	 	 /s/ Errol De Souza	 	 
	 

	 	Name:
	 	 

Errol De Souza	 	 
	 

	 	Title:	 	President and CEO	 	 
	 
	 	 	 	 	 	 
	 

	 	EYETECH PHARMACEUTICALS, INC.	 	 
	 
	 	 	 	 	 	 
	 

	 	By:	 	 /s/ David Guyer	 	 
	 

	 	Name:
	 	 

David R. Guyer	 	 
	 

	 	Title:	 	CIO	 	 

Confidential

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

89

 

Appendix 1

Sample Early Selection Criteria

	•	 	Aptamer has a [***]; If [***] for [***] to [***] from the [***] as [***] by [***].
	 
	•	 	[***] are [***] to [***] aptamer with [***], as [***] at the [***] of the [***].
	 
	•	 	Aptamer has [***] in [***].
	 
	•	 	Aptamer is [***] and/or [***] to by [***], and the [***].
	 
	•	 	[***] has [***]

	 	—	 	 [***] and [***]
	 
	 	—	 	 [***]

Confidential

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

90

 

Appendix 2Annual Research Plan

To be completed within 30 days of Effective Date

Confidential

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

91

 

Appendix 3

Sample Development Compound Criteria

	•	 	[***]
	 
	•	 	[***]
	 
	 	 	     [***] is [***] for [***]
	 
	•	 	[***] in [***]
	 
	 
	•	 	[***] has [***] for [***]

	 	•	 	[***] for [***] to [***]
	 
	 	•	 	[***] by [***]

	•	 	[***]

Confidential

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

92

 

Appendix 4

Sample Target Criteria

	•	 	[***] is [***] to [***]

	 	—	 	 [***]
	 
	 	—	 	 [***]

	•	 	Aptamer[***] is [***]

	 	—	 	 [***] of [***], and [***] are [***] to [***]
	 
	 	—	 	 [***] of [***] to [***]

	•	 	[***] is [***]

	 	—	 	 [***] can be [***] and [***] for [***]
	 
	 	—	 	 Aptamer [***] is [***] at [***]
	 
	 	—	 	 [***] Aptamer [***] are [***]
	 
	 	—	 	 [***] are [***]
	 
	 	—	 	 [***] are [***]
	 
	 	—	 	 [***] and [***] are [***]

Confidential

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

93

 

Appendix 5

Gilead-Eyetech Patent Portfolio

[***]

Confidential

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

94

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00151-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00151-of-00352.parquet"}]]